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Summary 
 
Monitoring pain in laboratory animals is essential from an animal welfare point 
of view as experimental procedures often involve surgeries, or other 
potentially harmful interventions. Moreover, the genetic modifications 
induced in disease modeling might impair the animal and induce some 
suffering. Properly treating pain is not only necessary for the animal wellbeing, 
but also eliminates possible data biases caused by nociception. Inflammation 
can also influence data and should therefore also be treated appropriately. 
Laboratory mice instinctively hide all signs of suffering. A routine observation 
and scoring of pain is therefore very difficult and highly subjective. More 
precise behavioral tests or measurements of blood corticosterone imply some 
additional stressful handling, which might further influence the experimental 
data.  In this work, we investigated the feasibility of an innovative monitoring 
of nociception based on the detection of gene expression level changes in 
the central nervous system.  This method could be applied to sentinel animals 
to assess the level of pain induced by a specific procedure. 
 
A wide set of elements is necessary for the transduction of the nociceptive 
message from the periphery to the central nervous system and its integration 
in brain. Monitoring the expression level changes of the genes encoding 
elements might help to identify genetic patterns characteristic of longer 
lasting nociception and might be used to monitor pain. In the first part of this 
project, we screened the literature and chose a set of 226 genes, which 
induce altered pain-related behaviors in transgenic animals experiments. We 
then built a low-density 70mer oligonucleotide microarray, and developed a 
single-color hybridization and normalization protocol, to detect changes in 
the expression level of these genes.  This protocol could be validated in a 
gene profiling experiment assessing the expression level differences between 
the brainstems, cortices and hippocampi of naïve NMRI mice. The normalized 
fold changes observed had similarity rates ranging from 66.7 to 100% with 
published whole genome microarray data comparing the expression levels in 
these parts of the brain. The experiments to measure gene expression 
changes linked to nociception were performed on NMRI mice, which had 
been subjected to a telemetric apparatus implantation, which induces a 
heart rate increase characteristic of pain in the post-operative recovery 
phase, and on control animals from the same strain, which underwent the 
same anesthetic and analgesic protocol, without surgery. A two-color 
microarray experiment was performed on whole brains. This experiment did 
not lead to any convincing data and was biased by a dye imbalance. A 
more precise analysis was therefore performed to monitor eventual expression 
changes in the brainstems, cerebelli, cortices, hippocampi and spinal cords 
of these animals. For these experiments, we followed the single color 
hybridization protocol, which we had previously developed. However, these 
measurements gave only a few artefactual results, which could not be 
confirmed by Real-Time PCR measurements.  
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In the second part of the project, a high-throughput Real-Time PCR analysis 
was performed on the 26 most promising candidate genes, to test if a more 
sensitive technique would detect some changes that the microarray missed. 
The experiments were carried out on 6 animals per condition, and the 
analyzed parts of the central nervous system were the cortex, the brainstem, 
the hippocampus, and the lumbar dorsal root ganglia. Only one gene 
showed a significant 2.2 time higher expression in the cortices of the operated 
animals: the serotonin receptor 5HTr1A. This difference could not be observed 
in an inflammatory pain model. Taken together, our data shows that the 226 
commonly known “pain genes” are therefore poor candidates for the 
establishment of a routine microarray test to monitor nociception.  
 
In the final part of the project, we performed a whole genome analysis using 
Affymetrix GeneChip® Mouse Exon 1.0 ST Arrays, on the spinal cords of 6 mice 
which underwent our surgical protocol and 6 control mice, in order to identify 
new candidate genes for the monitoring of nociception. After filtering, and a 
functional classification, we focused on 166 downregulated genes, and 96 
upregulated genes, which were mostly involved in cytoskeleton, cell motility, 
extracellular matrix and inflammation. A Bi-Clustering meta-analysis identified 
21 downregulated and 17 upregulated genes, which were involved in axonal 
sprouting and neuronal rearrangements. Another analysis of the 410 most 
relevant alternatively spliced genes also revealed that 10% of them were 
linked to cell motility. Taken together, these data indicate that genes involved 
in cell migration linked to inflammation, or in neuron movements 
characteristic of synaptic plasticity show a differential expression or are 
subjected to alternative splicing, and should be considered as potent 
candidate genes, for the establishment of a routine microarray tool designed 
to monitor nociception in the spinal cord of sentinel animals subjected to a 
potential painful experiment. Recent developments in the microarray 
technology have increased their sensitivity. Moreover, subtle events such as 
the alternative splicing underlying nociception in the spinal cord can now 
also be monitored. These assets open the door to new possibilities in the 
monitoring of pain. 
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Zusammenfassung 
 
Die genaue Überwachung von Versuchstieren ist aus Tierschutzgründen sehr 
wichtig, denn Operationen oder andere schmerzhafte Behandlungen sind 
Bestandteil vieler Experimente. Zusätzlich können induzierte genetische 
Veränderungen in Krankheitsmodellen das Tier beeinträchtigen und Leiden 
verursachen, welches mit Schmerzmitteln  behandelt werden sollte. Eine 
angemessene Schmerzbehandlung ist nicht nur notwendig für das tierische 
Wohlbefinden, sondern verhindert auch mögliche Datenabweichungen 
aufgrund von Schmerz und Entzündungsprozessen. Labormäuse verstecken 
instinktiv sämtliche Anzeichen von Leiden. Die routinemässige Beobachtung 
und objektive Erfassung von Schmerz ist deshalb sehr schwierig und überaus 
subjektiv. Genauere Verhaltensexperimente oder die Messung von 
Corticosteron im Blut sind mit Stress verbunden, was zu einer zusätzlichen 
Beeinflussung experimenteller Daten führen kann. Im Rahmen dieser Arbeit 
wurde die Eignung einer neuen Methode zur Schmerzerfassung untersucht, 
welche auf der Detektion von Veränderungen der Genexpression im 
Zentralen Nervensystem beruht.  
 
Der Übermittlung eines Schmerzsignals von der Peripherie zum Zentralen 
Nervensystem und seiner Integration ins Gehirn liegt ein umfangsreiches 
Zusammenspiel von Signalen zugrunde. Die Überwachung von Änderungen 
im Expressionsgrad der diesen Signalelementen zugrunde liegenden Genen 
könnte hilfreich dabei sein, genetische Muster zu identifizieren, welche 
charakteristisch sind für längerdauernden Schmerz und somit zur 
Schmerzbeobachtung beitragen könnten. 
 
Im 1. Teil dieses Projekts haben wir zunächst eine Gruppe von 226 Genen 
identifiziert, welche mit schmerzbedingten Verhaltensweisen in transgenen 
Tieresperimenten assoziiert werden. Dann konstruierten wir einen „low-density 
70mer oligonucleotide microarray“ und entwickelten ein Protokoll für eine 1-
Farben Hybridisierung und Normierung um Veränderungen im Expressions-
Niveau dieser Gene zu detektieren. Dieses Protokoll konnte in einem Gen-
Profiling-Experiment validiert werden, welches Unterschiede im 
Expressionsgrad zwischen Hirnstamm, Hirnrinde, und Hippocampus dreier 
naiver NMRI Mäuse analysierte. Die hier beobachteten normalisierten „fold 
changes“ zeigten Ähnlichkeiten im Bereich von 66.7 bis 100% verglichen mit 
bereits publizierten Daten aus das ganze Genom erfassenden Microarrays , 
welche die Expressionsniveaus in gleichen Teilen des Gehirns vergleichen. 
 
Experimente zur Messung von mit Schmerz verbundenen Änderungen in der 
Gen-Expression wurden mit NMRI Mäusen durchgeführt. Diese Mäuse wurden 
einer Telemetrie-Chip Implantation unterzogen, welche eine für die post-
operative Phase charakteristische Erhöhung der Herzfrequenz hervorruft. 
Kontroll-Mäuse desselbes Stammes waren ebenfalls Bestandteil dieses 
Experiments, sie wurden demselben Anästhesie- und Analgesie Protokoll 
unterzogen, allerdings ohne den operativen Eingriff. Es wurde ein 2-Farben-
Zusammenfassung 
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Microarray an kompletten Gehirnen durchgeführt. Dieses Experiment führte 
nicht zu aussagekräftigen Resultaten, deshalb wurde eine präzisere Analyse 
durchgeführt, um mögliche Expressionsänderungen in Hirnstamm, Kleinhirn, 
Hirnrinde, Hippocampus und Rückenmark zu erfassen. Bei diesen Versuchen 
folgten wir einem von uns im Vorfeld entwickelten Ein-Farben Hybridisierungs-
Protokoll. Diese Experimente ergaben jedoch nur wenige, artefakt-ähnliche 
Resultate, welche nicht durch Real-Time PCR Messungen bestätigt werden 
konnten. 
 
Eine Real-Time PCR Analyse mit hohem Durchsatz wurde im Rahmen des 2. 
Projektteils mit den 26 vielversprechendsten Kandidatengenen durchgeführt, 
um herauszufinden, ob eine empfindlichere Messtechnik Veränderungen 
detektieren könnte, welche eventuell vom Microarray nicht erkannt wurden. 
Für diese Versuche wurden 6 Tiere pro Bedingung verwendet und es wurden 
Hirnrinde, Hirnstamm, Hippocampus und die dorsalen Spinalganglien aus dem 
Lendenbereich untersucht. Nur ein Gen wies eine signifikante, um das 2.2 
fache erhöhte Expression in der Hirnrinde der operierten Tiere auf: der 
Serotonin Rezeptor 5HTr1A. Dieser Unterschied konnte an einem 
Entzündungsschmerzmodell nicht nachgewiesen werden. Insgesamt gesehen 
sind die 226 als „Schmerzgene“ bekannten Gene deshalb ungeeignet für die 
Etablierung eines routinemässig einsetzbaren Microarrays zur Überwachung 
der Schmerzwahrnehmung. 
 
Im letzten Teil dieses Projekts verwendeten wir Affymetrix GeneChip Mouse 
Exon 1.0 ST Arrays zur Analyse des gesamten Genoms des Rückenmarks von 6 
Mäusen, welche dem Operations-Protokoll unterzogen wurden, sowie 6 
Kontrollmäusen, mit dem Ziel neue Kandidatengene zur Überwachung der 
Schmerzwahrnehmung zu identifizieren. Nach vorangegangener Filtierung 
und funktioneller Klassifizierung konzentrierten wir uns  auf 166 herunter- sowie 
96- nach oben regulierte Gene, welche hauptsächlich Bestandteil sind von 
Zytoskelett, Zellbeweglichkeit, Extrazellulärer Matrix und 
Endzündungsprozessen. Eine „Bi-Clustering“ Meta-Analyse führte zur 
Identifizierung von 21 nach unten und 17 nach oben regulierten Genen, 
welche eine Rolle spielen bei der Ausbreitung von Axonen und bei neuronaler 
Neuanordnung. Zusätzlich erbrachte eine Analyse der 410 relevantesten 
alternativ gespleissten Gene, dass 10% von ihnen mit Zellbeweglichkeit in 
Verbindung stehen. Insgesamt zeigen diese Daten, dass Gene, welche mit 
entzündungdbedingter Zellwanderung oder mit für synaptische Plastizität 
charakteristische neuronale Bewegung in Verbindung stehen, eine 
unterschiedliche Expression aufweisen oder alternativem Spleissen unterzogen 
werden. Sie sollten deshalb als mögliche Kandidatengene für die Etablierung 
eines routinemässig-anwendbaren Microarray in Erwägung der Schmerz-
Wahrnehmung unter Verwendung des Rückenmarks von Sentineltieren vor 
einem potenziell Schmerzhaften Versuch herangezogen werden könnten 
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1 Introduction 
 
Genes dictate a wide variety of biological processes, and their role is 
constantly better understood. Since Mendel’s observations of inherited traits 
and phenotypes, a lot of progress has been made. Many diseases or 
predispositions have been linked to specific mutations and the general 
knowledge on genes is refined every day. The development of transgenic 
technology has allowed to knock-out or overexpress genes in cells to 
precisely study their function. The generation of transgenic animal models 
took research further by allowing the assessment of a gene’s relevance in a 
complete organism, and has opened the door to the study of the in-vivo 
consequences of a genetic modification. In parallel, genomic studies have 
also shown that genes are not static and do not have a constant expression 
level. Their expression can be repressed or enhanced by external or internal 
stimuli, and dictate a complex interplay of cellular processes, which are highly 
sensitive and adaptable. Understanding how the expression of genes specific 
to the central nervous system is altered in precise physiological, 
psychological, and behavioral conditions is a vast research domain, which 
could lead to the development of new diagnostic tools for complex 
processes such as pain and stress, which are difficult to measure objectively in 
laboratory animals. 
 
1.1 Pain and nociception 
 
The International Association for the Study of Pain (IASP) defines pain as an 
unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage. This word 
can describe a physical discomfort, or an emotional distress, and often a 
painful situation arises from the combination of these two components. In 
research, pain is described a sensory message, which warns an organism of a 
potential danger linked to an eventual injury or damage (Scholz and Woolf, 
2002). Due to their unpleasant characteristics, painful experiences are 
memorized and play an important role in the learning processes of 
vertebrates. Pain avoidance is essential for the survival of species, as it brings 
animals to run away from their predators and to avoid potential harmful 
situations.  
 
It has been shown that the development of an animal’s behavior can be 
influenced by painful stimuli. Male rats exhibit longer latencies than untreated 
control animals at the tail flick test, a common test for thermal pain, when 
they have been exposed to repeated morphine injections as pups (P1-P7) 
(Bhutta et al., 2001) They also show less locomotor activity than control 
animals, when they have been subjected as pups to repeated formalin 
injections causing inflammatory pain (P1-P7) (Bhutta et al., 2001). Lidow et al 
have also demonstrated that short-term exposure of rats neonates to an 
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inflammatory pain induced by a single carrageenan injection in the hindpaw 
induces long-term alterations in the withdrawal responses of this hindpaw to 
noxious heat and mechanical stimulation that persist in adult animals (Lidow 
et al., 2001). By performing wheat germ agglutinin-horseradish peroxidase 
stainings in the dorsal horns of adult rats, which had been subjected to a 
complete Freund’s adjuvant injection in the left hindpaw, Ruda et al. were 
able to show permanent segmental changes in primary nociceptive afferent 
axons, linked to this inflammatory treatment. The adult animals showed a 
significantly higher density of terminal stainings in the left dorsal horn than in 
the right one, in the lumbar and sacral region of the spinal cord. They also 
responded more rapidly to the formalin test (Ruda et al., 2000). Taken 
together, these studies show that painful stimulations experienced during 
development can induce anatomical and physiological changes, which can 
explain persistent altered reactions linked to pain in the adulthood. 
 
Pain is a subjective sensation and is therefore difficult to study objectively. It is 
a complex experience. Not only does it involve the transduction of noxious 
stimuli, but it also triggers an emotional reaction. Personal and social 
empathic experiences shape everyone’s perception of pain (Akitsuki and 
Decety, 2009). Moreover, recent studies have shown that hormone balances 
and gender influence the way pain is experienced by an individual. Women 
have generally a higher risk of developing chronic pain (Paller et al., 2009), 
and both male and female gonadal steroids are key factors in the gender 
differences in pain perception (Mensah-Nyagan et al., 2009; Paller et al., 
2009). Because of all these aspects, the assessment and the monitoring of 
pain is very difficult. In 2008, the Kyoto Protocol of IASP Terminology defined 
nociception as the “the neural processes of encoding and processing noxious 
stimuli” (Loeser and Treede, 2008). Because nociception relies on a series of 
physiological parameters, it is possible to study it objectively. Understanding 
the key mechanisms of nociception might provide further insights in pain 
processes and perception. 
 
 
1.1.1. Nociceptive neurons and mechanoceptors 
 
Two main groups of afferent sensory neurons, which differ in their size and 
conduction velocity, have been described: the neurons with A-fibers, and the 
neurons with C-fibers. These two categories also differ in their cytology. A-
fibers have first been described as having light somatas with a lot of 
neurofilaments, and C-fibers as having dark and smaller somatas, with less 
neurofilaments (Lawson, 1979; Lawson and Biscoe, 1979; Lawson and 
Waddell, 1991). Early studies had already described two types of sensations 
caused by an external stimulation: a localized, distinct pricking sensation, 
which was attributed to A fibers mechanoceptors, and an unpleasant dull 
and diffuse sensation, which resulted from the stimulation of C-fibers 
nociceptive neurons (Collins et al., 1960; Landau and Bishop, 1953). The A-
fibers were shown to be myelinated, to have the largest diameter and to 
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produce a rapid response, whereas the C fibers were described as non 
myelinated, with a small diameter and induced a slower response when 
stimulated. Later studies have refined these findings. 
 
Three types of sensory neurons have been described, according to the 
conduction velocity of their fibers: the Aα/β-, the Aδ- and the C- fibers (Figure 
1). In their study of sensory neurons innervating mouse skin, Kotzenburg et al. 
(1997) have shown that Aβ- fibers could be divided in two categories: the 
rapidly adaptive fibers (RA), which respond fast to a constant mechanical 
stimulation, and the slowly adaptive (SA) fibers, which show delayed 
discharges after similar stimulations. In adult outbred mice, the conduction 
velocity of RA fibers of the Saphenous nerve was 13.6 m/s, whereas for SA 
fibers, it had a value of 15.5 m/s. Aδ- fibers could also be divided in two 
categories: D hair fibers, which have a conduction velocity of 4.8 m/s and 
which responded to a von Frey filament stimulation of 1mN, and the high 
threshold mechanoceptors (MA), which respond to a stimulation of 5.6 mN 
and have a slower conduction velocity (7 m/s).  A noxious heat stimulation 
revealed that MA Aδ- fibers have a mean threshold of 42.5°C and an 
average discharge of 15.8 action potentials per stimulus, whereas C fibers 
have a mean threshold of 37.6°C and an average discharge of 22 action 
potential per stimulus (Koltzenburg et al., 1997). Other studies have shown that 
neurons with Aδ- fibers can be divided into two subsets. The neurons with type 
I Aδ- fibers, which have a thermal threshold of 52°C and are insensitive to 
capsaicin, an irritant compound frequently used in pain research. Neurons 
with type II Aδ- fibers of 45°C and are responding capsaicin, just like neurons 
with C-type fibers (Nagy and Rang, 1999).  
 
 
 
 
Figure 1: Adapted from Julius, D. Nature 413, 203-
210 (Julius and Basbaum, 2001). The 3 types of 
sensory neurons and their respective thermal 
threshold 
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A common misinterpretation in pain research, is the assumption that only C- 
and Aδ- fibers have nociceptive properties (Julius and Basbaum, 2001). The 
reality is in fact more complicated. In-vivo intracellular voltage recording 
studies made in dorsal root ganglia neurons of young guinea pigs have 
demonstrated that 42% of A fibers nociceptive neurons have a conduction 
velocity in the Aβ range (Djouhri et al., 1998), and similar data observed in 
cats (Koerber et al., 1988) or rats (Ritter and Mendell, 1992) show the existence 
of nociceptive, and non-nociceptive fibers of the Aα/β-, the Aδ- and the C- 
type. 
 
Although C fibers are commonly thought to be only transducing nociceptive 
signals, low threshold mechanoceptors (LTM) C-fibers, which respond to low 
intensity mechanical stimuli have also been identified (Bessou et al., 1971; 
Djouhri et al., 1998). Djhouri et al have demonstrated by analyzing intracellular 
voltage recordings from the somata of Guinea Pig’s DRG neurons, that LTM C-
fibers make up 8% of all C-fibers in the guinea pig, the rest being nociceptive 
fibers. In their study, the main difference between these fibers could be seen 
in the duration their respective action potentials. Indeed, nociceptive C-fibers 
neurons had longer lasting action potentials and after hyperpolarizations than 
LTM C- fibers (Djouhri et al., 1998). 
 
The amplitude of somatic action potentials has been shown to be generally 
greater in C- fibers than in A- type fiber neurons (Bessou et al., 1971). 
However, in the Aα/β-, the Aδ- or the C- fibers, the nociceptive units always 
have significantly larger somatic action potential overshoot phases than low-
threshold mechanoreceptors. The overshoot phase is the phase during which 
the action potential reaches its highest amplitude (Djouhri and Lawson, 2001). 
There are therefore differences between nociceptive fibers and 
mechanoceptors, which are true for all three categories of fibers. 
 
Taken together, these studies show that the key difference between C- and 
A- fibers is their proportion of nociceptive neurons over low threshold ones. 
Basically, the highest proportion of nociceptive neurons is found amongst C-
fiber type neurons. Aδ- fiber type neurons have a lower proportion of 
nociceptive neurons than C fiber-type ones, but this proportion is still higher 
than amongst Aα/β- fiber type neurons.  This explains why C-fibers and Aδ- 
fibers are preferably seen as the neurons involved in nociception. However, 
regardless of which CV type they belong to, nociceptive neurons have higher 
thermal and mechanical thresholds than LTM, and once this threshold is 
reached, they fire longer action potentials than LTMs followed by a prolonged 
after-hyperpolarization phase. Each nerve has a different proportion of Aα/β-, 
Aδ- and C- type fibers, and amongst each of these types, the proportion of 
LTM and nociceptive neuron varies (Koltzenburg et al., 1997).  These 
gradations in the ratio of nociceptive neurons versus LTM in each CV type of 
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neurons (and consequently in each nerve), the fundamental activation and 
firing differences between nociceptive neurons and LTM, as well conduction 
velocities differences between Aα/β-, Aδ- and C- type fibers, allow a fine 
tuning of the sensory messages, which range from normal to painful 
sensations. 
 
In normal conditions, the threshold of a stimulus applied at the periphery has 
to be high enough to trigger the activation of nociceptive neurons and the 
subsequent transduction of pain messages. However various factors, such as 
inflammation, injuries or malfunctions of the Central Nervous System (CNS), or 
neural plasticity can lead to changes in the pain signal activation threshold, 
and to neuropathic pain in the most severe cases (Scholz and Woolf, 2002). It 
is therefore essential to understand the various mechanisms which trigger and 
influence nociception.  
 
 
1.1.2. Activation of nociceptive neurons at the periphery 
 
 
Figure 2: Modified from Scholz, (Scholz and Woolf, 2002). Nociception mechanisms. At the 
periphery, a stimulus such as noxious heat, acidic stress, mechanical stress or noxious cold 
activates specific receptors. If the stimulus reaches a certain threshold, it activates 
nociceptive neurons, which will transmit the message through the dorsal root ganglias to 
the CNS. In the spinal cord, the message is processed into an immediate reflex reaction, 
and transmitted by the spinothalamic and the spinoparabrachial ascending pathways to 
the brain, to elicit a sensory and emotional reaction, and to possibly activate the 
descending inhibiting pathways.  
 
 
An interesting ability of nociceptive neurons is their ability to detect a variety 
of systems at the periphery. In that sense, they differ from sensory neurons of 
the olfactory or visual system, which only detect one type of stimulus and 
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activate neurons through G-protein coupled receptors (Kato and Touhara, 
2009; Shichida and Morizumi, 2007). Nociceptive neurons can be activated 
by noxious heat, noxious cold as well as pressure, mechanical stress, or 
chemical assaults, and must therefore have a wide variety of receptors and 
transduction molecules that allow them to respond to each of these stressors, 
as seen on Figure 2. 
 
 
1.1.2.1 Response to noxious heat 
 
A key molecule in the stimulation of nociceptive neurons by noxious heat is 
the vanilloid receptor VR1, which has first been described and cloned as the 
capsaicin receptor. Sequence analyses have shown that this receptor is an 
838 amino acids long, hydrophilic protein, with 6 transmembrane domains, 
and an amino-terminal hydrophilic segment (432 amino acids) containing a 
proline-rich region followed by three ankyrin repeats. This structure is similar to 
transient receptor potential channels (Caterina et al., 1997), (TRP channels), a 
family of channels, which has been shown to be activated by G protein 
coupled or tyrosine kinase receptors, which activate phospholipase C (Julius 
and Basbaum, 2001). 
 
Further studies have shown that this receptor is not only activated by noxious 
heat and by capsaicin, but also by protons (Tominaga et al., 1998; Welch et 
al., 2000). In their work, Tominaga et al have shown that the rat VR1 receptor 
has a thermal threshold of 43°C, which coincides with the thermal threshold of 
Aδ- and C- fibers. Interestingly, extracellular Ca2+ is necessary for the cell 
desensitization mediated by the interaction of capsaicin or protons with the 
VR1 receptor. However, the desensitization, which is caused by a heat 
activation of the VR1 receptor, is not calcium dependent. These observations 
suggest that the action mechanisms of capsaicin and heat on the VR1 
receptor are different. However, capsazepine, a competitive antagonist of 
capsaicin blocks capsaicin-, heat- as well as proton-evoked current. This 
means that the action mechanism of capsaicin and heat are nevertheless 
similar to some degree (Tominaga et al., 1998). Welch et al have taken this 
work further by inducing expression of different mutated rat VR1 receptors 
isoforms in Xenopus laevis oocytes to analyze them by patch clamp. They 
were able to show that that 3 amino acid residues localized near the pore of 
the VR1 contribute to the activation pathway by capsaicin, as a mutation in 
this site modifies the response to this compound without altering the 
receptor’s sensitivity to heat or protons (Welch et al., 2000). 
 
In vivo studies of knockout mice, which do not express the VR1 receptor, 
brought the knowledge on heat-evoked nociception further. These mice 
have 3 times less heat sensitive C-fibers. Extracellular recordings performed on 
lumbar spinal cord neurons showed that VR1-/- mice show similar responses to 
mechanical stimuli, but altered responses to noxious heat. Interestingly, 
behavioral studies showed that these mice reacted to temperatures in the 
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range of the threshold of the VR1 receptor, but not to temperature higher 
than 50°C. However, measurements performed on cultured DRG neurons 
from these mice showed that neurons have defects in low-threshold but not in 
high-threshold heat-evoked currents (Caterina et al., 2000). This might be 
explained by the existence of another heat-activated receptor, the vanilloid 
receptor-like 1 (VRL-1), which also has a TRP structure. To perform functional 
studies of this receptor, its expression has been induced in Xenopus oocytes 
and HEK293 human embryonic kidney cells. VRL-1 appears to have a thermal 
threshold of 52°C, and is not activated by capsaicin or protons. Histological 
studies of adult rat spinal cords and sensory ganglia have shown that VRL-1 is 
expressed in a subset of Aδ- fibers. This could explain why the type Aδ- fibers 
have a thermal threshold of 52°C. Northern Blot analyses revealed that VRL-1 
messenger RNA is expressed in tissues other than sensory ganglia and spinal 
cord, including lung, spleen, intestine, and brain (most subregions), which 
means that VRL-1 may be activated by stimuli other than noxious heat outside 
of the CNS (Caterina et al., 1999). 
 
 
1.1.2.2 Response to noxious cold 
 
Two important channels in the nociceptive neurons activation by noxious 
cold are the transient receptor potential melastin 8 channel (TRPM8) and the 
transient receptor potential ankyrin 1 (TRPA1). Patch clamp recordings have 
shown that TRPM8 enables the detection of temperatures that encompass all 
of the innocuous cool (15–28°C) and part of the noxious cold (8–15 °C) range 
(McKemy et al., 2002). Knockout TRPM8-/- show less behavioral responses 
linked to cooling sensations.  is a TRPM8 agonist, which induces “wet dog 
shakes” and “jumping” behaviors when injected i.p. in wildtype (wt) mice. 
TRPM8-/- mice showed none of these behaviors after an ilicin injection, and 
TRPM8-/+ mice jumped significantly less than wt ones (Colburn et al., 2007). By 
comparing the firing rates of cultured skin neurons subjected to decreasing 
temperatures, Bautista et al showed, that TRPM8-/- mice exhibit less firing from 
C-fibers, as well as a lower basal firing rate. The same analysis conducted on 
Aδ- fibers showed that these fibers also react to cold, with about 4.5 times 
more Aδ- fibers firing observed in wt mice than in TRPM8-/- mice (Bautista et 
al., 2007). Other studies have shown, that TRPM8 activation by cold can have 
an analgesic effect on mice, which were subjected to a formalin injection in 
the hindpaw. This could not be seen in TRPM8-/- mice (Dhaka et al., 2007). 
Taken together, these results show that TRPM8 is essential for the transduction 
of noxious cold, but is also an essential player of the analgesic effect linked to 
cooling. 
 
The research done TRPA1 has not provided such clear results on its 
involvement in noxious cold sensation. Intracellular calcium imaging 
experiments have shown TRPA1 is found in a subpopulation of sensory 
neurons, in which it is co-expressed with VR1 but not with TRPM8 (Story et al., 
2003). Patch clamp measurements have demonstrated that the threshold of 
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activation of TRPA1 is 17°C (Sawada et al., 2007). On the other hand, recent 
studies on TRPA1 deficient mice have shown that this gene is essential for 
mechanoception. TRPA1-/- mice had a normal sensitivity to acute cold, but 
their C-fiber nociceptors had action potential firing rates 50% lower than those 
in wt C-fibers across a wide range of force intensities. Their A!-fiber 
mechanonociceptors only had reduced firing after stimulations at high 
intensity forces (Kwan et al., 2009). 
 
1.1.2.3 Response to mechanical stress 
 
An important familiy of ion channels involved in the detection of mechanical 
stress is the Degenerin / Epithelial Sodium channel (DEG/ENaC). The members 
of this family have two transmembrane domains and a large extracellular 
loop. These domains form homomeric or heteromeric channels that are 
blocked by amiloride, a common sodium channel blocker, and have been 
shown to be permeable to sodium (Corey and Garcia-Anoveros, 1996; 
Garcia-Anoveros and Corey, 1996). This family of genes is expressed in a wide 
variety of organisms, ranging from nematodes to mammals (Garcia-Anoveros 
et al., 1995). BNC1 is a member of the DEG/ENaC, which has been identified 
in peripheral mechanosensory terminals of DRG neurons and has been shown 
to respond to acidic stimuli (Garcia-Anoveros et al., 2001; Lingueglia et al., 
1997). The generation of a BNC-/- mouse showed however that this receptor is 
activated by mechanical stress, as these knockout mice have a reduced 
sensitivity to hair movement (Price et al., 2000). Another interesting gene of 
the DEG/ENaC family, which has been shown to be involved in 
mechanoception, is the Dorsal Root Acid Sensing Ion Channel (DRASIC), 
which has first been identified as an H+ gated channel (Waldmann and 
Lazdunski, 1998). However, DRASIC null mice had an increased sensitivity to 
light touch, but showed a delayed response to noxious pinch, acid or noxious 
heat. It has been since then postulated that his channel is a part of a 
heteromultimeric complex, which has a different composition among 
functionally distinct sensory neurons (Price et al., 2001). An interesting feature 
of the DEG/ENaC genes expressed in the CNS is that they seem to be 
involved in mechanoception, mechanical stress and acid-induced 
nociception. On the other hand, TRPA1 has been shown to be involved in 
mechanoception and noxious cold stimulation (Kwan et al., 2009). This tends 
to show, that one channel can be involved in various functions, depending 
on the type of sensory neuron it is expressed and which type of complex it is 
part of. 
 
Another important element for mechanoception and pain related to 
mechanical stress is extracellular ATP. Ion gated voltage channels, which are 
activated by ATP (P2X receptors) as well as G-protein coupled ATP receptors 
(P2Y receptors) have been identified in rat sensory neurons  (Burnstock, 1981; 
Krishtal et al., 1988). Nakamura et al. provided valuable information on the 
role of these receptors in mechanosensitivity.  By inducing expression of P2Y1 
receptor in Xenopus laevis, they were able to show that a mechanical 
Introduction 
 
 25 
stimulus caused an autocrine release of ATP by the transfected oocyte, and a 
subsequent activation of the P2Y1 receptor, which leads to a 350nA current 
(Nakamura and Strittmatter, 1996). The same mechanism might activate P2Y 
receptors at sensory nerve terminal endings, and might be involved in 
mechanoception and nociception.  
 
 
 
1.1.3 Nociceptive message processing in the Spinal Cord 
 
The cell bodies of nociceptive neurons are located in the dorsal root ganglia, 
and the first synapse in the transmission of a nociceptive message is in the 
dorsal horn of the spinal cord. The dorsal horn contains 2 principal structures: 
the marginal zone (lamina I) and the substantia gelatinosa (lamina II) (Lawson 
et al., 1997; Willis, 2007).  Spinal electrophysiological recordings performed on 
rat lamina I neurons have shown that 74% of the neurons of this region are 
nociceptive specific. 18% of these neurons react to various noxious stimuli, 
and have therefore been characterized as polymodal nociceptive (HPC). The 
other 26% have a wide dynamic range (WDR), and respond to noxious as well 
as benign stimuli. In the lamina V, which is a deeper region of the spinal cord, 
the majority of the neurons show a WDR. However, the WDR neurons of the 
lamina I have a higher threshold of excitation than the ones from lamina V, 
This tends to show, that lamina I WDR neurons are involved in nociception, 
whereas lamina V neurons are mostly involved in the transmission of innoxious 
stimuli (Seagrove et al., 2004). 
 
 
1.1.3.1 The lamina I and the ascending pathways 
 
Lamina I neurons project mainly in a contralateral way to various sites in the 
brain: the periaqueductal grey matter (PAG), the lateral parabrachial area, 
the nucleus of the solitary tract and the medullary reticular formation (Burstein 
et al., 1990a; Burstein et al., 1990b; Todd, 2002; Todd et al., 2000). 
Immunocytochemistry studies have shown 80% of the lamina I neurons, which 
project to the thalamus, the periaqueductal grey matter, the parabrachial 
area as well as to the caudal ventrolateral medulla, express the neurokinin 1 
receptor (NK1) (Marshall et al., 1996; Todd et al., 2000). Substance P binds the 
NK1 receptor and leads to the internalization of this receptor. It has been 
shown, that rat lamina I neurons show an internalization of the receptor, as 
well as dendritic reorganization after an acute noxious stimulation. This 
indicates, that the NK1 receptor positive neurons, which project to higher 
centers, are involved in the transmission of a nociceptive signal (Mantyh et al., 
1995). 
 
Intrathecal injections of a Substance P-Saporin conjugate leads to a selective 
ablation of the lamina I neurons. The conjugate is internalized by NK1-
expressing lamina I neurons, and once in the cell, Saporin blocks protein 
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synthesis, which ultimately induces cell death. Rats, which have been treated 
that way exhibit significantly decreased responses to an intraplantar 
capsaicin injection. The mechanical and thermal hyperalgesia induced by 
this treatment is also diminished in the treated animals. 28 days after the 
injection, the treated rats exhibited a 75% decrease in the nocifensive 
behavior induced by a unilateral injection of capsaicin into the hindpaw 
(Mantyh et al., 1997). These results show the relevancy of the lamina I 
ascending pathways to the brainstem, as well as the importance of these 
pathways in the integration of the nociceptive message, and the generation 
of both a behavioral and an affective response to the stimulus. 
 
 
1.1.3.2 The lamina II and the descending pathways 
 
Histological studies of rat lumbar spinal cord have shown clear differences 
between the structures of the lamina I and II. While the former contains 
neurons with long axons, which project to higher CNS centers, the latter is 
formed of small neurons with intrinsic projections and local terminations (Todd, 
2002; Woolf and Fitzgerald, 1983). However, the lamina II neurons appear to 
play a central role in pain modulation, as they receive two main inputs: one 
coming from the periphery conveyed through nociceptive neurons, and 
another coming from the brain through inhibitory descending pathways. 
Intracellular recordings in adult rat spinal cord slices have demonstrated that 
both Aδ- and C-fiber afferents release synaptic transmitters that elicit fast 
glutamate excitatory post synaptic potentials neurons in Lamina II neurons 
(Yoshimura and Jessell, 1989a, b). Another important molecule involved in the 
modulation of nociception at the lamina II level is GABA. Histological studies 
on rats have shown that laminae I-III have a high density of GABA 
immunoreactive neurons. Two weeks after unilateral sciatic nerve injury, no 
more GABAergic neurons could be seen. The deficit could be observed in the 
spinal dorsal horn both on the ipsilateral and the contralateral sides to the 
injured member.  Moreover, a behavioral analysis of these animals indicated 
that they exhibit thermal hyperalgesia (Moore et al., 2002). More recent 
studies on rats have however demonstrated that here is no loss of neurons 
from laminae I–III in similar nerve injures models model, and that the animals 
exhibit allodynia even if no neuronal death was observed in the dorsal horn 
(Polgar et al., 2005; Polgar and Todd, 2008). 
 
The main descending inhibitory pathways, which modulate pain at the 
lamina II level, involve the noradrenergic and the serotonergic system. 
Noradrenergic neurons projecting from the nucleus ceruleus form synaptic 
contacts with lamina II neurons (Westlund et al., 1982). Histological studies 
have indicate that most dorsal horn axons possessing the α2C adrenergic 
receptor are excitatory spinal interneurons, which form synaptic connections 
with lamina II neurons. (Olave and Maxwell, 2003), and in-vivo whole cell 
patch clam recordings performed on rat spinal cords suggest that 
noradrenaline has two effects the lamina II. On one hand, it induces a 
Introduction 
 
 27 
hyperpolarization of the excitatory interneurons, which inhibits the 
transduction of the nociceptive message, and thereby reduces the noxious 
stimuli-induced excitatory-post synaptic current measured on the lamina II 
neurons.  On the other hand, it produces an antinociceptive effect by acting 
directly on the postsynaptic lamina II neurons through the α2C-adrenergic 
receptor, which induces a G-protein-mediated activation of K+ channels 
receptors and leads to an outward current (Sonohata et al., 2004). 
 
Serotonergic neurons coming from the raphe magnus in the brainstem have 
projections which form synaptic contacts with lamina I and lamina II neurons 
(Morales et al., 1998). Contradictory observations have been made on the 
effects of serotonin on the dorsal horn neurons. Whole-cell recordings from 
substantia gelatinosa neurons in spinal cord slices from ovariectomized rats 
which exhibit hyperalgesia, have shown that serotonin inhibits afferent C-
fibers presynaptically through the HT1A-Like Receptor, which subsequently 
leads to a reduction of the excitatory post-synaptic current measured on the 
lamina II neurons, and an analgesic effect on the animals (Ito et al., 2000). On 
the other hand, an excitatory pronociceptive effect of the 5HT3 receptor has 
been identified in electrophysiological studies. A significant decrease in the 
electrically evoked responses of dorsal horn neurons of rats subjected to the 
formalin test could be observed after a treatment with the selective 5HTr3 
antagonist ondansetron. This suggests, that this receptor is normally involved in 
the maintenance of the nociceptive message (Green et al., 2000). Taken 
together, these findings indicate that the serotonergic descending pathway 
can modulate nociceptive messages in various manners, depending on 
which serotonin receptor is involved.  
 
 
1.1.4 Pain processing and integration in the Brain 
 
1.1.4.1 The Pain Matrix 
 
In humans, the responses to pain sensation involve a complex network which 
is commonly referred to as the “Pain matrix”, and is largely distributed in the 
brain. The neuroanatomical structure of this network can be divided into the 
sensory-discriminatory and the affective-cognitive-evaluative components.  
The sensory-discriminatory areas are the primary (S1) and the secondary (S2) 
somatosensory cortex, the posterior parts of the insula and the thalamus. The 
areas involved in the affective-cognitive-evaluative processes are the 
anterior part of the insula, the anterior cingulated cortex (ACC) and the 
prefrontal cortex (PFC) (Albe-Fessard et al., 1985). A meta-analysis of brain 
imaging data obtained by positron emission tomography (PET) and functional 
magnetic resonance (FMRI) performed on healthy subjects and on patients 
suffering from chronic pain has shown that the pain matrix cannot always be 
so clearly defined. While the main regions involved in acute pain perception 
are the S1, S2, insula, the ACC, the prefrontal cortex (PFC), and the thalamus, 
other regions such as the basal ganglia, cerebellum, amygdala, the 
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hippocampus, and the areas within the parietal and temporal cortices can 
also show some activity depending on the state and the condition of the 
tested individual (Apkarian et al., 2005). These areas are illustrated in Figure 3. 
 
 
 
 
Figure 3: From Apkarian, (Apkarian et al., 2005). Cortical and sub-cortical regions involved in pain 
perception, and the integration of the nociceptive message. The locations of brain regions are color-
coded in the scheme drawing and in an example MRI. (a) Scheme shows the regions, their inter-
connectivity and afferent pathways. (b) The areas corresponding to those shown in the schematic are 
shown in an anatomical MRI, on a coronal slice and three sagittal slices as indicated on the coronal 
slice. The pain matrix areas are the secondary somatosensory cortices (S1, S2, red and orange), anterior 
cingulate (ACC, green), insula (blue), thalamus (yellow), and prefrontal cortex (PF, purple). Other 
regions indicated on this figure include: primary and supplementary motor cortices (M1 and SMA), 
posterior parietal cortex (PPC), posterior cingulate (PCC), basal ganglia (BG, pink), hypothalamus (HT), 
amygdala (AMYG), parabrachial nuclei (PB), and periaqueductal gray (PAG). 
 
 
Positron emission tomography (PET) recordings studies have shown, that 
immersing the hand of a patient in ice water is a painful stimulus, which 
produces significant increases in regional cerebral blood flow (rCBF) within 
the contralateral secondary somatosensory (S2) and insular cortex, bilaterally 
in the thalamus and cerebellum, and medially in the cerebellar vermis. The 
patients also grade the stimulus as being unpleasant. When the patients 
receive an intravenous injection with Fentanyl, a µ-opioid receptor agonist, 
the grades they give to the stimulus indicate that they do not perceive it as 
painful, and their PET recordings reveal that all their cortical and subcortical 
responses to noxious cold are reduced. However, the same recordings 
performed on patients, who are subjected to unpleasant vibration on their 
forearm indicate an activation of the primary S1 cortex, which remains 
unaffected by a treatment with Fentanyl. The treated patients also continue 
to grade their stimulation as painful (Casey et al., 2000). These findings 
indicate that different painful stimuli activate different components of the 
pain matrix. 
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Chronic pain states can also provide valuable information on brain areas 
involved in the processing of a nociceptive message. FMRI studies performed 
on brains of patients suffering from postherpetic neuralgia (PHN) have shown 
that spontaneous pain, induced by this condition, activates affective and 
sensory-discriminative areas, such as the thalamus, the S1 and S2, insula and 
the ACC as well as areas involved in emotion, hedonics, reward, and 
punishment such as the central striatum, the amygdala, the orbital frontal 
cortex, and the ventral tegmental area. The patients were treated with 
lidocaine patches, and brain FMRI recordings were performed to check 
whether this treatment could decrease the activity recorded in these areas. 
Interestingly, the sensory and affective activations could only be inhibited 
after 6h of treatment, while the activity in the striatum and amygdala – which 
are reward-related regions – decreased only after 2 weeks of treatment 
(Geha et al., 2007).  This data shows, that chronification processes activate 
sensory regions, but also elicit emotional responses, which are differently 
integrated, and cannot be simply reversed with the same treatment. It can 
be hypothesized that the chronification of pain induces changes in the brain 
pain-related circuitry. The participation of hedonic/reward sub-cortical areas 
increase with time, while the sensory-representational cortical areas could be 
gradually less involved, making the condition perhaps more sub-conscious 
and impacting on motivational drives (Geha et al., 2007). 
 
 
1.1.4.2 Activation of the descending pathways 
 
The periaqueductal gray-rostral ventromedial medulla (PAG-RVM) activation 
system of the descending pathways has been widely studied. The PAG 
receives inputs from limbic forebrain structures such as the ACC, the 
amygdala (AMY), the dorsomedial nucleus of the hypothalamus, and the 
medial prefrontal cortex (MPC), and projects to the RVM in the brainstem. In 
the RVM, structures such as the raphe magnus and the adjacent reticular 
formation project to the dorsal horn, and therefore play a pivotal role in pain 
modulation (Fields, 1985, 2000; Hermann et al., 1997). Early experiments have 
shown that it is possible to perform an exploratory laparotomy in rats, without 
using any chemical anesthetics after stimulating the PAG (Reynolds, 1969). 
Since then, it has been shown that the PAG-RVM system is involved in 
analgesia mediated by cannabinoids (Hohmann et al., 2005), opioids (Loyd 
and Murphy, 2009; Yaksh et al., 1976) and by cyclooxygenase inhibitors (Leith 
et al., 2007). Figure 4 illustrates the various inputs and outputs of the PAG-RVM 
system. 
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Figure 4: Scheme representing PAG-RVM system in a midline cut of the 
mouse brain. The PAG-RVM system exerts bidirectional control over 
dorsal horn nociceptive processing, and the DRt and VLM in the caudal 
medulla. The PAG receives important direct and indirect inputs from 
limbic forebrain areas including anterior cingulate cortex (ACC), 
amygdala (AMY), dorsomedial nucleus of the hypothalamus (DMH), and 
medial prefrontal cortex (MPC). It projects to the RVM, which integrates 
the response, and can lead to a inhibitory or stimulating effect. The 
dorsal reticular nucleus of the caudal medulla (DRt) and the 
ventrolateral quadrant of the caudal medulla (VLM) are also involved in 
descending modulating pathways. The DRt is thought to be facilitating, 
and VLM primarily inhibitory, although it may, like the RVM, have both an 
inhibitory and facilitatory influence. 
 
 
Depending on the conditions, the RVM is able to trigger analgesia or 
hyperalgesia. In-vivo recordings of the activation of RVM neurons in rats and 
observations of a tail flick reflex after a noxious heat stimulus revealed that this 
structure contains “on-cells”and “off-cells” which have different firing profiles.  
The on-cells are excited and their firing increases after the noxious stimulus. For 
the off-cells, on the other hand, a decrease in the firing is measured after the 
stimulus; this indicates that these cells are then inhibited. There is clear 
segregation between these two cell populations along the mediolateral axis 
of the RVM (Fields et al., 1983), but further recordings in the spinal cords have 
shown that both cell types project to the laminae I, II and V of the spinal cord, 
which are precisely the areas which receive inputs from sensory and 
nociceptive neurons (Fields et al., 1995). A third group, the “neutral cells” did 
not respond to noxious stimuli, or gave variable responses. These 3 cell types 
respond differently to iontophoretic applications of morphine. The on-cells are 
inhibited, but the off-cells and the neutral cells do not exhibit any clear 
changes. However, if morphine is applied locally, the on-cells get depressed, 
whereas the “off-cells” get continuously activated. The firing of the neutral 
cells remains unaffected by either morphine application types (Heinricher et 
al., 1992). This data suggests that these 3 cell types contribute differently to 
the descending pathways and to pain modulations.  
 
Iontophoretic applications of bicuculline methiodide, a GABA a receptor 
antagonist, in the RVM of rat suppressed the tail flick reflex, and reduced the 
firing of off-cells. The activity of on- and neutral cells however remained 
unchanged by this treatment. This suggests that GABA inhibition of off-cells is 
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essential for the tail flick reflex (Heinricher et al., 1991; Heinricher and Kaplan, 
1991). Moreover, rat RVM infusion with a selective µ-opioid agonist inhibited 
on cells, which led in most cases to a subsequent activation of off-cells 
correlated with a suppression of the heat-evoked tail flick (Heinricher et al., 
1994). Taken together, these data suggest that on-cells are inhibitory GABA-
ergic interneurons, which form synaptic contacts with off-cells. The on-cells 
start fire upon activation of the µ-opioid receptor, release GABA and 
subsequently inhibit the constitutive firing of the off-cells, which leads to 
analgesia. Given that both cell types project to the dorsal horn, a complex 
interplay of inhibition and activation can directly and indirectly modulate 
nociception at the RVM- and spinal-levels. The firing profile and role of neutral 
cells is to date less understood. Histological studies of the rat have shown that 
these cells are serotonergic, which is not the case of on- or off-cells (Potrebic 
et al., 1994), which tends to show, that they are also involved in pain 
modulation. 
 
 
1.1.5 Inflammatory pain 
 
Inflammation is a process, which is closely linked to injuries. Cells of the 
immune system infiltrate the site, in order to protect the organism from a 
possible infection. This process involves the interplay of a wide variety of 
cytokines, chemokines, growth factors and other diffusible components, 
which contribute to pain and tend to elicit hyperalgesia. It has for instance 
been shown in the rat that an intraplantar injection of CFA triggers a 
reduction of the latency in the hotplate test as well as the mechanical 
threshold in the Von Frey filaments tests. The inflammation induced by the 
CFA induces a significant elevation of the TNF-α, interleukine1β (IL-1β) and 
NGF at the site of injection. Interestingly, intraplantar TNF-α injections induce 
short, dose-dependent increases in thermal and mechanical sensitivity, which 
can also lead to an increase of the IL-1β and NGF concentration at the site of 
injection. The hyperalgesia can be significantly attenuated by prior 
administrations of anti-NGF antiserum (Woolf et al., 1997). This data shows that 
soluble factors alone can lead to a sensitization, which is similar to the one 
observed during a complete inflammatory process involving cell infiltration. 
Similarly, it has been shown in mice that intraperitoneal injections of zymosan 
and acetic acid induced a writhing behavior characteristic of pain. This 
response decreased when a lavage of the peritoneal cavity, which 
eliminates macrophages and resident mast cells, was performed prior to the 
injection, and increased when the mice were pre-treated with thioglycolate, 
a compound, which enhances the responses of macrophages. Interestingly, 
a pre-treatment with an anti-interleukin-8 serum partially inhibited the writhing 
behavior, but on the other hand a combined injection with a TNF-α, IL-1β and 
interleukin-8 induced the writhing (Ribeiro et al., 2000).   
 
Neutrophils are the first cells, which are detected at the injury site. They 
produce chemokines, which mediate the infliltration of the site by other 
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leukocytes (Antony et al., 1985). Chemokine receptors are G-protein coupled, 
and are not only expressed in cells from the immune system. Indeed, 
chemokines and their receptors are found in the CNS, and are even essential 
for the development of the brain, as shown by the early lethality and the 
severe deficit in the brain development of transgenic mice, which do not 
express the stromal cell derived factor 1 and its receptor CXCR4 (Ma et al., 
1998). While neutrophils and macrophages trigger neuroinflammation at the 
periphery, glial cells are responsible for the same process in the CNS. It has 
been demonstrated histologically that rats, which have been subjected to a 
plantar injections of formalin or zymosan – 2 compounds causing mechanical 
allodynia - exhibited a higher rate of glial activation and IL-1β in their spinal 
cords, 1 to 6 hours after the treatment (Sweitzer et al., 1999).  
 
 
 
Figure 5: Modified from Scholz, J. (Scholz and Woolf, 2002). Inflammatory Pain 
processing. When an injures occurs at the periphery, Cells from the immune system 
infiltrate the site, and release chemokines, cytokines and other soluble substances 
necessary to the coordination of the inflammatory reaction. These substances lower 
the activation thresholds of nociceptive neurons, and lead to an increased pain 
sensation for the subject, to stimulus, which would not be noxious under normal 
conditions. 
 
 
The mitogen-activated protein kinases (MAPKs) seem to play an important 
role in pain sensitization during inflammation. This family of proteins contains 3 
main subgroups: the extracellular signal regulated kinases (ERKs), the p38 
kinases, and the c-Jun N-terminal kinases (JNK), which represent 3 different 
signaling cascade responding to a range of extracellular stimuli, and leading 
to transcriptional and non-transcriptional regulation (Johnson and Lapadat, 
2002). ERK kinases are for instance involved in Bradykinin mediated 
hypersensitivity. Bradykinin is a vasodilatator peptide, which is produced after 
a tissue injury, contributes to inflammation by increasing vascular 
permeability, and is also involved in pain sensitization (Couture et al., 2001). 
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The Bradykinin receptor B2 is a G-coupled receptor, which is expressed on 
DRG neurons (Wang et al., 2005). In situ hybridization studies coupled with 
immunohistochemistry and patch clamp recordings have been made in rats, 
and have shown that the B2 receptor, and the protein kinases A and Cδ are 
coexpressed in lamina II neurons. By interacting with those receptors, 
Bradykinin activates the two previously mentioned kinases, which then recruit 
ERK kinases to lead to an increase of AMPA and NMDA receptor-mediated 
current. This process therefore facilitates glutamatergic post-synaptic 
responsiveness, and ultimately leads to hyperalgesia (Kohno et al., 2008). 
 
The p38 kinases also play a central role in pain processes linked to 
inflammation, and are activated by the Nerve Growth Factor (NGF), IL-1β and 
TNF-α among other factors (Widmann et al., 1999). Ji et al. have shown in rats, 
that p38 is expressed in C-fiber neurons, and contributes to thermal 
hyperalgesia caused by the inflammation induced by a CFA intraplantar 
injection. NGF levels increase during the inflammation at the site of the injury. 
It gets retrogradely transported to the cell body, where it activates p38, which 
enhances the translation and transport of the VR1 (TRPV1) receptor towards 
the periphery, a process, which maintains a hypersensitivity to heat. An 
intrathecal injection of a selective p38 inhibitor (SB203580) prior to the CFA 
injection inhibits this mechanism, and reduces the thermal hyperalgesia 
observed after the injection (Ji et al., 2002; Woolf et al., 1994). Given that the 
VR1 receptor is also activated by H+, this regulation might therefore also 
contribute to sensitivity to the acidic stress induced by the H+ release at injury 
site during inflammatory processes (Scholz and Woolf, 2002).  
 
Another cascade, which leads to an increased sensitivity to pain, involves 
p38. The activation of high-threshold C-fibers leads to the release of 
substance P and glutamate in the dorsal horn, which activate respectively 
the post synaptic NK1 and NMDA receptors, elicit an increase of the 
intracellular Ca2+ concentration and activate phospholipase A2 (PLA2). This 
enzyme mediates the release of arachidonic acid from cellular membranes, 
which is then converted into prostaglandins, by cyclooxygenases (COX) 
(Lazarewicz et al., 1990). Prostaglandins participate to the inflammatory 
processes, and the subsequent pain by lowering thermal threshold. This can 
be assessed in a hot plate test. Intrathecal applications of a p38 inhibitor (SD-
282) lead to a decrease of the Prostaglandin E2 (PGE2) release and of the 
subsequent thermal hyperalgesia. This means that p38 is involved in PLA2 
mediated inflammatory pain (Svensson and Yaksh, 2002). 
 
The role of the JNK kinases in inflammatory pain is not as clearly defined. It has 
been shown by immunohistochemistry that a peripheral axotomy of the 
sciatic nerve in rats induces an activation of JNK, and c-Jun binding to 
activator protein 1 (AP-1) to induce gene expression. This mechanism might 
be involved in axonal sprouting, and might be one of the explanations for 
neuropathic pain (Kenney and Kocsis, 1998). 
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1.2 Genes involved in pain mechanisms 
 
1.2.1 Transgenic mice and pain 
 
Many knockout mice, which exhibit altered pain behaviors have been 
generated. Some have been described previously in this introduction, but 
other animal models, which do not express specific channels, have a 
modified neuronal activity, and exhibit uncommon responses to pain. They 
therefore have an important role in pain research.   
 
Voltage gated sodium channels play an essential role in the generation and 
the propagation of sensory or nociceptive signals. By disrupting the SCN11A 
gene, Priest et al. have been able to generate NAv1.9 knockout mice. 
Although patch clamp recordings made on dissociated DRG neurons from 
these mice revealed no difference in the passive membrane properties and 
action potential characteristics between the NAv1.9-/- and the wt mice, 
behavioral tests showed that NAv1.9-/- had a shorter late response to the 
formalin test then wt animals (Priest et al., 2005).  
 
In other studies, the Cre-loxP system has been used to generate specific 
knockout mice, which had a deletion of the NAv1.7 in their nociceptive 
neurons only. These animals had a reduced responsiveness to mechanical 
stress in the Randall-Selitto test, which was correlated with a reduced 
electrophysiological response of lamina V neurons after a mechanical stress. 
Moreover, these animals did not develop any thermal of mechanical 
hyperalgesia linked to inflammation caused an intraplantar CFA injection 
Nassar, 2004 #117}. This study could show the essential role of the NAv1.7 
channel in nociception and pain, and also explains why humans, which have 
a mutated NAv1.7 channel appear to be pain insensitive (Cox et al., 2006). 
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Figure 6: Modified from Scholz, J. Nature Neuroscience 5, 1062 - 1067 (2002) (Scholz and Woolf, 2002). 
Sum up of the essential genes involved in the generation, transmission, integration and modulation of 
the nociceptive signal from the periphery to the central nervous system. 
 
 
Some other proteins than channels have been shown to be essential for a 
normal transduction of the pain signal. The Downstream Regulatory Element 
Antagonistic Modulator (DREAM) is a transcription factor that regulates the 
expression of many genes including c-fos. It was the first identified 
transcription factor, which could be blocked by Ca2+ (Carrion et al., 1998).  
DREAM-/- mice exhibit a significantly longer delay time in their tail flick 
response to noxious heat, and the mechanical threshold required to induce 
withdrawal of the paw after pressure, is significantly higherin these mice than 
in wt animals. They also show less writhes after intraperitoneal injections of 
MgSO4, which produces an immediate visceral pain, or of acetic acid, which 
induces inflammatory pain. Moreover, the DREAM knockout animals have 
elevated levels of prodynorphin mRNA and dynorphin, which is an 
endogenous ligand of the κ opiate receptor (Cheng et al., 2002; Costigan 
and Woolf, 2002). This data shows the variety of elements, which can underlie 
a single knockout’s altered pain behavior phenotype: transcription factors, 
receptors and ligands. 
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1.2.2 Pain gene databases 
 
Because many genes seem to induce a pain related phenotype in transgenic 
or knockout animals, a classification has been necessary. J. Mogil and his 
team at the Pain Genetics Lab in Canada have established an internationally 
recognized database of the known “pain genes” (Lacroix-Fralish et al., 2007). 
To date, the database counts 283 genes, and is regularly updated. To 
establish this database, they considered 3 criteria of inclusion: 
 
• The mutant animals had to have a null expression of only one gene. 
• The mice had to be tested on a behavioral assay of nociception, injury 
or stimulus induced hypersensitivity or stress-induced inhibition of 
nociception. 
• At least one statistically relevant difference in either direction had to be 
visible between the mutant and the wild-type mice.  
 
In 2007, the pain gene database contained the categories summed up on 
Figure 7. 
 
 
 
Figure 7: Modified from LaCroix-Fralish et al., 2007 Functional classification of the 
genes present in the Pain Gene Database.  
 
In a similar way, we have established a list of pain related genes at the 
beginning this project. A literature search was performed to find potential 
genes related to pain. The genes, which were included, fulfilled at least one 
of those criteria: 
 
• A mutant animal for the gene of interest had to have an altered 
response to a characteristic behavioral test of pain (mechanical, 
thermal, or inflammatory induced hyperalgesia). 
• The gene product induced a modified response to a characteristic 
behavioral test of pain (analgesia, allodynia or hyperalgesia) if injected 
into wt animals. 
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• The gene induced a stress or anxiety phenotype to transgenic animals. 
 
We established a list of 230 genes. Half of them were also in the pain gene 
database established by J. Mogil’s group. The other half were linked to stress 
and anxiety processes. Here is a description of the main categories we 
selected: 
 
• Channels and receptors: This category is very wide and counts key 
players which have a role in the peripheral (such as VR1, DRASIC, etc…) 
and central (such as GABA receptors, the NAv1.9 channel, etc…) 
processes of nociception. 
 
• Signal transduction: This category is also very diverse and contains 
genes such as MAP kinases, p38 kinases and CREB. 
 
• Neuropeptides: For example Subtance P, and other members of the 
Tachykinin family.  
 
• Oxydative Stress: For example cytochromes . 
 
• Hormone related genes: For example the pro-opiomelanocortin gene 
gives rise to many splice variants, which encode the various 
components of the melanocortins family such as the adreno- 
corticotropic hormone (ACTH).  
 
• Neurotrophins: For example BDNF, and GDNF.  
 
• Heat shock proteins: For example HSP72.  
 
• Cytokines, chemokines and related: For example IL-1β, IL-8 and TNF-α. 
 
 
The genes previously described in this introduction were all present in our pain 
genes list. Appendix 1 lists all of these genes with examples of their function, 
and literature references. 
 
 
1.2.3 Assessing pain in laboratory mice by monitoring gene expression 
changes? 
 
Mice live in constant fear of their predators and therefore show little 
behaviors, which might reveal that they are suffering. In laboratory settings, 
health observations of the animals depend on scoresheets, which give 
variable results from one observer to the other. This can be problematic in 
research, because mice are very commonly used as model animals for 
diseases and pain must be monitored for animal welfare purposes as well as 
for experimental reasons. Therefore, other tools have to be used to monitor 
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pain in laboratory mice, and their development represents a great topic in 
animal welfare research. One approach to objectively measure pain in 
laboratory animals, could be to find genes, which show a variation in their 
expression levels depending on the pain intensity and to test how they 
behave in known pain models 
 
Recent data have shown that pain does indeed induce specific gene 
expression changes in defined models. Histological stainings performed in rat 
spinal cords after an intraplantar formalin injection revealed, that the genes 
encoding the leukocyte common antigen (LCA/CD45), the MHC class I 
antigen, and CD11c are both more expressed in the activated microglia 3 
days after the injection and reach their peak expression levels after 7 days (Fu 
et al., 2009).  
 
Performing a nerve injury triggers a hyperexcitability of afferent nociceptive 
fibers, and is therefore often used in research as a model for chronic pain. In 
their study, Persson et al have assessed whether this model induces gene 
expression changes in the DRGs of 5 mice strains. Their microarray analysis 
revealed that an average of 2552 genes is significantly regulated in DRGs of 
the tested animals, 3 days after the nerve constriction. However, only 5.6% of 
these genes had a significant regulation across all the 5 strains, and were 
correlated to pain behavior such as tactile hypersensitivity. The differential 
expression between injured and control animals could be validated for 2 
genes: the Na+ channel SCN11, which was correlated with levels of 
spontaneous pain behavior and Trpm8, which was correlated with heat 
hypersensitivity (Persson et al., 2009). 
 
In another study, microarray analyses have been performed on dorsal root 
ganglia of rats, which had been subjected to an intraperitoneal injection of 
Paclitaxel, a compound used in chemotherapies, which causes painful 
peripheral neuropathies. The results showed that 38 genes were 
downregulated and 60 genes were upregulated in the treated animals. 
Interestingly, 26 of the 60 upregulated genes were linked to inflammation. 
One of these genes, the matrix metalloproteinase-3 seemed to be responsible 
for the recruitment and accumulation of macrophages in the DRG of the 
treated animals, a process, which might induce the neuropathy and the 
subsequent painful sensation (Nishida et al., 2008). 
 
In humans, gene expression level analyses in the CNS are more difficult, 
because they require dissection of tissues. However, microarray analyses 
performed on inflamed oral mucosa tissue samples 3 hours after a tooth 
removal have revealed, that 25 genes linked to inflammation cascade were 
upregulated, including IL-6, CCL2 and CXCL2 as well as other cytokines, 
chemokines and their receptor. These upregulations were correlated with a 
higher pain sensation reported by the patients (Wang et al., 2009). 
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Taken together, these results show that nociception and inflammation induce 
expression level changes in the periphery, as well as in the central nervous 
system. However, no study has ever been done on the expression profiles of 
the genes listed in the pain gene database in various pain models, in order to 
check, whether they present a constant behavior, which might be 
characteristic of nociception, and could be used to monitor pain objectively. 
 
1.3 Pain models studied in this project 
 
During in the course of this project, we focused on a surgical pain model, but 
also performed quantitative real-time PCR measurements to study an 
inflammatory pain model. 
 
 
1.3.1 Surgical pain model: telemetric apparatus implantation. 
 
A lot of experiments performed on laboratory animals involve surgery. This can 
be problematic because the results observed might be influenced by the 
nociceptive processes, which are happening in the animal. It is therefore 
important to carefully monitor pain in operated animals. In their study on 
laboratory mice and surgical pain, Arras et al. have demonstrated by using 
telemetry, that monitoring the heart rate (HR), the electrocardiogram (ECG), 
the core body temperature (BT) and locomotor activity (ACT) can give 
precious information on the level of pain experienced by an mouse after 
surgery (Arras et al., 2007). 
 
In the surgical pain model, eight weeks before the beginning of the 
experiments, TA10ETA-F20 transmitters (Data Sciences International, St. Paul, 
MN, USA) are implanted in NMRI mice. After the recovery phase, a 
laparotomy followed by a vasectomy was performed on the operated 
animals, and the controls were only anesthetized. Within the operated and 
control groups, one subgroup received a Caprofen analgesic treatment 
(RimadylTM, Pfizer Inc., NY, USA), one subgroup received a Flunixin analgesic 
treatment (Biokema FlunixineTM), and one subgroup received no analgesic 
treatment. Measurements of the heart rate showed that the operated 
animals, which did not receive any analgesic treatment had the highest 
values after the operations. The 2 groups treated with analgesia had values, 
which were higher than their non-operated controls, but the heart rate of 
these animals was still lower than the one of the animals, which did not 
receive any analgesia after surgery. At the end of the first day, HR values of 
the 2 groups treated with analgesia returned to normal, but the ones of the 
untreated operated animals remained higher.  
 
Interestingly, when the results were plotted as 12 hours mean values over the 3 
days following the surgery, the HR of the operated animals without analgesia 
appeared to be significantly increased during the first 24 hours, and during 
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the first dark phase (01-12h post surgery) in the operated animals treated with 
flunixin. Moreover, the body weight of the operated animals with no pain 
treatment decreased during in the first 3 days post-surgery, and their food 
and water consumption also decreased during the first two days after the 
intervention. During these 2 days the animals of this group had an 
unstructured territory, with no defined nest and a confused distribution of the 
nesting material in the habitat. All this data indicate that the animals were 
experiencing a painful recovery, which was impairing their normal behavior. 
 
An interesting feature of telemetry is the possibility to detect different levels of 
pain. Indeed, telemetric measurements performed directly after the 
implantation revealed that the heart rate of the animals was impaired for 3 
days (Figure 8) in both the untreated group, and the group treated with 
flunixin. This tends to show that a highly invasive procedure like a telemetric 
apparatus implantation causes a higher level of pain than the vasectomy for 
the animal, and that the heart rate increase cannot be diminished by the use 
of non-steroidal anti-inflammatory drug (NSAID) (Arras, 2007; Cinelli et al., 
2006) 
 
 
 
 
Figure 8: Modified from Arras et al, 2007 (Arras, 2007). Heart rate variations measured by telemetry. A. 
During 3 days after the implantation, the heart rate of the animals is increased. This cannot be 
prevented by the use of analgesics like flunixin. B. After a recovery period of 6 weeks, the heart rate 
returned to normal. C. During 3 days after the vasectomy, the heart rate of the animals is increased. This 
was also observed during the first 12 hours following the surgery, in the flunixin-treated animals. 
 
 
1.3.2 Inflammatory pain model: immunization with a BHV-1 virus 
 
Immunizations are routinely performed on laboratory animals, to produce 
polyclonal antibodies.  The common procedure consists in injecting 
inactivated antigene mixed with CFA, a solution containing mycobacterial 
cell walls and mineral oils, which enhances the immune response. Further 
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injections with incomplete Freund’s Adjuvant (IFA) are also often performed, 
to boost the immune response (Stills, 2005). Although adverse effects such as 
death, immobility, abscesses and necropsy have been reported, no real 
assessment of the pain level of these animals has been performed (Leenaars 
et al., 1998). However, as previously addressed in this work, inflammation 
elicits pain which  not only impairs the well being of the animal, but can also 
bias the outcome of an experiment. 
 
To address these issues, Arras et al. have implanted TA10ETA-F20 transmitters 
(Data Sciences International, St. Paul, MN, USA) to mice from a strain called 
129S/Ev-IFNabRtmAgt, which does not express the α/β interferon receptor 
(Muller et al., 1994). This strain mounts a strong IgG2a-dominated antibody 
response but shows no signs of infection, when inoculated with the Bovine 
Herpes Virus 1 (BHV-1). The animals were randomly divided into 3 groups, 
which were subjected to 3 different protocols. The first group received a UV-
inactivated BHV-1 combined with CFA intraperitoneal injection followed by a 
booster immunization with IFA 28 days later. The second group was subjected 
to the same protocol, but was treated with Caprofen once daily during the 3 
days which followed the primary immunization, and during one day after the 
booster injection. The mice from the third group underwent a different 
protocol. They received an intraperitoneal injection of live BHV-1 virus in cell 
culture medium. No booster was used in this protocol. 
 
All three protocols were successful for immunizations, as high titers of BHV-1-
specific IgG2a and IgG2b were found in every immunized animal. The booster 
immunizations revealed enhanced the BHV-1 specific IgG1, IgG2a and IgG2b 
titers. The telemetric measurements were used to detect heart rate changes 
significant of pain. The animals, which underwent the first immunization 
protocol, had a significantly elevated heart rate during the first 24 hours. In 
the second light phase, the elevation did not reach significance. After the 
booster immunization, the heart rate was also elevated during 24 hours. For 
the animals, which were subjected the second protocol, a significant 
increase in the heart rate was observed in the first 24 hours, but the values 
returned to normal more rapidly, because of the analgesic treatment, and no 
more increase was detected afterwards. The booster induced a significant 
increase during the first night only. The animals, which were immunized 
according to the third protocol, did not exhibit any significant heart rate 
change (M. Arras, unpublished data). 
 
Measurements performed on the food and water consumption revealed, that 
it dropped to 80% on the first day following the first immunization protocol, as 
well as the booster of the fist protocol. However, no significant changes could 
be observed in the animals, which were subjected to the two other protocols. 
 
Taken together, this data suggests that an immunization with BHV-1 virus in 
CFA followed by a boosted induces a heart-rate increase, which is related to 
pain, according to previous studies (Arras, 2007; Arras et al., 2007). The use of 
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Caprofen reduces the duration of the heart rate increase observed both after 
the immunization and the booster. Immunization protocols can therefore be 
an interesting way to study the effects of induced inflammatory pain on an 
organism.  
 
1.4 Microarray technology 
 
DNA microarrays are widely used today in gene expression analyses. This 
technology is derived from the ‘dot plot’ assays, which were developed to 
analyze cloned DNA sequences using highly radioactive, 32P-labeled DNA or 
RNA probes (Kafatos et al., 1979). However, the real development of 
microarrays started when spotting technology was developed enough to 
enable the switch from membrane to solid surfaces for the spotting of the 
probes. Schena et al were the first to describe a real microarray protocol. 
They spotted 48 cDNAs with an average size of 1kb derived from arabidopsis 
mRNA, on a glas surface. They established a protocol to prepare fluorescent 
cDNA samples from the total arabidopsis mRNA, by incorporating fluorescein 
or lissamine. By labeling 2 different samples with either one of the 
fluorochromes, and by hybridizing an appropriately titrated mix of both 
samples on the array, they were able to detect fluorescence intensity 
differences, which were correlated to gene expression differences between 
the 2 samples (Schena et al., 1995). 
 
This hybridization principle remained virtually identical in most custom-made 
arrays, even though the technology went through several optimization steps. 
Nowadays, microarrays can be spotted with either cDNAs or 70mer 
oligonucleotides, which present the advantage of giving stronger signals and 
of being less affected by background artifacts (Koltai and Weingarten-Baror, 
2008; Lyons, 2003). Moreover, studies have shown that microarray results 
obtained on slides spotted with 70mer oligos designed to be in the 3’ terminal 
of the genes, were more accurate, and were better correlated to results 
obtained by real-time-PDR, than results obtained on cDNA-arrays (Zhu et al., 
2005). Another important improvement was the development of in-vitro 
transcription protocols, which allowed the production and use of antisense 
RNA (aRNA) for the samples. These protocols combine the T7 technology for 
reverse transcription of the mRNA into double stranded cDNA, which is then 
transcribed in-vitro into aRNA. Given that the probes spotted on the slide are 
designed to be in the sense orientation, the hybridization can occur optimally. 
The biggest advantage of aRNA technology is the higher amount of material, 
which can be amplified from the total RNA extracted (Wang et al., 2000).   
This method also presents the advantage of allowing the use of amino-allyl-
UTP. These modified UTP integrate in the aRNA molecule like UTP, and N- 
hydroxysuccinimidyl ester-coupled (NHS-) fluorescent dyes bind to the amino-
allyl group during the labeling reaction. This indirect labeling method 
bypasses the use of bulky fluorescent dyes, which have to be directly during 
the reverse transcription step in older cDNA microarray sample preparation 
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protocols and can lead to aberrations. It therefore increases the fidelity of the 
amplified aRNA sample to the original mRNA extracted. The most common 
dyes used today for aRNA labeling are NHS-Cy3 and NHS-Cy5 (Holloway et 
al., 2002). 
 
 
The slides have also evolved. Glass slides are still the favorite support, because 
of their low fluorescence, transparency, resistance to high temperature, and 
their physical rigidity. However a variety of coating techniques have been 
developed to enhance the binding of the probes. Initially, coating glass slides 
with poly-L-lysine was highly popular because of the low costs of this 
technique. These surfaces still give good results and are therefore still used in 
research (Lyons, 2003). However, more recent studies show that epoxy-
coated slides give strong signal, have a better inter- and intra-slide 
performance (Sauer et al., 2009). In this project, we used SciChip EPOXY slides 
from Scienion®, coated with a polysiloxane layer, which provides a high 
density of coupling groups as well as a high homogeneity of the surface 
functionality 
 
1.4.1 Competitive hybridization protocols  
 
Most custom made microarrays are used for gene expression experiments. 
The most common protocols consist in competitive hybridizations with of two 
samples labeled with two different dyes on one slide (see Figure 9 for a 
scheme). These protocols are derived from the original experiments 
performed by Schena et al (Schena et al., 1995). 
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Figure 9: Principle of competitive hybridization of two aRNA samples labeled either with Cy3 or Cy5. If 
a gene is more expressed in tissue 1, the spot corresponding to that gene will have a stronger Cy3 
signal. If a gene is more expressed in tissue 2, the spot corresponding to that gene will have a stronger 
Cy5 signal. Both signals will be equal if a gene has comparable expression levels in both tissues 
 
 
In order to observe the gene expression level changes between 2 tissues, the 
total RNA of both tissues has to be separately extracted, reverse transcribed 
into cDNA and amplified in aRNA. Each sample is then labeled separately 
with either Cy3 (emission at 575nm) or Cy5 (emission at 660 nm), which are 
respectively commonly called the “green” and “red” dyes. A sample mix 
containing equal amounts of the Cy3- and the Cy5-labelled aRNAs is then 
hybridized on the chip. The slide is then scanned, to measure the signals 
intensities coming from the Cy3 and the Cy5 dyes in each spot. Each spot 
contains the oligonucleotides, which are specific for one gene. Therefore, if a 
gene is more expressed in the tissue from which the aRNA has been labeled 
with Cy3, the intensity of the Cy3 signal will be higher than the one coming 
from Cy5 for the spot representing this gene. The opposite is true, if another 
gene is more expressed in the tissue from which the aRNA has been labeled 
with Cy5. This system is widely used in custom-made microarrays, but also in 
commercially available chips produced by Agilent Technologies (Santa 
Clara, Ca, USA). 
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1.4.2 Affymetrix GeneChip® Mouse Exon 1.0 ST Array 
 
Commercially available chips produced by Affymetrix are nowadays widely 
used to study expression level changes across the whole genome. Recent 
developments have pushed the technology even further, and allow the 
monitoring of expression level changes at the exon level, thereby revealing 
alternative splicing events, which, by recent estimates, affects as many as 
94% of all human genes (Pohl et al., 2009; Wang et al., 2008). 
 
The first concept of the exon chip was elaborated by Clark et al. and was 
designed for humans (Clark et al., 2007). By scanning bioinformatically all the 
data available in Ensembl, GenScan, Twinscan, SLAM, among others, they 
defined every region, which corresponded to a putative exon as a Probe 
Selection Region (PSR).  The probes were then designed as 25mer 
oligonucleotides, so that 90% of all PSRs were covered by a probeset of 4 
probes (Figure 10). All PSRs of length greater than 17 nucleotides were 
covered by at least one probe. In case a PSR was shorter than 25 nucleotides, 
the probe was designed with a central target sequence, and surrounding 
genomic sequences filling out the 25mer. The probesets were also designed 
to take alternative 5’ or 3’ splice sites into consideration. If there was 
sequence evidence of overlapping exons with different edges, which 
suggested alternative and acceptor and donor sites, the exon was divided 
into multiple PSRs, which took in account the multiple splice variants, and 
appropriate probesets for each PSR (i.e. splice variants of the exon) were 
designed.  
 
As for other GeneChip® arrays, the probes were synthesized in situ on a glass 
surface, according to a proprietary protocol from Affymetrix. The sample 
preparation was also different than the previously described protocol, it 
consisted in a total RNA extraction with random hexamer/T7 promoter 
oligonucleotides as primers followed by a reverse transcription and a second 
strand synthesis to obtain a double stranded cDNA. From this cDNA a 
complementary RNA (cRNA) was transcribed in vitro. The cRNA was then 
again reverse transcribed into cDNA for which the second strand was also 
synthesized. This cDNA was then fragmented and end labeled with a biotin-
conjugated nucleotide analog (DLR-1a; Affymetrix, Inc.)  
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Figure 10: From Clark et al, Genome Biol. 2007; 8(4): R64. The Input sequences were analyzed on a 
variety of publicly available databases, in order to define all the putative exons – or PSR – of every 
gene. The probes were then designed, so that 90% of all the PSR had one probeset of 4 probes specific 
for it.  
 
In order to analyze the signals, they used an algorithm, which normalized 
exon signals obtained by the 4 probes of a probeset to the signal obtained for 
the gene as a whole, by all the probes that cover that gene. In their 
experiments, Clark et al. identified tissue specific exons comparing 16 different 
healthy human tissues. They were able to validate 86% of the tissue specific 
exons by real-time PCR (Clark et al., 2007). 
 
The Affymetrix GeneChip® Mouse Exon 1.0 ST Array was developed following 
the same process for the murine genome. These arrays were used in the final 
part of this project. 
 
1.5 Project description and relevancy 
 
1.5.1 Rational of the project 
 
Pain is a highly subjective sensory experience, which arises from the 
combination of physiological and emotional processes. In humans, it is 
possible to assess the level of pain in most cases, because patients who suffer 
indicate that they are not feeling well. In animals, the signals an observer has 
to monitor are different from a species to the other, and can be very difficult 
to detect. Therefore, the monitoring of nociception could give a more precise 
and objective estimation of the pain level an animal is experiencing. When a 
nociceptive message is triggered by an external stimulus and transmitted to 
the CNS, it activates a wide series of molecules from the nervous and 
inflammatory systems (Julius and Basbaum, 2001; Scholz and Woolf, 2002). 
These are all products of genes, or are substrates for proteins, which are 
encoded by genes. In postoperative phases or longer lasting inflammations, 
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the painful sensation lasts longer and it seems possible that gene expression 
changes occur to maintain the noxious signal’s transmission and integration, 
at the various “checkpoints” of the nervous system: the periphery, the DRG, 
the spinal cord, and within the brain. 
 
Transgenic technology has made it possible to suppress the expression of 
specific genes in animals, and the studies of knockout mice have indicated 
mutation or suppression of certain genes can facilitate or inhibit behaviors 
related to pain (Lacroix-Fralish et al., 2007). These genes therefore probably 
play an essential role in the generation and transmission of a nociceptive 
signal. Considering this information, it seems possible, that some of those “pain 
genes” undergo expression changes, which are essential to maintain longer 
lasting painful sensation. These expression changes could be measured with 
microarrays in the brain, the spinal cord, or in the DRGs and could give an 
objective way to monitor nociception in various lasting pain models. 
 
 
1.5.2 Aims of the project 
 
This project had the following goals: 
 
• The establishment of a database of the commonly known pain genes. 
- Scanning of the literature on knockout animals and systemic 
applications to find the most potent candidate genes involved in 
nociception, fear and anxiety. 
- Establishment of a database of these genes. 
 
• The establishment of a microarray for the analysis of these genes in the 
CNS, which could possibly be used as a diagnostic tool for nociception 
and pain. 
- Define RNA extraction and labeling protocols for the optimal study 
of gene expression in the CNS. 
- Design probes, spotting and hybridization conditions for the 
microarray analysis of these genes. 
- Define normalizations and data acquisition procedures for the 
interpretation of the results 
 
• The validation of the microarray protocol for the analysis of the genes in 
the CNS, by comparing the results obtained in published data. 
- Perform hybridization reactions with various parts of the CNS. 
- Search literature and microarray databases to find data to validate 
the gene expression changes observed 
 
• Measurements of gene expression changes in the CNS between 
animals in pain and control animals 
- Perform hybridization reactions with various parts of the CNS of mice 
in the telemetric apparatus implantation pain model to detect gene 
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expression changes characteristic of nociception in each of these 
parts. 
 
• Validation of the data by Real-Time PCR 
- Establish Real-Time PCR conditions for an optimal high throughput 
analysis of the set of genes, which showed differential expression in 
the surgical pain model in each analyzed part of the CNS. 
- Compare the behavior of these genes in similar parts of the CNS in 
mice, which underwent the BHV1-immunization, characteristic of an 
inflammatory pain model. 
 
• Discover new genes, which might be linked to nociception. 
- Perform a microarray analysis in the CNS at the exon level using 
Affymetrix GeneChip® Mouse Exon 1.0 ST Arrays to detect new 
candidate genes, which show gene expression level changes, or 
alternative splicing modifications linked to the surgical pain model. 
- Define the main new functional categories of genes, which could be 
possibly used to monitor nociception. 
 
 
1.5.3 Relevancy of the project for animal welfare 
 
Laboratory animals are widely used in research for experiments, which require 
painful surgical procedures. Moreover, pain must be considered as an 
important aspect in research on topics such as inflammation, cancer or 
infectious diseases.  This can be problematic from an experimental point of 
view, as pain can influence the data observed, but most importantly, it is 
important that efforts are taken to minimize the animal’s suffering during the 
experiment. Russel and Burch were the first researchers to focus on laboratory 
animal welfare issues. In their studies from 1952, they defined inhumanity in 
animal experiments, by grading the level of distress the animals were 
subjected to. Their work was the stepping stone of the 3R principles: replace, 
reduce and refine. These rules are still internationally recognized and applied 
in animal research. In that sense, pain assessments in laboratory animals are 
very important to ensure that an experiment is not causing some unnecessary 
suffering to an animal. It is also essential to be able to clearly monitor pain, in 
order to ensure that stress and pain do not bring bias to the data. For 
instance, the activation of the nociceptive system could modify the outcome 
of studies on the central nervous system, as it modifies the neuronal activity. 
Classical methods for pain assessment such as blood corticosterone 
measurements imply some extra handling of the animal, which can add 
some extra stress to the animal and further bias the data (Enthoven et al., 
2008; Schmidt et al., 2005). Other methods for pain assessments require 
behavioral tests performed on cohorts of animals, which cannot be 
performed routinely during a health check of each animal (Schaefer et al., 
2009). It is therefore necessary to develop new diagnostic tools to monitor 
pain animals. The analysis of the physiological processes underlying 
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nociception offers a potent new way to assess pain in laboratory animals. 
However, methods like electrophysiology or patchclamp (Caterina et al., 
1997; Djouhri et al., 1998; Priest et al., 2005) demand quite elaborate settings 
and skills, and can therefore not be used in every day diagnostics. 
 
Mice show moderate behaviors, which might indicate that they are 
experiencing pain. This feature is an advantage for them to survive in their 
natural environment, however it renders the assessment of pain very difficult in 
an experimental setting. Current methods to monitor pain in research facilities 
rely on observations of the animals and scoresheets annotations, which give 
variable results from one observer to the other. Moreover, mice will hide their 
suffering even more, when an observer is in the room. Another way to assess 
stress and possibly pain is the measurement of blood corticosterone levels 
(Enthoven et al., 2008; Schmidt et al., 2005). However, this method presents 
the disadvantage of requiring a handling of the animals, which induces some 
additional stress and ultimately biases the results. 
 
Monitoring nociception analyzing gene expression changes in the CNS could 
provide some valuable information on the level of pain experienced by an 
animal. A microarray analysis, or a series of Real-Time PCR reactions on the 
appropriate pain genes could be performed on sentinel animals routinely 
before starting a procedure. This could indicate the pain severity for the 
animal, and appropriate analgesic measures could then be applied. 
Moreover, this technique could also be used to monitor the possible level of 
pain experienced by a transgenic animal, because of the specific mutation 
or gene deletion it carries. It would allow researchers to take appropriate 
measures to reduce the suffering of this animal and would therefore 
contribute greatly to animal welfare. 
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2. Results 
 
2.1 Low density microarray design 
 
In order to analyze gene expression changes linked to nociception in the 
central nervous system of mice, we established a low-density microarray. 230 
genes were selected according to their relevancy in pain research. The 
genes had been previously characterized as inducing behaviors 
characteristic of pain in transgenic animals mouse models in which these 
genes were either knocked out or overexpressed. Half of the genes we had 
chosen to study were also listed in a known pain gene database established 
by Prof. J. Mogil’s group in Montreal, Canada (Lacroix-Fralish et al., 2007). The 
other half consisted in genes associated to stress. The various categories of 
genes we chose to analyze are listed in table 1. A more detailed list, 
containing each gene’s name and described function, as well as their 
identifier on the microarray, their accession numbers, and relevant literature 
references can be found in Appendix 1. 
 
 
Table 1: Sum up of the genes, which were included in the study and spotted on the microarray. The 
genes are grouped by function. The positive control genes and the spikes genes were used for 
normalization purposes. The negative control genes were used to control the relevancy of the 
hybridization protocols. 
 
Gene Family Number of genes Examples 
Receptors 97 GABA receptors, Glucocorticoid receptor, 
Opioid receptors, Serotonin receptors 
Signal Transduction 29 Phospholipase C Gamma, MAP kinases, JNK... 
 
Neuropeptides 13 Enkephalin, Neuropeptide Y, Tachykinin… 
 
Oxidative Stress 6 Cytochromes… 
 
Hormone related genes 4 Adrenocorticotropic hormone, Corticotropin 
releasing hormone binding protein... 
Neurotrophins 3 NGF, BDNF… 
 
Heat shock 4 HSP 27, HSP 72… 
 
Channels 3 Sodium channel type IX, Calcium channel P/Q 
type alpha 1 
Cytokine-related genes 14 Interleukin 10, Interleukin 4… 
 
Others 26 Steroidogenic Factor 1, Nociceptin, DREAM… 
 
Positive controls 19 Tubulin, Beta Actin… 
 
Negative controls 11 Bacterial genes, non-genomic randomly 
generated sequences 
Spikes 8 Specific non-genomic sequences used later for 
normalization 
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Two types of controls were used for our microarray study. The negative 
controls were sequences, which are not expressed in the murine central 
nervous system such as bacterial gene or randomly generated sequences. 
The positive control genes were ubiquituously expressed (for example: Beta 
Actin). These genes were expected to have a high signal, and could be used 
for orientation purposes as well as to monitor the quality of the hybridization 
reactions.  
 
The slide went through 3 optimization phases. In all designs, the 70-mer 
oligonucleotide sequences were spotted in triplicates over 4 blocks. Each 
block was spotted in duplicates in order to have 6 replicates per gene to 
ensure statistical robustness. The first slide design can be seen in Appendix 2. 
This version contained only 218 genes. Spots containing Cy3 or Cy5 solely (dye 
control spots) and empty spots of 3x SSC were used as scanning and 
orientation controls.  In the second design, the spots containing only the dyes 
were not spotted anymore, to minimize risks of dye carry over during spotting. 
The positive and negative controls were spotted in the first and last column, 
as well as in the two middle columns of each block. For orientation purposes, 
a positive control was spotted at the beginning of each block, followed by 3x 
SSC. The end of each block contained only 3x SSC. Each block’s asymmetry 
allowed a quick slide orientation of the slide after scanning. A scheme of the 
second slide design can be seen in Appendix 3. The third design was used for 
the experiments on parts of the central nervous, and for the validation of the 
one color hybridization protocol. This batch of slides was spotted with a 
Genetix contact printer, which allows a fast and reliable slide printing. The 
spots were spotted horizontally over the blocks, and not in a standard 
increasing order. This new shuffling separated genes of similar families on 
different blocks, to ensure that high signals from a certain family of genes 
were indeed due to each gene, and not to a spotting carry over from one 
specific member of the family. For blocks 1 and 3, positive controls were 
spotted in the first and the last lines, as well as in the middle of the blocks next 
to a line of negative controls. On the other hand, for blocks 2 and 4, negative 
controls in were spotted in the first and the last lines along with 3xSSC, as well 
as in the middle of the blocks next to a line of positive controls. The spikes 
were spotted on the fifth line of the first 2 blocks; the last 2 blocks had 3xSSC 
spotted instead. Appendix 5 shows graphically how this slide was designed. 
 
 
2.2 Whole brain microarray experiments 
 
The first set of experiments we performed consisted in analyzing gene 
expression changes related to nociception in the whole brain of mice. Three 
NMRI mice were anesthetized with Sevofluorane and underwent a telemetric 
apparatus implantation, after which they were treated twice daily with an 
intraperitoneal injection of Flunixin. As controls, 3 NMRI mice underwent the 
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same anesthesia and analgesia protocol but did not undergo any surgery. 
After two days, the mice were sacrificed. Their brains were dissected out, and 
the RNA was extracted, amplified and labeled for microarray hybridization. 
This analysis was carried out on the first design of the microarray. Figure 1 
shows the scanned slides. On each slide a competitive hybridization was 
carried out: the brain antisense RNA (aRNA) of interst was labeled with Alexa-
555 and a Reference mouse brain aRNA, which was identical between each 
slide was labeled with Alexa-647. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Scanned slides of the whole brain experiment.  The slides had been spotted 
according to the first chip design. Animals 18, 19 and 20 were operated and treated 
with analgesia. Animals 23, 24, and 25 underwent the same anesthetic and analgesic 
treatment, with no surgery. On each slide, the brain aRNA of interest is labeled with 
Alexa-555 and the reference mouse brain aRNA was labeled with Alexa-647. The 
hybridization quality was good with very little background, well-formed spots, and 
comparable intensity between triplicates of the same gene. On all slides, most spots 
appear yellow, suggesting little expression changes between the analyzed brains and 
the reference brains.  
 
 
For each slide, scatter plots representing the raw signal intensities in the brain 
of interest in function of the reference mouse brain signals were calculated 
(Figure 2). On all slides, the Alexa-555 signals were generally stronger than the 
Alexa-647 ones, especially for the genes, which had low expression levels. 
Graphically, each scatter plot was shifted towards the Y-axis representing the 
Alexa-555 signals. All scatter plots of the raw signals were narrow, and did not 
indicate big expression changes between the analyzed brains and the 
reference brains. As expected, the Cy3 and Cy5 signals from the dye control 
spots were each located on the appropriate side of the scatter plot, but not 
in a symmetrical way. Both spots had a signal of approximately 105 in the 
appropriate channel. The Cy3 spot had a residual signal of 100 in the red 
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channel, whereas the residual green signal for the Cy5 spot was of about 
1200. This once again indicated a general dye imbalance, with general 
higher green signals. An analysis of variance (P Value = 0.1) was performed to 
compare the gene expression changes between the 3 operated animals and 
the 3 control ones. No gene passed the test, and therefore, no significant 
gene expression changes could be observed on the raw signals between the 
brains of the operated animals and the brains of the control animals. 
 
Locally weighted scatter plot smoothing, or Loess, combines linear least 
square regression with non-linear regression. The advantage of this function is 
that it normalizes each points of a curve independently, to fit the curve of 
highest density. It is therefore commonly used as a normalization tool to 
correct dye imbalances or printing biases, which affect mostly genes with low 
signal in microarray data. We also applied Loess normalization, which did alter 
the dye imbalance, and aligned the scatter plots on the midline. However, 
the asymmetry between the Cy3 and Cy5 control spots remained identical as 
for the raw values, suggesting that this normalization was not robust enough 
to completely overcome the general higher green signal. The normalized 
scatter plots can be seen on Figure 3. As for the raw values, an analysis of 
variance was performed to compare the gene expression changes between 
the 3 operated animals and the 3 control ones.  In that case too, no 
significant gene expression changes could be observed when analyzing the 
normalized values. 
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Figure 2: Scatter plots comparing of the Alexa-555 labelled brain of interest’s raw signals in function 
of a reference brain aRNA raw signal. Brains 18, 19, and 20 were dissected from operated mice, and 
brains 21, 22, 23 were from control animals. The scatter plots are asymmetric, with a general higher 
green signal. This effect particularly affects the genes with signals lower than 1000. This can be seen 
by a shift of the plot towards the Y-axis, and a higher residual green signal for the Cy5 control spot 
than the residual red signal for the Cy3 control spot. 
 
 
Results 
 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Scatter plots comparing of the Alexa-555 labelled brain of interest’s normalized signals in 
function of a reference brain aRNA normalized signal. Brains 18, 19, and 20 were dissected from 
operated mice, and brains 21, 22, 23 were from control animals. The Loess normalization partially 
corrected the dye imbalance. The scatter plots are aligned on the midline. However, the residual 
green signal of the Cy5 spot still remains higher than the residual green signal of the Cy3 spot. This 
suggests, that the dye imbalance has not been completely corrected by the Loess normalization. 
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Equal amounts of brain 19 aRNA labeled with Alexa-555 and reference brain 
aRNA labeled with Alexa-647 were hybridized on one slide spotted according 
to the first version of the microarray.  On another slide from the same batch, 
the same amounts of Brain 19 aRNA labeled with Alexa-647 and reference 
brain aRNA labeled with Alexa-555 were hybridized. The only difference 
between the two hybridization reactions was the dye swap between the 
samples. Scatter plots of the raw data were established and indicated a 
general higher green signal on both slides, evidenced by a dissymmetry 
between the Cy3 and Cy5 spots (Figure 4). The scatter plots were shifted 
towards the Y-axis on which the green signals were scaled, regardless of 
whether it represented aRNA derived from Brain 19 or from the reference 
mouse brain. This proves that the shift towards the Alexa-555 signals is due to a 
dye imbalance, and not to a biological event, which leads to a general 
higher gene expression in one sample. 
 
 
 
 
 
 
 
Figure 4: Dye swap experiment. A competitive hybridization of brain 19 aRNA and 
reference aRNA was performed twice on identical slides. The dyes used for the aRNA 
labeling were however swapped between these two hybridizations. On scatter plot A, 
illustrating the first hybridization, the Brain 19 aRNA was labeled with Alexa-555, and the 
reference brain aRNA was spotted with Alexa-647. On scatter plot B, illustrating the second 
hybridization, the reference brain aRNA was labeled with Alexa -555 and the Brain 19 aRNA 
was labeled with Alexa-647. Both plots show an asymmetry between the Cy3 and Cy5 
spots, as well as a shift towards the Alexa-647, regardless of which sample was labeled with 
this dye. This general higher green signal is therefore caused by a dye imbalance, and not 
by a biological regulation. 
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2.3 Microarray experiments with specific regions of the central 
nervous system  
 
In order to have a refined analysis of the genetic regulation processes linked 
to nociception, we decided to carry a further analysis on parts the central 
nervous system. To bypass the dye imbalance we observed in previous 
experiments, and the difficulties linked to the statistical normalization of a low 
number of genes, we developed a hybridization protocol for single samples 
labeled with Cy5. The normalization was based on a set of ubiquitously 
equally expressed positive control genes, and consisted in bringing the signals 
of this set of genes at equal levels, and further normalize the other genes 
accordingly. In this experiment, the operated mice underwent the same 
surgical and analgesic protocol as previously described, and the 3 control 
animals underwent the same anesthetic and analgesic protocol as the 
operated animals.  After a recovery of 2 days, the animals were sacrificed, 
and the brainstem, the cerebellum, the hippocampus, the cortex and the 
spinal cord of each animal were dissected, the RNA extracted, and the 
mRNA amplified into aRNA, that was labeled with Cy5 for hybridization.  After 
hybridization, each part of the brain was analyzed separately. We analyzed 
the raw data, as well as the data normalized according to the set of positive 
genes spotted on our slide. For each part of the central nervous system, 
scatter plots were established, and the genes were filtered on a volcano plot. 
This method consists in plotting the genes according to their fold change 
between the 2 conditions, and their p=values. It is then possible to screen the 
genes according to their significance and their fold change expression 
difference. We selected the genes, which had a P Value lower than 0.05 and 
the fold change higher than 1.5 in one condition or another.  
 
2.3.1 Microarray results in the cortex  
 
In the cortex, no genes could be filtered, either on the raw values or on the 
normalized values. In both cases, the scatter plots were aligned on the 
midline, with no significant genes showing a high fold change towards one 
condition or the other. The scatter plots and the volcano plots can be seen 
on Figure 5. 
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Figure 5: Scatter plots and volcano plots of the genes expression levels changes measured in the cortex. 
The scatter plots are narrow, aligned on the midline and show no significant difference between the 3 
operated animals and the 3 contol ones, both on the raw and normalized values. After a filtering on a 
volcano plot, no genes have a P Value < 0.05 and a fold change > 1.5. 
 
2.3.2 Microarray results in the brainstem 
 
In the brainstem, the comparison between the animals, which had 
undergone surgery and the 3 animals, which served as controls revealed 
some significant gene expression level differences. Both the scatter plots of 
the raw and normalized values showed no general shift towards one 
condition (Figure 6). The filtering on a volcano plot of the raw signals unveiled 
only one gene, which was 1.5 times more expressed in the animals, which had 
endured pain (Table 2a). This gene is the Neuropeptide Y receptor type 5. The 
same analysis on the normalized signals revealed that 6 genes had a P Value 
lower than 0.05 and were more than 1.5 times downregulated in the 
operated animals (Table 2b).  Two of those genes were however negative 
control genes, which had low expression levels, and were therefore more 
likely to show fold changes, and appear as false positives in such an analysis.  
 
We performed Real-Time PCR measurements of the regulated genes in order 
to confirm the results, however no correlation could be established between 
the microarray measurements and the Real-Time PCR results. The results 
obtained on the microarray are therefore probably due to artifacts. 
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Figure 6: Scatter plots and volcano plots of the genes expression levels changes measured in the 
brainstem. The scatter plots are aligned on the midline and show significant differences between the 3 
operates animals and the 3 control ones, especially on the normalized values. The volcano plots 
confirmed this tendency. The filtering was performed with a P Value < 0.05 and a fold change > 1.5. For 
the raw signals, 1 gene was 1.5 times more expressed in the brainstems of the operated animals. For the 
normalized values, 6 genes were downregulated in the brainstems of the operated animals. 
 
 
 
 
Table 2: Regulated genes in the brainstem filtered on a volcano plot with a P Value < 0.05 and a fold 
change > 1.5.  
 
2a: Filtering performed on raw signals. There is no correlation between the regulation observed on the 
microarray and the Real-Time PCR measurements. 
 
M i c r o a r r a y
CT Operated CT Control Fold Change Fold Change
Neuropeptide Y receptor type 5 (Npy5r)NM_016708 Mean=8.83, STD DV= 0.65Mean=8.87, STD DV=0. 69 1.03 1.5
Real Time PCR
Gene Name Gene ID, NCBI
 
 
 
2b: Filtering performed on normalized signals. There is no correlation between the regulation observed 
on the microarray and the Real-Time PCR measurements. 
 
M i c r o a r r a y
CT Operated CT Control Fold Change Fold Change
Vanilloid-receptor TrpV5 NM_001007572 - - - -1.52
Vanilloid-1 receptor (VR1) Oligo 1 NM_001001445 Mean=6.2, STD DV=0.72 Mean=6.11, STD DV=0.47 -1.07 -1.53
Serotonin receptor: 5-HTr6 NM_021358 Mean=9.32, STD DV=0.41 Mean=9.46, STD DV=0.53 1.1 -1.54
E coli bioA gene E100000750 - - - -1.55
Randomly generated negative control 4 - - - -1.58
Serotonin receptor: 5-HTr4 Oligo 2 NM_008313 Mean=4.69, STD DV=0.20 Mean=4.96, STD DV=0.61 1.2 -1.81
Gene Name Gene ID, NCBI
Real Time PCR
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2.3.3 Microarray results in the cerebellum 
 
The microarray analysis carried out in the cerebellum revealed some 
differences between the signals measured in the operated animals and in the 
control ones. The scatter plots for both the raw and the normalized values 
were aligned on the midline. The spots appeared quite spread between the 2 
fold lines indicating that some regulations were present, especially for the 
normalized values. However, the volcano plot of the normalized values 
showed that most genes have a high P value. This compromised the 
significance of the regulations observed (Figure 6). We filtered both the raw 
and the normalized signals on their respective volcano plots, to select the 
genes, which have a fold change higher than 1.5 in one condition or another, 
and a P value lower than 0.05. On the raw values (Table 3a), 15 genes 
showed a regulation, amongst which 13 were upregulated, and 2 were 
downregulated in the operated animals. For the normalized values (Table 3b), 
only one gene showed a differential expression:  the Neuropeptide Y receptor 
type 6, which was 5.5 times more expressed in the animals which endured 
pain. 
 
We performed Real-Time PCR measurements of most of those genes, to 
possibly confirm the gene expression changes we had observed either on the 
raw signals or on the normalized ones. None of the regulations could also be 
seen in the Real-Time PCR analysis. The gene regulations we observed in the 
cerebellum were therefore not reproducible. 
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Figure 6: Scatter plots and volcano plots of the genes expression levels changes measured in the 
cerebellum. The scatter plots are aligned on the midline and quite widely spread, which tends to 
indicate differences between the 3 operated animals and the 3 control ones, especially. However, the 
volcano plots showed that the P Value of most genes was high, which indicated that the changes 
observed were not significant. The filtering was performed with a P Value < 0.05 and a fold change > 
1.5. For the raw signals, 15 genes were regulated by nociception in the cerebellum. For the normalized 
values, only one gene was regulated in the cerebellum of the operated animals. 
 
 
 
Table 3: Regulated genes in the cerebellum filtered on a volcano plot with a P Value < 0.05 and a fold 
change > 1.5.  
 
3a: Filtering performed on raw signals. There is no correlation between the regulations observed on the 
microarray and the Real-Time PCR measurements. 
 
M i c r o a r r a y
CT Operated CT Control Fold Change Fold Change
Neuropeptide Y receptor type 5 (Npy5r) NM_016708 Mean=11.98, STD DV= 0.27Mean=12.09, STD DV=0. 11 1.08 4.01
Randomly generated negative control 4 - - - 2.31
MAP kinase 1 (=Erk2) NM_011949 Mean=4.81, STD DV= 0.34Mean=5.03, STD DV=0.38 1.17 2.13
Somatostatin receptor 1 NM_009216 - - - 2.01
Sodium- and chloride-dependent GABA 
transporter 1
NM_178703
Mean=4.06, STD DV=0.66 Mean=3.93, STD DV=0.61 -1.09 1.97
Guanine nucleotide binding protein, alpha 0 NM_010308 Mean=2.97, STD DV=0.34 Mean=3.03, STD DV=0.28 1.04 1.96
Nerve Growth Factor alpha (NGF) NM_010915 Mean=3.57, STD DV=0.25 Mean=3.25, STD DV=0.37 -1.25 1.81
Alpha-2C adrenergic receptor NM_007418 Mean=7.61, STD DV=0.46 Mean=7.79, STD DV= 0.54 1.13 1.77
F2rl2 NM_010170 - - - 1.66
Vanilloid-1 receptor (VR1) Oligo 1 NM_001001445 Mean=1.58, STD DV=0.33 Mean=1.69, STD DV=0.21 1.08 1.61
Cytochrome P450 21A1 (CYP21a1) NM_009995 - - - 1.57
NMDA-receptor NMDA1 NM_008169 Mean=8.41, STD DV=0.62 Mean=8.56, STD DV=0.75 1.11 1.57
Serotonin receptor: 5-HTr4(e) Y09588 Mean=10.29, STD DV=0.57Mean=10.34, STD DV=0.42 1.03 1.54
Creb3 NM_013497 Mean=3.15, STD DV=0.29 Mean=3.03, STD DV=0.09 -1.09 -1.66
Proopiomelanocortin NM_008895 Mean=6.82, STD DV=0.13 Mean=7.24, STD DV=0.18 1.34 -1.69
Gene Name Gene ID, NCBI
Real Time PCR
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3b: Filtering performed on normalized signals. There is no correlation between the regulations observed 
on the microarray and the Real-Time PCR measurements. 
 
M i c r o a r r a y
CT Operated CT Control Fold Change Fold Change
Neuropeptide Y receptor type 6 (Npy6r) NM_010935.3 Mean=4.04, STD DV= 0.23Mean=4.2, STD DV=0. 47 1.11 5.543
Gene Name Gene ID, NCBI
Real Time PCR
 
 
2.3.4 Microarray results in the hippocampus 
 
In the hippocampus, the quality of the hybridization was good as evidenced 
by the scatter plots, which were aligned on the midline and did not show a 
general shift towards one condition (Figure 7). The volcano plot of the raw 
signals however revealed that no genes had a fold change higher than 1.5, 
and a P value lower than 0.5. The same filtering was carried out on the 
normalized values, and the only gene, which satisfied the criteria, was a 
negative control gene (randomly generated negative control 4), which was 
2.2 times more expressed in the hippocampi of the operated animals. This 
gene was obviously a false positive, therefore, no significant gene expression 
differences linked to nociception could be observed in the hippocampus. 
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Figure 7: Scatter plots and volcano plots of the genes expression levels changes measured in the 
hippocampus. The scatter plots were aligned on the midline and showed no significant difference 
between the 3 operated animals and the 3 control ones, both on the raw and normalized values. After 
a filtering of the raw signals on a volcano plot, no genes had a P Value < 0.05 and a fold change > 1.5. 
The same filtering applied to the normalized values revealed one false positive gene, which was 2.2 
times more expressed in the operated animals: the randomly generated negative control 4. Therefore, 
no real significant differences could be observed. 
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2.3.5 Microarray results in the spinal cord 
 
 
 
Figure 8 : Scatter plots and volcano plots of the genes expression levels changes measured in the spinal 
cord. The scatter plots show a lot of genes with signals below 10. These spots are more subject to local 
background variation, or to biases linked to aRNA amplification from low amounts of total RNA. This 
appears on the scatter plots as a shift towards one condition or the other for the low intensity genes, 
and a general flat aspect of the plots, which cannot be corrected with a normalization procedure. A 
filtering on the volcano plots was nevertheless performed, and showed that 6 genes had a raw signal 
which were at least 1.5 times downregulated in the operated animals and a P Value lower than 0.05. 
For the normalized values, 3 genes showed the same features. 
 
 
A microarray analysis was carried out on the lumbar part of the spinal cord. 
The scatter plots revealed that the quality of the hybridizations was not 
optimal. The signals were in the same range as in the other parts of the 
central nervous system, with the highest values approaching 105, however 
most of the signals of the signals below 100 appeared very spread towards 
one condition or the other. This tendency does not disappear after 
normalization. The amount of total RNA extracted from the spinal cord was in 
average 10 times lower than in the other parts of the CNS. The genes, which 
had a low expression levels, might have therefore not been sufficiently 
amplified. This could explain the variability in the low signals. The hybridization 
quality was however good with little background. A filtering on volcano plot 
was performed to see if some significant changes could be observed. As 
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previously, we selected the genes, which have a fold change higher than 1.5, 
and a P Value lower than 0.05. The scatter plots and the volcano plots can be 
seen on Figure 8. When analyzing the raw signals, 6 genes appeared highly 
downregulated in the spinal cords of the operated animals, with fold changes 
ranging from -245 to -1488. When considering the normalized values, only 3 
genes show a significant downregulation ranging from -18 to -62 (Table 4). 
However, one has to consider, that these genes had very low signals ranging 
between 0 and 10, and could have been subjected to variability linked to 
aRNA amplification or background. Because of the critical amount of total 
RNA and the low signals of the genes, no Real-Time PCR measurements were 
performed to verify these results. 
 
 
Table 4: Regulated genes in the spinal cord filtered on a volcano plot with a P Value < 0.05 and a fold 
change > 1.5.  
 
4a: Filtering performed on raw signals.  
 
Gene Name Gene ID, NCBI 
Fold change in Pain 
Microarray 
ribosomal protein L13 (Rpl13) NM_016738 -245.10 
Endothelin receptor B NM_007904 -436.68 
Serotonin receptor: 5-HTr6 NM_021358 -564.97 
MAP kinase 1 (=Erk2): mitogen-activated protein NM_001038663 -1408.45 
Vanilloid receptor-like protein 1 (VRL-1), TrpV2 NM_011706 -1470.59 
Peroxisome proliferator activated receptor delta NM_011145 -1488.10 
 
4b: Filtering performed on normalized signals. There is no correlation between the regulations observed 
on the microarray and the Real-Time PCR measurements. 
 
Gene Name Gene ID, NCBI 
Fold change in Pain 
Microarray 
GAPDH NM_008084 -18.349 
Opioid receptor sigma 1 (Oprs1) NM_011014 -25.381 
Opioid receptor kappa 3 isoform B (Kor3B) AF043277 -61.728 
 
 
2.4 Microarray protocol validation 
 
Given the lack of significant reproducible results of the microarray 
experiments comparing parts of the central nervous system between 
operated mice and control ones, we decided to see if some significant results 
could be observed using the same microarray protocol in another 
experiment. For the 3 NMRI mice, which had not been operated, we 
analysed the expression levels of our set of genes between the brainstem, the 
cortex, and the hippocampus using the same slides and the same 
hybridization protocol with samples labeled with Cy5 solely. As previously, the 
raw and normalized data were filtered on a volcano plot, to select only the 
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genes, which were 1.5 times more expressed in one part of the brain, and had 
a P value lower than 0.05. The results we obtained were than compared with 
the ones obtained by Hovatta (Hovatta et al., 2005). In their study, they have 
assessed the expression profiles of the whole genome in parts of the central 
nervous sytem of 6 inbred mice strains: 129S6/SvEvTac, A/J, C3H/HeJ, 
C57BL/6J, DBA/2J, and FVB/NJ. They have worked with Affymetrix Murine 
Genome U74 Version 2 Arrays, and their results are stored in the GEO dataset, 
under the following ID number: GDS1406. 
 
2.4.1 Brainstem against cortex hybridizations 
 
This experiment consisted in comparing the expression levels of our set on 
genes in the brainstems and the cortex of the 3 control mice. The scatter plots 
of the signals were well aligned on the midline, with some genes showing a 
significant regulation in the cortex or the brainstem. The normalized values 
were also well aligned, but tended to show more regulations. Like in the 
previous experiment, the significant genes were filtered on volcano plots for 
both the raw, and the normalized values (Figure 9). Only the genes, which 
showed a 1.5 times regulation in either parts of the brain, and had a P Value 
of 0.05, were kept. When considering the raw values, 11 genes were 
significantly regulated, and when considering the normalized values, 6 genes 
were regulated (Table 5). There was one obvious false positive gene among 
the 11 regulated genes filtered from the raw signals: the randomly generated 
negative control 4. Four genes appeared to be regulated both on the raw 
signals and the normalized ones: the Proteinase-activated receptor 1 and the 
Heat Shock Protein 70kD, which were more expressed in the Brainstem, and 
Egr1, and Neuropeptide 1, which were more expressed in the Cortex.  
 
. 
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Figure 9: Scatter plots and volcano plots comparing the expression levels on the 230 genes of interest in 
the cortex and in the brainstem of 3 unoperated NMRI mice. The scatter plots of both the raw and the 
normalized signals showed genes, which were more regulated in one part of the brain. The volcano 
plots were used to filter the genes, which had a 1.5 times or higher signal in one part of the brain, and a 
P Value lower than 0.05. 11 genes were significantly differentially expressed according to the raw 
signals, and 6 genes were significantly differentially expressed according to the normalized values. 
 
 
2.4.1.1 Brainstem against cortex hybridizations, raw signals comparisons 
 
To assess the relevance of our results, we checked whether the differential 
expressions, which we had observed between the brainstem and the cortex, 
could also be observed in the GEO set n°: GDS1406. We compared the fold 
changes observed in our experiments with the fold changes of these genes 
reported for each of the 6 analyzed strains in the GDS1406. 
 
The comparisons with of our raw microarray data with the GDS1406 results for 
the 129S6/SvEvTac, C3H/HeJ, C57BL/6J and DBA/2J strains were similar. Out of 
the 11 differentially expressed genes observed in our microarray analysis of 
the raw signals, 7 showed a similar expression profile in the GDS1409 GEO set, 
3 showed a different expression pattern, and 1 was a false positive (randomly 
generated negative control 4), Therefore, the proportion of regulated genes, 
which showed a similar behavior on both platforms, was 64%, when 
comparing our raw results obtained with NMRI mice with the GDS1406 data of 
either one of the 4 strains mentioned above. In the comparisons with 
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129S6/SvEvTac, C57BL/6J and DBA/2J, the 3 genes, which showed different 
regulations between our microarray results and the GDS1409 data set, were 
Proopiomelanocortin, the 5-HTr5B serotonin receptor, and Neurotrophin-3. In 
comparisons with C3H/HeJ the 3 genes, which behaved differently on the 
two platforms were Proopiomelanocortin, the Heat-Shock protein 70kD, and 
Neurotrophin-3. 
 
In the comparisons of our raw microarray signals with the GEO datasets of the 
A/J and the FVB/NJ strains, 8 genes showed a similar behavior on both 
platforms, 2 showed a different behavior, and one was a false positive, 
(randomly generated negative control 4), for which no data could be found 
in the GEO data base. Therefore, in these 2 comparisons, the proportion of 
genes, which showed a similar behavior on both platforms is 73%. In the 
comparison with the A/J strain, the 2 differently regulated genes were 
Proopiomelanocortin, and Neurotrophin-3. In the comparison with the FVB/NJ 
strain, the 2 differently regulated genes were the 5-HTr5B serotonin receptor, 
and Neurotrophin-3.  The comparisons between our raw microarray and the 
GDS1409 data set for each of the 5 analyzed strains are regrouped in Table 5. 
 
 
 
Table 5: Differentially expressed genes between the brainstem and the cortex obtained in the raw data 
microarray analysis. Comparison of the signals and the fold changes of these genes, with their 
expression profiles published on the GDS1406 GEO data sets for 6 inbred strain mice. 
 
a. Comparison with the GDS1406 GEO data set for the 129S6/SvEvTac strain: 64% similarity  
 
 
b. Comparison with the GDS1406 GEO data set for the A/J strain: 73% similarity 
 
 
c. Comparison with the GDS1406 GEO data set for the C3H/HeJ strain: 64% similarity 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem  Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 93.58 108.60 53.11 3.39 2.04 Same
Proopiomelanocortin (POMC) NM_008895 427.3 163.4 31.68 68.25 2.62 0.46 Different
Tyrosine hydroxylase NM_009377 561.4 238.9 671.01 80.08 2.35 8.38 Same
Catechol-O-methyl Transferase (COMT) NM_007744 396 166.3 355.58 108.13 2.38 3.29 Same
Randomly generated negative control 4 25.4 12.44 2.04 No Data
Heat shock protein 70kD protein 5 NM_022310 795.1 407.7 1086.68 636.08 1.95 1.71 Same
Serotonin receptor: 5-HTr5(B) NM_010483 123.6 71.28 26.52 48.89 1.73 0.54 Different
Neurotrophin-3 (NT-3) NM_008742 82.61 50.03 8.41 25.15 1.65 0.33 Different
Serotonin transporter (SET) NM_010484 54.17 33.03 977.44 15.82 1.64 61.80 Same
Egr1 (zif/268) NM_007913 136.1 478.8 13.31 35.13 0.28 0.38 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 1'481 146.56 394.60 0.25 0.37 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem  Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 93.58 33.74 12.63 3.39 2.67 Same
Proopiomelanocortin (POMC) NM_008895 427.3 163.4 77.93 85.18 2.62 0.91 Different
Tyrosine hydroxylase NM_009377 561.4 238.9 329.20 78.32 2.35 4.20 Same
Catechol-O-methyl Transferase (COMT) NM_007744 396 166.3 372.99 171.05 2.38 2.18 Same
Randomly generated negative control 4 25.4 12.44 2.04 No Data
Heat shock protein 70kD protein 5 NM_022310 795.1 407.7 116.83 10.12 1.95 11.54 Same
Serotonin receptor: 5-HTr5(B) NM_010483 123.6 71.28 76.25 51.84 1.73 1.47 Same
Neurotrophin-3 (NT-3) NM_008742 82.61 50.03 5.08 32.04 1.65 0.16 Different
Serotonin transporter (SET) NM_010484 54.17 33.03 743.20 15.50 1.64 47.95 Same
Egr1 (zif/268) NM_007913 136.1 478.8 278.32 2981.00 0.28 0.09 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 1'481 113.01 442.62 0.25 0.26 Same
GDS1406Microarray
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem  Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 93.58 56.67 17.00 3.39 3.33 Same
Proopiomelanocortin (POMC) NM_008895 427.3 163.4 53.22 55.44 2.62 0.96 Different
Tyrosine hydroxylase NM_009377 561.4 238.9 489.09 81.51 2.35 6.00 Same
Catechol-O-methyl Transferase (COMT) NM_007744 396 166.3 321.28 130.31 2.38 2.47 Same
Randomly generated negative control 4 25.4 12.44 2.04 No Data
Heat shock protein 70kD protein 5 NM_022310 795.1 407.7 934.08 791.69 1.95 1.18 Different
Serotonin receptor: 5-HTr5(B) NM_010483 123.6 71.28 45.34 32.80 1.73 1.38 Same
Neurotrophin-3 (NT-3) NM_008742 82.61 50.03 13.07 15.58 1.65 0.84 Different
Serotonin transporter (SET) NM_010484 54.17 33.03 1017.13 11.73 1.64 86.75 Same
Egr1 (zif/268) NM_007913 136.1 478.8 212.54 2994.30 0.28 0.07 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 1'481 92.78 497.32 0.25 0.19 Same
Microarray GDS1406
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d. Comparison with the GDS1406 GEO data set for the C57BL/6J strain: 64% similarity 
 
 
e. Comparison with the GDS1406 GEO data set for the DBA/2J strain: 64% similarity 
 
 
 
f. Comparison with the GDS1406 GEO data set for the FVB/NJ strain: 73% similarity 
 
 
 
 
 
2.4.1.2 Brainstem against cortex hybridizations, normalized signals 
comparisons 
 
As mentioned previously, the filtering on volcano plot of the normalized 
microarray data showed that 6 genes were differentially expressed between 
the cortex and the brainstem (Figure 9). We compared our signals and fold 
changes, with the signals obtained on 6 different inbred mouse strains 
published on the GDS1406 GEO data set. For 5 strains comparison, we 
obtained 100% similarity between the changes observed on the 2 platforms. 
The comparison of our data with the GDS1406 data for C3H/HeJ showed that 
1 of the 6 differentially expressed gene behaved differently on the two 
platforms. This gene is the Heat Shock Protein 70kD. We observed a 1.99 times 
upregulation in the Brainstem, but the GDS1406 dataset reports that the 
expression levels of this gene are identical in the cortex and the Brainstem. 
The list of genes, and the comparisons with the GDS1406 dataset for each 
strain can be seen in Table 6. 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 93.58 55.19 23.49 3.39 2.35 Same
Proopiomelanocortin (POMC) NM_008895 427.3 163.4 44.29 85.72 2.62 0.52 Different
Tyrosine hydroxylase NM_009377 561.4 238.9 348.23 106.01 2.35 3.28 Same
Catechol-O-methyl Transferase (COMT) NM_007744 396 166.3 346.65 129.68 2.38 2.67 Same
Randomly generated negative control 4 25.4 12.44 2.04 No Data
Heat shock protein 70kD protein 5 NM_022310 795.1 407.7 963.94 412.52 1.95 2.34 Same
Serotonin receptor: 5-HTr5(B) NM_010483 123.6 71.28 30.11 49.56 1.73 0.61 Different
Neurotrophin-3 (NT-3) NM_008742 82.61 50.03 5.63 27.20 1.65 0.21 Different
Serotonin transporter (SET) NM_010484 54.17 33.03 916.24 12.93 1.64 70.89 Same
Egr1 (zif/268) NM_007913 136.1 478.8 255.72 2684.78 0.28 0.10 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 1'481 93.76 471.69 0.25 0.20 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 93.58 50.80 19.51 3.39 2.60 Same
Proopiomelanocortin (POMC) NM_008895 427.3 163.4 66.48 63.35 2.62 1.05 Different
Tyrosine hydroxylase NM_009377 561.4 238.9 339.98 102.20 2.35 3.33 Same
Catechol-O-methyl Transferase (COMT) NM_007744 396 166.3 342.20 144.31 2.38 2.37 Same
Randomly generated negative control 4 25.4 12.44 2.04 No Data
Heat shock protein 70kD protein 5 NM_022310 795.1 407.7 895.76 687.02 1.95 1.30 Same
Serotonin receptor: 5-HTr5(B) NM_010483 123.6 71.28 34.65 50.77 1.73 0.68 Different
Neurotrophin-3 (NT-3) NM_008742 82.61 50.03 4.93 33.24 1.65 0.15 Different
Serotonin transporter (SET) NM_010484 54.17 33.03 959.89 9.62 1.64 99.78 Same
Egr1 (zif/268) NM_007913 136.1 478.8 173.78 4276.39 0.28 0.04 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 1'481 106.28 411.50 0.25 0.26 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 93.58 53.62 19.06 3.39 2.81 Same
Proopiomelanocortin (POMC) NM_008895 427.3 163.4 210.88 70.09 2.62 3.01 Same
Tyrosine hydroxylase NM_009377 561.4 238.9 567.42 74.36 2.35 7.63 Same
Catechol-O-methyl Transferase (COMT) NM_007744 396 166.3 327.75 113.75 2.38 2.88 Same
Randomly generated negative control 4 25.4 12.44 2.04 No Data
Heat shock protein 70kD protein 5 NM_022310 795.1 407.7 1013.70 751.74 1.95 1.35 Same
Serotonin receptor: 5-HTr5(B) NM_010483 123.6 71.28 37.59 44.11 1.73 0.85 Different
Neurotrophin-3 (NT-3) NM_008742 82.61 50.03 5.45 15.13 1.65 0.36 Different
Serotonin transporter (SET) NM_010484 54.17 33.03 1085.01 11.62 1.64 93.41 Same
Egr1 (zif/268) NM_007913 136.1 478.8 199.17 3856.58 0.28 0.05 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 1'481 92.44 368.86 0.25 0.25 Same
Microarray GDS1406
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Table 6: Differentially expressed genes between the Brainstem and the Cortex obtained in the 
normalized data microarray analysis. Comparison of the signals and the fold changes of these genes, 
with their expression profiles published on the GDS1406 GEO data sets for 6 inbred strain mice. 
 
a. Comparison with the GDS1406 GEO data set for the 129S6/SvEvTac strain: 100% similarity 
 
 
b. Comparison with the GDS1406 GEO data set for the A/J strain: 100% similarity 
 
 
 
c. Comparison with the GDS1406 GEO data set for the C3H/HeJ strain: 83% similarity 
 
 
 
 
d. Comparison with the GDS1406 GEO data set for the C57BL/6J strain: 100% similarity 
 
 
 
e. Comparison with the GDS1406 GEO data set for the DBA/2J strain: 100% similarity 
 
 
f. Comparison with the GDS1406 GEO data set for the FVB/NJ strain: 100% similarity 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem  Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.45 0.13 55.09 19.43 3.42 2.84 Same
Nerve growth factor-specific tyrosine kinase receptor NTRK2, TrkB NM_008745 0.76 0.38 144.96 5.90 2.02 24.59 Same
Heat shock protein 70kD protein 5 NM_022310 1.14 0.57 1086.68 636.08 1.99 1.71 Same
JNK2 Oligo1 NM_016961 1.68 0.93 573.52 27.97 1.81 20.50 Same
Egr1 (zif/268) NM_007913 0.18 0.67 282.20 4038.20 0.28 0.07 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.53 2.00 146.56 394.60 0.27 0.37 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem  Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.45 0.13 33.74 12.63 3.42 2.67 Same
Nerve growth factor-specific tyrosine kinase receptor NTRK2, TrkB NM_008745 0.76 0.38 116.83 10.12 2.02 11.54 Same
Heat shock protein 70kD protein 5 NM_022310 1.14 0.57 926.55 568.09 1.99 1.63 Same
JNK2 Oligo1 NM_016961 1.68 0.93 516.33 29.78 1.81 17.34 Same
Egr1 (zif/268) NM_007913 0.18 0.67 278.32 2981.00 0.28 0.09 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.53 2.00 113.01 442.62 0.27 0.26 Same
GDS1406Microarray
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem  Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.45 0.13 56.67 17.00 3.42 3.33 Same
Nerve growth factor-specific tyrosine kinase receptor NTRK2, TrkB NM_008745 0.76 0.38 103.07 20.35 2.02 5.06 Same
Heat shock protein 70kD protein 5 NM_022310 1.14 0.57 934.08 791.69 1.99 1.18 Different
JNK2 Oligo1 NM_016961 1.68 0.93 543.09 32.31 1.81 16.81 Same
Egr1 (zif/268) NM_007913 0.18 0.67 212.54 2994.30 0.28 0.07 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.53 2.00 92.78 497.32 0.27 0.19 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.45 0.13 55.19 23.49 3.42 2.35 Same
Nerve growth factor-specific tyrosine kinase receptor NTRK2, TrkB NM_008745 0.76 0.38 171.91 3.42 2.02 50.27 Same
Heat shock protein 70kD protein 5 NM_022310 1.14 0.57 963.94 412.52 1.99 2.34 Same
JNK2 Oligo1 NM_016961 1.68 0.93 545.24 28.49 1.81 19.14 Same
Egr1 (zif/268) NM_007913 0.18 0.67 255.72 2684.78 0.28 0.10 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.53 2.00 93.76 471.69 0.27 0.20 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.45 0.13 50.80 19.51 3.42 2.60 Same
Nerve growth factor-specific tyrosine kinase receptor NTRK2, TrkB NM_008745 0.76 0.38 106.33 7.13 2.02 14.91 Same
Heat shock protein 70kD protein 5 NM_022310 1.14 0.57 895.76 687.02 1.99 1.30 Same
JNK2 Oligo1 NM_016961 1.68 0.93 459.27 30.66 1.81 14.98 Same
Egr1 (zif/268) NM_007913 0.18 0.67 173.78 4276.39 0.28 0.04 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.53 2.00 106.28 411.50 0.27 0.26 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Cortex Brainstem Cortex FC in Brainstem FC in Brainstem of results
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.45 0.13 53.62 19.06 3.42 2.81 Same
Nerve growth factor-specific tyrosine kinase receptor NTRK2, TrkB NM_008745 0.76 0.38 34.50 26.60 2.02 1.30 Same
Heat shock protein 70kD protein 5 NM_022310 1.14 0.57 1013.70 751.74 1.99 1.35 Same
JNK2 Oligo1 NM_016961 1.68 0.93 384.48 23.23 1.81 16.55 Same
Egr1 (zif/268) NM_007913 0.18 0.67 199.17 3856.58 0.28 0.05 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.53 2.00 92.44 368.86 0.27 0.25 Same
Microarray GDS1406
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2.4.2 Hippocampus vs. brainstem hybridizations 
 
The goal of this experiment was to compare the expression levels of the 230 
genes spotted on our chip between the hippocampi and the brainstems of 3 
control animals. For both the raw and the normalized values, the scatter plots 
of signals in these two regions were perfectly aligned on the midline, with 
genes showing regulations in either the brainstem or the hippocampus (Figure 
10). We filtered the signals on a volcano plot to select the genes, which had a 
1.5 higher expression in one part of the brain or the other, and a P Value lower 
than 0.05 (Figure 10). The analysis of the raw signals showed that 10 genes 
satisfied those criteria. Two of these genes had a more than 2 fold 
overexpression in the brainstem: Tyrosine Hydroxylase and the Proteinase-
Activated Receptor 1. The 8 other genes were upregulated in the 
hippocampus. Table 7 contains the genes, which are differentially expressed 
between the brainstem and the hippocampus. The filtering on volcano plots 
of the normalized data showed that 18 genes show different expression levels 
in these two parts of the brain (Figure 10).  Amongst these genes, 5 were more 
expressed in the brainstem, and 13 were more expressed in the 
hippocampus.  
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Figure 10: Scatter plots and volcano plots comparing the expression levels on the 230 genes of interest in 
the hippocampi and in the brainstems of 3 unoperated NMRI mice. The scatter plots of both the raw 
and the normalized signals show genes, which were more regulated in one part of the brain. The 
volcano plots were used to filter the genes, which had a 1.5 times or more higher signal in one part of 
the brain, and a P Value lower than 0.05. The positive genes were highlighted in red. 10 genes were 
significantly differentially expressed according to the raw signals, and 18 genes were significantly 
differentially expressed according to the normalized values. 
 
 
2.4.2.1 Hippocampus against brainstem hybridizations, raw signals 
comparisons 
 
The filtering of the raw signals on the volcano plot revealed that 10 genes are 
differentially expressed between the brainstem and the hippocampus (Figure 
10). The expression profiles of these genes were compared to the expression 
profiles observed in 6 different inbred strains, which were published on the 
GDS 1406 GEO data set. The data we observed had a high similarity with the 
GEO set data. The GDS1406 set on the C3H/HeJ strain had a 100% similarity 
with our data. The results obtained for the 129S6/SvEvTac and the A/J strains 
had 90% similarity with our data. When comparing our data with the GDS1406 
values for the DBA/2J and the FVB/NJ strains, the similarity was 80%, and when 
comparing our data with the results obtained for the C57BL/6J strain, the 
similarity was 70%.  
 
Our results showed that the Proteinase-activated Receptor 1 (PAR1) was 2.16 
times more expressed in the brainstem. A similar observation could only be 
made in one of the strains analyzed in the GDS1406 dataset: C3H/HeJ. In that 
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strain, the PAR1 gene was 1.59 times more expressed in the brainstem than in 
the hippocampus. The five strains analyzed in the GDS1406 dataset showed 
no difference in the expression levels of that gene between these two regions 
of the brain.  
 
In the DBA/2J and the FVB/NJ strains, the GDS1406 dataset reported no 
difference in the expression of the MAPK1 gene between the brainstem and 
the hippocampus. Our microarray results however showed a 1.79 times higher 
expression of that gene in the hippocampus. Additionally to this, our 
measurement made with 2 different oligos for Beta-Actin revealed that the 
expression level of that gene was about 1.85 times higher in the hippocampus 
than in the brainstem. This observation could be confirmed in all the strains 
analyzed in the GDS1406 GEO data set, except in C57BL/6J. In that strain, the 
expression levels of the Beta-Actin gene were identical in the hrainstem and 
in the Hippocampus.  
 
The rest of the 10 genes showed similar expression profiles on both platforms, 
for each strain. The list of differentially expressed genes between the 
brainstem and the hippocampus, their raw signals, and their fold changes on 
both platforms can be seen in Table 7. 
 
 
Table 7: Differentially expressed genes between the brainstem and the hippocampus obtained in the 
raw data microarray analysis. Comparison of the signals and the fold changes of these genes, with their 
expression profiles published on the GDS1406 GEO data sets for 6 inbred mice strains. 
 
a. Comparison with the GDS1406 GEO data set for the 129S6/SvEvTac strain: 90% similarity 
 
 
b. Comparison with the GDS1406 GEO data set for the A/J strain: 90% similarity 
 
 
 
c. Comparison with the GDS1406 GEO data set for the C3H/HeJ strain: 100% similarity 
 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 561.4 228.4 671.005 110.235 2.46 6.09 Same
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 146.6 108.595 84.735 2.16 1.28 Different
Epsin 1 NM_010147 3'550 5'582 1273.095 1904.575 0.64 0.67 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 181.7 325.1 39.03 66.09 0.56 0.59 Same
Actin, beta cytoplasmic (ACTB) Oligo 2 NM_007393 1'562 2'849 199.175 318.235 0.55 0.63 Same
Actin, beta cytoplasmic (ACTB) NM_007393 1'532 2'881 199.175 318.235 0.53 0.63 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 774.8 146.56 476.415 0.47 0.31 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 251.7 765.6 687.6 1734.975 0.33 0.40 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 330.7 1'006 247.115 797.485 0.33 0.31 Same
Protein kinase C, gamma (Prkcc) NM_011102 77.86 304.1 158.59 1532.34 0.26 0.10 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 561.4 228.4 329.195 105.995 2.46 3.11 Same
Proteinase-activated receptor 1 PAR1, F2r NM_010169 316.9 146.6 80.665 73.98 2.16 1.09 Different
Epsin 1 NM_010147 3'550 5'582 1374.355 1821.515 0.64 0.75 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 181.7 325.1 25.785 47.655 0.56 0.54 Same
Actin, beta cytoplasmic (ACTB) Oligo 2 NM_007393 1'562 2'849 134.435 298.595 0.55 0.45 Same
Actin, beta cytoplasmic (ACTB) NM_007393 1'532 2'881 134.435 298.595 0.53 0.45 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 774.8 14.655 169.26 0.47 0.09 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 251.7 765.6 737.605 1887.585 0.33 0.39 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 330.7 1'006 300.995 882.02 0.33 0.34 Same
Protein kinase C, gamma (Prkcc) NM_011102 77.86 304.1 154.3 1443.905 0.26 0.11 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 561.4 228.4 489.085 124.6 2.46 3.93 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 316.9 146.6 138.825 87.49 2.16 1.59 Same
Epsin 1 NM_010147 3'550 5'582 1194.395 1871.445 0.64 0.64 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 181.7 325.1 33.445 40.915 0.56 0.82 Same
Actin, beta cytoplasmic (ACTB) Oligo 2 NM_007393 1'562 2'849 268.94 364.185 0.55 0.74 Same
Actin, beta cytoplasmic (ACTB) NM_007393 1'532 2'881 268.94 364.185 0.53 0.74 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 774.8 92.78 377.62 0.47 0.25 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 251.7 765.6 656.78 1728.635 0.33 0.38 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 330.7 1'006 294.395 824.735 0.33 0.36 Same
Protein kinase C, gamma (Prkcc) NM_011102 77.86 304.1 172.26 1487.21 0.26 0.12 Same
Microarray GDS1406
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d. Comparison with the GDS1406 GEO data set for the C57BL/6J strain: 70% similarity  
 
 
 
e. Comparison with the GDS1406 GEO data set for the DBA/2J strain: 80% similarity 
 
 
 
f. Comparison with the GDS1406 GEO data set for the FVB/NJ strain: 80% similarity 
 
 
 
 
2.4.2.2 Hippocampus against brainstem hybridizations, normalized 
signals comparisons 
 
The low-density microarray analysis of the normalized signals revealed that 18 
genes were differentially expressed between the brainstem and the 
hippocampus (Figure 10). In order to validate this data, we compared these 
observations with the results published for these genes on the GDS1406 GEO 
data sets of 6 inbred mice. The comparisons of the differently expressed 
genes fold changes with the ones published for the either the 129S6/SvEvTac 
or the C3H/HeJ strains revealed 94.4% similarity.  When comparing our results 
with the data observed in A/J mice, the similarity was 88.9%. The comparisons 
of our data with the results measured in the C57BL/6J strain revealed a 
similarity of 83.3%, and when compared with the published results for DBA/2J 
or FVB/NJ, the similarity was 77.8%. 
 
Amongst the 18 differentially expressed genes observed in our analysis, the 
Proteinase-Activated Receptor 1A showed a different expression profile in the 
5 strains analyzed in the GDS1406. According to our results, this gene was 2.28 
times more expressed in the brainstem. The GEO set reported similar 
expression levels of that gene in the brainstem in the hippocampus in all the 
strains, except C3H/HeJ, in which the gene showed a 1.6 times higher 
expression level in the brainstem. This result confirmed the data we observed 
in our microarray for Proteinase-Activated Receptor 1A. 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 561.4 228.4 348.225 75.745 2.46 4.60 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 316.9 146.6 83.415 78.645 2.16 1.06 Different
Epsin 1 NM_010147 3'550 5'582 1156.1 1971.9 0.64 0.59 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 181.7 325.1 37.825 65.025 0.56 0.58 Same
Actin, beta cytoplasmic (ACTB) Oligo 2 NM_007393 1'562 2'849 279.25 284.69 0.55 0.98 Different
Actin, beta cytoplasmic (ACTB) NM_007393 1'532 2'881 279.25 284.69 0.53 0.98 Different
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 774.8 11.585 140.635 0.47 0.08 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 251.7 765.6 415.77 1258.195 0.33 0.33 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 330.7 1'006 199.465 690.82 0.33 0.29 Same
Protein kinase C, gamma (Prkcc) NM_011102 77.86 304.1 119.29 1528.635 0.26 0.08 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 561.4 228.4 339.975 115.885 2.46 2.93 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 316.9 146.6 96.3 98.69 2.16 0.98 Different
Epsin 1 NM_010147 3'550 5'582 1384.6 1776.96 0.64 0.78 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 181.7 325.1 41.53 45.09 0.56 0.92 Different
Actin, beta cytoplasmic (ACTB) Oligo 2 NM_007393 1'562 2'849 152.22 229.22 0.55 0.66 Same
Actin, beta cytoplasmic (ACTB) NM_007393 1'532 2'881 152.22 229.22 0.53 0.66 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 774.8 106.275 454.915 0.47 0.23 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 251.7 765.6 501.13 1953.865 0.33 0.26 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 330.7 1'006 227.415 808.79 0.33 0.28 Same
Protein kinase C, gamma (Prkcc) NM_011102 77.86 304.1 199.1 1526.41 0.26 0.13 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 561.4 228.4 567.42 122.20 2.46 4.64 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 316.9 146.6 94.69 94.70 2.16 1.00 Different
Epsin 1 NM_010147 3'550 5'582 1281.36 1665.97 0.64 0.77 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 181.7 325.1 35.89 39.00 0.56 0.92 Different
Actin, beta cytoplasmic (ACTB) Oligo 2 NM_007393 1'562 2'849 243.38 359.20 0.55 0.68 Same
Actin, beta cytoplasmic (ACTB) NM_007393 1'532 2'881 243.38 359.20 0.53 0.68 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 364 774.8 92.44 414.08 0.47 0.22 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 251.7 765.6 540.14 2104.34 0.33 0.26 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 330.7 1'006 228.06 730.55 0.33 0.31 Same
Protein kinase C, gamma (Prkcc) NM_011102 77.86 304.1 169.36 1683.14 0.26 0.10 Same
Microarray GDS1406
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In the low-density microarray normalized results, the Heat Shock Protein 70kD 
showed a 1.57 times higher expression in the brainstem. The same observation 
was made in the GDS1406 dataset of the129S6/SvEvTac strain. However, in 
the other 5 strains from that data set, the gene was almost equally expressed 
in these two parts of the brain. 
 
Our microarray contained 2 different oligos to measure 2 transcripts variants 
of the MAP Kinase 1. Our results showed a consistent 1.69 times higher 
expression of both MAP Kinase 1 transcript variants in the Hippocampus. This 
observation could be confirmed in the GDS1406 GEO data set for the 
129S6/SvEvTac, A/J and C3H/HeJ strains. However, in the 4 remaining strains, 
this gene was equally expressed in the hippocampus and the brainstem. 
 
The GDS1406 dataset for the C57BL/6J strain revealed 2 differences with our 
data, which were not present in the datasets of the other strains. In that set, 
the expression level of the Ubiquitin C gene was comparable in the brainstem 
and the hippocampus, whereas this gene was 1.59 times more expressed in 
the Bbainstem according to our microarray data. Similarily, our data showed 
that beta-Actin was 1.75 times more expressed in the hippocampus, and the 
GDS1406 data set reported no difference in the expression levels of that gene 
between in the brainstems and the hippocampi of C57BL/6J mice. The list of 
differentially expressed genes between the brainstem and the hippocampus, 
their raw signals, and their fold changes on both platforms can be seen in 
Table 8. 
 
 
 
Table 8: Differentially expressed genes between the brainstem and the hippocampus obtained in the 
normalized data microarray analysis. Comparison of the signals and the fold changes of these genes, 
with their expression profiles published on the GDS1406 GEO data sets for 6 inbred mice strains. 
 
a. Comparison with the GDS1406 GEO data set for the 129S6/SvEvTac strain: 94.4% similarity 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 0.825 0.31 671.005 110.235 2.66 6.09 Same
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.452 0.198 108.595 84.735 2.28 1.28 Different
JNK2 Oligo1 NM_016961 1.68 0.828 573.52 273.2 2.03 2.10 Same
Ubiquitin C (housekeeping) NM_019639 9.881 6.217 4654.77 2693.325 1.59 1.73 Same
Heat shock protein 70kD protein 5 NM_022310 1.142 0.729 1086.68 687.29 1.57 1.58 Same
Heat shock protein 72 (HSP72) NM_008301 0.142 0.218 100.14 197.92 0.65 0.51 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 0.262 0.443 39.03 66.09 0.59 0.59 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 1 NM_011949 0.158 0.267 39.03 66.09 0.59 0.59 Same
Mus musculus actin, beta, cytoplasmic (Actb), mRNA NM_007393 2.284 3.879 199.175 318.235 0.59 0.63 Same
Brain derived neurotrophic factor (BDNF) NM_007540 0.0979 0.17 246.96 442.755 0.58 0.56 Same
Actin, beta cytoplasmic (ACTB) NM_007393 2.242 3.922 199.175 318.235 0.57 0.63 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.532 1.044 146.56 476.415 0.51 0.31 Same
Protein kinase C epsilon type NM_011104 0.0869 0.182 129.94 349.43 0.48 0.37 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.385 0.901 8.795 83.47 0.43 0.11 Same
Egr1 (zif/268) NM_007913 0.184 0.454 282.2 574.185 0.41 0.49 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.336 1.007 687.6 1734.975 0.33 0.40 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 0.453 1.371 247.115 797.485 0.33 0.31 Same
Protein kinase C, gamma (Prkcc) NM_011102 0.105 0.414 158.59 1532.34 0.25 0.10 Same
Microarray GDS1406
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b. Comparison with the GDS1406 GEO data set for the A/J strain: 88.9% similarity 
 
 
c. Comparison with the GDS1406 GEO data set for the C3H/HeJ strain: 94.4% similarity 
 
 
d. Comparison with the GDS1406 GEO data set for the C57BL/6J strain: 83.3% similarity  
 
 
e. Comparison with the GDS1406 GEO data set for the DBA/2J strain: 77.8% similarity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 0.825 0.31 329.195 105.995 2.66 3.11 Same
Proteinase-activated receptor 1 PAR1, F2r NM_010169 0.452 0.198 80.665 73.98 2.28 1.09 Different
JNK2 Oligo1 NM_016961 1.68 0.828 516.325 281.585 2.03 1.83 Same
Ubiquitin C (housekeeping) NM_019639 9.881 6.217 3898.715 2783.76 1.59 1.40 Same
Heat shock protein 70kD protein 5 NM_022310 1.142 0.729 926.545 762.115 1.57 1.22 Different
Heat shock protein 72 (HSP72) NM_008301 0.142 0.218 101.895 225.19 0.65 0.45 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 0.262 0.443 25.785 47.655 0.59 0.54 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 1 NM_011949 0.158 0.267 25.785 47.655 0.59 0.54 Same
Mus musculus actin, beta, cytoplasmic (Actb), mRNA NM_007393 2.284 3.879 134.435 298.595 0.59 0.45 Same
Brain derived neurotrophic factor (BDNF) NM_007540 0.0979 0.17 202.165 461.74 0.58 0.44 Same
Actin, beta cytoplasmic (ACTB) NM_007393 2.242 3.922 134.435 298.595 0.57 0.45 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.532 1.044 113.005 376.765 0.51 0.30 Same
Protein kinase C epsilon type NM_011104 0.0869 0.182 132.075 566.39 0.48 0.23 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.385 0.901 14.655 169.26 0.43 0.09 Same
Egr1 (zif/268) NM_007913 0.184 0.454 278.315 431.37 0.41 0.65 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.336 1.007 737.605 1887.585 0.33 0.39 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 0.453 1.371 300.995 882.02 0.33 0.34 Same
Protein kinase C, gamma (Prkcc) NM_011102 0.105 0.414 154.3 1443.905 0.25 0.11 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 0.825 0.31 489.085 124.6 2.66 3.93 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 0.452 0.198 138.825 87.49 2.28 1.59 Same
JNK2 Oligo1 NM_016961 1.68 0.828 543.09 253.375 2.03 2.14 Same
Ubiquitin C (housekeeping) NM_019639 9.881 6.217 5348.915 3400.735 1.59 1.57 same
Heat shock protein 70kD protein 5 NM_022310 1.142 0.729 934.075 930.24 1.57 1.00 Different
Heat shock protein 72 (HSP72) NM_008301 0.142 0.218 95.435 228.575 0.65 0.42 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 0.262 0.443 33.445 40.915 0.59 0.82 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 1 NM_011949 0.158 0.267 33.445 40.915 0.59 0.82 Same
Mus musculus actin, beta, cytoplasmic (Actb), mRNA NM_007393 2.284 3.879 268.94 364.185 0.59 0.74 Same
Brain derived neurotrophic factor (BDNF) NM_007540 0.0979 0.17 179.535 387.955 0.58 0.46 Same
Actin, beta cytoplasmic (ACTB) NM_007393 2.242 3.922 268.94 364.185 0.57 0.74 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.532 1.044 92.78 377.62 0.51 0.25 Same
Protein kinase C epsilon type NM_011104 0.0869 0.182 164.11 587.81 0.48 0.28 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.385 0.901 21.405 130.79 0.43 0.16 Same
Egr1 (zif/268) NM_007913 0.184 0.454 212.54 525.57 0.41 0.40 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.336 1.007 656.78 1728.635 0.33 0.38 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 0.453 1.371 294.395 824.735 0.33 0.36 Same
Protein kinase C, gamma (Prkcc) NM_011102 0.105 0.414 172.26 1487.21 0.25 0.12 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 0.825 0.31 348.225 75.745 2.66 4.60 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 0.452 0.198 83.415 78.645 2.28 1.06 Different
JNK2 Oligo1 NM_016961 1.68 0.828 545.24 320.35 2.03 1.70 Same
Ubiquitin C (housekeeping) NM_019639 9.881 6.217 5332.58 4415.38 1.59 1.21 Different
Heat shock protein 70kD protein 5 NM_022310 1.142 0.729 963.935 706.905 1.57 1.36 Same
Heat shock protein 72 (HSP72) NM_008301 0.142 0.218 97.645 262.955 0.65 0.37 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 0.262 0.443 37.825 65.025 0.59 0.58 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 1 NM_011949 0.158 0.267 37.825 65.025 0.59 0.58 Same
Mus musculus actin, beta, cytoplasmic (Actb), mRNA NM_007393 2.284 3.879 279.25 284.69 0.59 0.98 Same
Brain derived neurotrophic factor (BDNF) NM_007540 0.0979 0.17 194.79 472.3 0.58 0.41 Same
Actin, beta cytoplasmic (ACTB) NM_007393 2.242 3.922 279.25 284.69 0.57 0.98 Different
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.532 1.044 93.76 619.8 0.51 0.15 Same
Protein kinase C epsilon type NM_011104 0.0869 0.182 128.35 472.47 0.48 0.27 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.385 0.901 11.585 140.635 0.43 0.08 Same
Egr1 (zif/268) NM_007913 0.184 0.454 255.72 786.305 0.41 0.33 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.336 1.007 415.77 1258.195 0.33 0.33 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 0.453 1.371 199.465 690.82 0.33 0.29 Same
Protein kinase C, gamma (Prkcc) NM_011102 0.105 0.414 119.29 1528.635 0.25 0.08 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 0.825 0.31 339.975 115.885 2.66 2.93 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 0.452 0.198 96.3 98.69 2.28 0.98 Different
JNK2 Oligo1 NM_016961 1.68 0.828 459.27 296.805 2.03 1.55 Same
Ubiquitin C (housekeeping) NM_019639 9.881 6.217 6223.38 3879.245 1.59 1.60 Same
Heat shock protein 70kD protein 5 NM_022310 1.142 0.729 895.76 845.655 1.57 1.06 Different
Heat shock protein 72 (HSP72) NM_008301 0.142 0.218 133.195 245.525 0.65 0.54 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 0.262 0.443 41.53 45.09 0.59 0.92 Different
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 1 NM_011949 0.158 0.267 41.53 45.09 0.59 0.92 Different
Mus musculus actin, beta, cytoplasmic (Actb), mRNA NM_007393 2.284 3.879 152.22 229.22 0.59 0.66 Same
Brain derived neurotrophic factor (BDNF) NM_007540 0.0979 0.17 181.685 347.915 0.58 0.52 Same
Actin, beta cytoplasmic (ACTB) NM_007393 2.242 3.922 152.22 229.22 0.57 0.66 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.532 1.044 106.275 454.915 0.51 0.23 Same
Protein kinase C epsilon type NM_011104 0.0869 0.182 120.72 414.35 0.48 0.29 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.385 0.901 15.83 102.375 0.43 0.15 Same
Egr1 (zif/268) NM_007913 0.184 0.454 173.78 493.335 0.41 0.35 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.336 1.007 501.13 1953.865 0.33 0.26 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 0.453 1.371 227.415 808.79 0.33 0.28 Same
Protein kinase C, gamma (Prkcc) NM_011102 0.105 0.414 199.1 1526.41 0.25 0.13 Same
Microarray GDS1406
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f. Comparison with the GDS1406 GEO data set for the FVB/NJ strain: 77.8% similarity 
 
 
2.4.3 Hippocampus vs. cortex hybridizations 
 
In this experiment, we compared the expression levels of the 230 genes of 
interest in the hippocampus and in the cortex of 3 control NMRI mice, which 
had not been subjected to any surgery. The scatter plots of the raw signals 
were well aligned on the midline, with most genes located between the 2 
fold change lines. The scatter plots of the normalized values showed similar 
features  (Figure 11). Both the raw and normalized signals were filtered on a 
volcano plot in order to select the genes, which had a 1.5 times higher 
expression in one of the analyzed part of the brain, and a P Value lower than 
0.05 (Figure11). The analysis of the raw signals revealed that 14 genes were 
significantly differentially more expressed in the hippocampus. No genes had 
a higher expression in the cortex. The same analysis performed on the 
normalized signals showed that 3 genes were significantly differentially 
expressed between the two parts of the brain. Neuropeptide Y appeared to 
be 1.9 times more expressed in the cortex, whereas the AMPA1 ionotropic 
glutamate receptor and the Neuropeptide Y receptor type 2 showed 
respectively a 2.3 and a 3.6 higher expression in the hippocampus.  
 
 
2.4.3.1 Hippocampus vs. cortex hybridizations, raw signals comparisons 
 
In the low-density microarray analysis of the raw signals, 14 genes appeared 
to be more expressed in the hippocampus. As previously, we compared the 
intensities and the fold changes of these genes with data, which had been 
published on the GDS1406 GEO data set for 6 different inbred mice strains. 
According to our microarray analysis, both the vanilloid receptor 1 (VR1) and 
the vanilloid receptor 5 (TrpV5) appeared to be 1.5 times more expressed in 
the hippocampus than in the cortex. However, no data could be found on 
the GEO datasets for these genes. 
 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Brainstem Hippocampus Brainstem Hippocampus FC in Brainstem FC in Brainstem of results
Tyrosine hydroxylase NM_009377 0.825 0.31 567.42 122.20 2.66 4.64 Same
Proteinase-activated receptor 1  PAR1, F2r NM_010169 0.452 0.198 94.69 94.70 2.28 1.00 Different
JNK2 Oligo1 NM_016961 1.68 0.828 384.48 296.92 2.03 1.29 Same
Ubiquitin C (housekeeping) NM_019639 9.881 6.217 5654.23 4364.03 1.59 1.30 Same
Heat shock protein 70kD protein 5 NM_022310 1.142 0.729 1013.70 1080.57 1.57 0.94 Different
Heat shock protein 72 (HSP72) NM_008301 0.142 0.218 66.96 197.17 0.65 0.34 Same
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 2 NM_011949 0.262 0.443 35.89 39.00 0.59 0.92 Different
MAP kinase 1 (=Erk2): mitogen-activated protein kinase 1, Transcript variant 1 NM_011949 0.158 0.267 35.89 39.00 0.59 0.92 Different
Mus musculus actin, beta, cytoplasmic (Actb), mRNA NM_007393 2.284 3.879 243.38 359.20 0.59 0.68 Same
Brain derived neurotrophic factor (BDNF) NM_007540 0.0979 0.17 217.00 397.63 0.58 0.55 Same
Actin, beta cytoplasmic (ACTB) NM_007393 2.242 3.922 243.38 359.20 0.57 0.68 Same
Neuropeptide Y, Preproneuropeptide Y NM_023456 0.532 1.044 92.44 414.08 0.51 0.22 Same
Protein kinase C epsilon type NM_011104 0.0869 0.182 103.46 483.88 0.48 0.21 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.385 0.901 28.54 115.66 0.43 0.25 Same
Egr1 (zif/268) NM_007913 0.184 0.454 199.17 383.60 0.41 0.52 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.336 1.007 540.14 2104.34 0.33 0.26 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 0.453 1.371 228.06 730.55 0.33 0.31 Same
Protein kinase C, gamma (Prkcc) NM_011102 0.105 0.414 169.36 1683.14 0.25 0.10 Same
Microarray GDS1406
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Figure 11: Scatter plots and volcano plots comparing the expression levels on the 230 genes of interest in 
the hippocampus and in the cortex of 3 non-operated NMRI mice. The scatter plots of both the raw and 
the normalized signals showed genes, which were more regulated in one part of the brain. The volcano 
plots were used to filter the genes, which had a 1.5 times or more higher signal in one part of the brain, 
and a P Value lower than 0.05. The positive genes were highlighted in red. 14 genes were significantly 
differentially expressed according to the raw signals, and 3 genes were significantly differentially 
expressed according to the normalized values. 
 
 
 
In the 3 following mice strains: 129S6/SvEvTac, A/J and C3H/HeJ, 3 genes 
showed a different expression profile on the 2 platforms. The Tissue 
Plasminogen Activator, which was 1.52 times more expressed in the 
hippocampus according to our microarray data, appeared to be about 1.3 
times more expressed in the cortex of these 3 inbred mice strains. The low-
density microarray revealed, that the Neuropeptide Y receptor type 6 was 
1.56 times more expressed in the hippocampus of the 3 NMRI mice we tested. 
However, in the GDS1406 datasets for the 129S6/SvEvTac and the C3H/HeJ, 
the expression of this gene was similar in both parts. In A/J mice, the 
Neuropeptide Y receptor type 6 was 1.96 times more regulated in the cortex. 
Similarly, the expression of the Brain Derived Neurotrophic Factor (BDNF) was 
1.75 times higher in the hippocampus than in the cortex, but the GEO dataset 
for the 129S6/SvEvTac, A/J and the C3H/HeJ revealed a respectively 1.44, 
1.58 and 2.15 times higher expression in the cortex. For these three strains, the 
similarity in the behavior of the 14 regulated genes was 57%, however, if we 
considered only the genes which could be verified on the GEO datasets, and 
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exclude the false positive which appeared in our results, the similarity jumped 
to 72.7%. 
 
The GDS1406 dataset for both the C57BL/6J and the DBA/2J strains showed 
that the expression of the Tissue Plasminogen Activator shows were similar in 
the cortex and the hippocampus. However, our microarray data reported a 
1.52 times higher expression in the hippocampus. A similar discrepancy was 
seen in these strains for BDNF and the Neurotrophin-3 (NT-3) genes. In the 
C57BL/6J strain, the BDNF and NT-3 genes were respectively 1.3 and 1.2 times 
upregulated in the cortex, and in the DBA/2J strains, these genes were 
respectively 2.37 and 1.04 times more expressed in the cortex. Our low-density 
microarray showed a 1.75 times higher expression in the hippocampus of both 
these genes. 
 
In addition to those differences, 2 other genes could not be confirmed, when 
comparing the microarray results with the GDS1406 data for the C57BL/6J 
strain. The Neuropeptide Y receptor Type 6 and the P2x Purinoceptor 7 both 
showed a 1.56 times higher expression in the hippocampus than in the cortex, 
according to our microarray results. The GEO set for the Neuropeptide Y 
receptor type 6 in the strain mentioned above showed a 1.87 times higher 
expression in the cortex. For the P2x Purinoceptor 7, a 1.34 times higher 
expression in the cortex was reported. Taken together, 43% of the 14 genes, 
which appeared regulated in our microarray results, behaved the same way 
in the GDS1409 sets for the C57BL/6J strain. However, if we did not consider 
the obvious false positive, and the 2 genes, for which no data could be found 
in the GEO sets, the percentage of similarity increased to 54.5%. 
 
In the DBA/2J strain, one additional gene showed a different behavior, than 
what we had measured on our microarray. Our data showed that the 
serotonin receptor 5-HTr5(B) had a 1.54 times higher expression in the 
hippocampus than in the cortex. However, the GDS1406 dataset of the 
DBA/2J strain reported no differences in the expression of that gene in the two 
regions of interest. The Neuropeptide Y receptor type 6 also showed a 
different behavior in the GDS1406 of the DBA/2J mice strains. According to 
that dataset, this gene was 2.34 times more expressed in the cortex. Our 
microarray results reported the opposite in NMRI mice. The comparisons of the 
behavior of the 14 significantly regulated genes on the microarray, with the 
GDS1406 dataset for the DBA/2J strain showed 43% similarity. But just as 
mentioned above, the percentage of similarity increased to 54.5% if we did 
not consider the obvious false positive, and the 2 genes, for which no data 
could be found in the GEO sets. 
 
In the FVB/NJ strain, only 2 genes, out of the 14 significantly regulated genes 
from our microarray study showed a different expression profile in the 
GDS1406 GEO data set. According to our microarray results, the Serotonin 
Receptor 5-HTr5(B), the Neuropeptide Y Receptor type 6 and BDNF were 
respectively 1.54 times, 1.56 times and 1.75 times more expressed in the 
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hippocampus than in the cortex. In the GDS1406 dataset for the FVB/NJ strain, 
the Serotonin Receptor 5-HTr5(B) levels were equal in both parts of the brain, 
and the Neuropeptide Y receptor type 6 and BDNF were respectively 1.21 
and 1.64 times more expressed in the cortex. Overall, 50% of the 14 
significantly differentially expressed genes in the low-density microarray 
experiment could be confirmed in the GDS1406 data set for the FVB/NJ strain. 
However, if we did not include the randomly generated negative control 4 
and the 2 genes, for which no data could be found in the GEO sets, the 
percentage of similarity increased to 63.6%. The list of differentially expressed 
genes between the hippocampus and the cortex, as well as the comparisons 
with the GDS1406 GEO datasets for each of the 6 inbred mice strains can be 
seen in Table .9 
 
Table 9: Differentially expressed genes between the hippocampus and the cortex obtained in the raw 
data microarray analysis. Comparison of the signals and the fold changes of these genes, with their 
expression profiles published on the GDS1406 GEO data sets for 6 inbred mice strains. 
 
a. Comparison with the GDS1406 GEO data set for the 129S6/SvEvTac strain: 57% similarity 
 
 
 
b. Comparison with the GDS1406 GEO data set for the A/J strain: 57% similarity 
 
 
 
c. Comparison with the GDS1406 GEO data set for the C3H/HeJ strain: 57% similarity 
 
 
 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Tissue plasminogen activator (Plat) NM_008872 96.67 146.5 293.265 216.165 0.66 1.36 Different
Vanilloid-1 receptor (VR1) Oligo 3 NM_001001445 55.5 86.11 0.64 No Data
Vanilloid-receptor TrpV5 NM_001007572 59.75 92.19 0.65 No Data
Serotonin receptor: 5-HTr5(B) NM_010483 71.28 110.2 48.89 60.53 0.65 0.81 Same
P2X purinoceptor 7 NM_011027 39.67 62.72 99.64 151.56 0.63 0.66 Same
Neuropeptide Y receptor type 6 (Npy6r) NM_010935 48.42 75.78 10.735 9.845 0.64 1.09 Different
12.44 21.04 0.59 False Positive
Brain derived neurotrophic factor (BDNF) NM_007540 71.44 125.6 637.77 442.755 0.57 1.44 Different
Neurotrophin-3 (NT-3) NM_008742 50.03 94.14 25.145 27.805 0.53 0.90 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 521.9 1'006 433.255 797.485 0.52 0.54 Same
Protein kinase C, gamma (Prkcc) NM_011102 150.4 304.1 132.305 1532.34 0.49 0.09 Same
Mus musculus tubulin, alpha 6 (Tuba6), mRNA, Oligo 2 NM_009448 47.11 95.81 3109.225 4539.28 0.49 0.68 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 302.6 765.6 1001.865 1734.975 0.40 0.58 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 181.5 666.9 81.19 278.865 0.27 0.29 Same
Randomly generated negative control 4
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Tissue plasminogen activator (Plat) NM_008872 96.67 146.5 293.04 228.1 0.66 1.28 Different
Vanilloid-1 receptor (VR1) Oligo 3 NM_001001445 55.5 86.11 0.64 No Data
Vanilloid-receptor TrpV5 NM_001007572 59.75 92.19 0.65 No Data
Serotonin receptor: 5-HTr5(B) NM_010483 71.28 110.2 51.84 52.935 0.65 0.98 Same
P2X purinoceptor 7 NM_011027 39.67 62.72 116.98 140.2 0.63 0.83 Same
Neuropeptide Y receptor type 6 (Npy6r) NM_010935 48.42 75.78 27.12 13.825 0.64 1.96 Different
Randomly generated negative control 4 12.44 21.04 0.59 False Positive
Brain derived neurotrophic factor (BDNF) NM_007540 71.44 125.6 728.21 461.74 0.57 1.58 Different
Neurotrophin-3 (NT-3) NM_008742 50.03 94.14 32.04 38.56 0.53 0.83 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 521.9 1'006 558.45 882.02 0.52 0.63 Same
Protein kinase C, gamma (Prkcc) NM_011102 150.4 304.1 111.54 1443.905 0.49 0.08 Same
Mus musculus tubulin, alpha 6 (Tuba6), mRNA, Oligo 2 NM_009448 47.11 95.81 2830.79 4814.15 0.49 0.59 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 302.6 765.6 951.44 1887.585 0.40 0.50 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 181.5 666.9 84.82 400.38 0.27 0.21 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Tissue plasminogen activator (Plat) NM_008872 96.67 146.5 269.305 217.045 0.66 1.24 Different
Vanilloid-1 receptor (VR1) Oligo 3 NM_001001445 55.5 86.11 0.64 No Data
Vanilloid-receptor TrpV5 NM_001007572 59.75 92.19 0.65 No Data
Serotonin receptor: 5-HTr5(B) NM_010483 71.28 110.2 32.8 50.385 0.65 0.65 Same
P2X purinoceptor 7 NM_011027 39.67 62.72 109.395 143.85 0.63 0.76 Same
Neuropeptide Y receptor type 6 (Npy6r) NM_010935 48.42 75.78 18.9 16.94 0.64 1.12 Different
12.44 21.04 0.59
Brain derived neurotrophic factor (BDNF) NM_007540 71.44 125.6 834.775 387.955 0.57 2.15 Different
Neurotrophin-3 (NT-3) NM_008742 50.03 94.14 15.58 35.32 0.53 0.44 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 521.9 1'006 647.45 824.735 0.52 0.79 Same
Protein kinase C, gamma (Prkcc) NM_011102 150.4 304.1 132.535 1487.21 0.49 0.09 Same
Mus musculus tubulin, alpha 6 (Tuba6), mRNA, Oligo 2 NM_009448 47.11 95.81 2816.85 4535.595 0.49 0.62 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 302.6 765.6 1083.025 1728.635 0.40 0.63 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 181.5 666.9 79.77 331.22 0.27 0.24 Same
Microarray GDS1406
Randomly generated negative control 4
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d. Comparison with the GDS1406 GEO data set for the C57BL/6J strain: 43% similarity  
 
 
e. Comparison with the GDS1406 GEO data set for the DBA/2J strain: 43% similarity 
 
 
 
f. Comparison with the GDS1406 GEO data set for the FVB/NJ strain: 50% similarity 
 
 
 
2.4.3.2 Hippocampus vs. cortex hybridizations, normalized signals 
comparisons 
 
The filtering on volcano plot of the normalized signals revealed that 3 genes 
were differentially expressed between the hippocampus and the cortex. One 
gene had a 1.91 times higher expression level in the cortex: Neuropeptide Y. 
The two other genes were the AMPA1 Glutamate Ionotropic Receptor, and 
the Neuropeptide Y Receptor Type 2, and they respectively had a 2.32 times 
and a 3.57 times higher expression in the hippocampus. In the 5 strains, the 
GDS1406 GEO dataset for Neuropeptide Y showed a different expression 
profile than what was observed in the low-density microarray analysis. In the 
129S6/SvEvTac, A/J, DBA/2J and FVB/NJ, the expression levels of that gene 
were identical in the hippocampus and in the cortex and in the C57BL/6J 
strain, it was 1.32 times higher in the hippocampus. However, in the C3H/HeJ 
strain, Neuropeptide Y had a 1.32 higher expression level in the cortex, 
thereby confirming the observation made on the low-density microarray. 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Tissue plasminogen activator (Plat) NM_008872 96.67 146.5 217.065 227.425 0.66 0.95 Different
Vanilloid-1 receptor (VR1) Oligo 3 NM_001001445 55.5 86.11 0.64 No Data
Vanilloid-receptor TrpV5 NM_001007572 59.75 92.19 0.65 No Data
Serotonin receptor: 5-HTr5(B) NM_010483 71.28 110.2 49.555 71.12 0.65 0.70 Same
P2X purinoceptor 7 NM_011027 39.67 62.72 152.61 113.485 0.63 1.34 Different
Neuropeptide Y receptor type 6 (Npy6r) NM_010935 48.42 75.78 23.565 12.57 0.64 1.87 Different
Randomly generated negative control 4 12.44 21.04 0.59
Brain derived neurotrophic factor (BDNF) NM_007540 71.44 125.6 612.565 472.3 0.57 1.30 Different
Neurotrophin-3 (NT-3) NM_008742 50.03 94.14 27.2 23.605 0.53 1.15 Different
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 521.9 1'006 395.045 690.82 0.52 0.57 Same
Protein kinase C, gamma (Prkcc) NM_011102 150.4 304.1 111.1 1528.635 0.49 0.07 Same
Mus musculus tubulin, alpha 6 (Tuba6), mRNA, Oligo 2 NM_009448 47.11 95.81 2966.765 5407.045 0.49 0.55 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 302.6 765.6 926.875 1258.195 0.40 0.74 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 181.5 666.9 92.75 416.41 0.27 0.22 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Tissue plasminogen activator (Plat) NM_008872 96.67 146.5 246.55 200.26 0.66 1.23 Different
Vanilloid-1 receptor (VR1) Oligo 3 NM_001001445 55.5 86.11 0.64 No Data
Vanilloid-receptor TrpV5 NM_001007572 59.75 92.19 0.65 No Data
Serotonin receptor: 5-HTr5(B) NM_010483 71.28 110.2 50.77 53.455 0.65 0.95 Different
P2X purinoceptor 7 NM_011027 39.67 62.72 118.785 134.925 0.63 0.88 Same
Neuropeptide Y receptor type 6 (Npy6r) NM_010935 48.42 75.78 33.51 14.33 0.64 2.34 Different
Randomly generated negative control 4 12.44 21.04 0.59
Brain derived neurotrophic factor (BDNF) NM_007540 71.44 125.6 826.03 347.915 0.57 2.37 Different
Neurotrophin-3 (NT-3) NM_008742 50.03 94.14 33.235 31.805 0.53 1.04 Different
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 521.9 1'006 541.23 808.79 0.52 0.67 Same
Protein kinase C, gamma (Prkcc) NM_011102 150.4 304.1 116.1 1526.41 0.49 0.08 Same
Mus musculus tubulin, alpha 6 (Tuba6), mRNA, Oligo 2 NM_009448 47.11 95.81 2742.35 5258.19 0.49 0.52 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 302.6 765.6 895.95 1953.865 0.40 0.46 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 181.5 666.9 120.95 304.84 0.27 0.40 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Tissue plasminogen activator (Plat) NM_008872 96.67 146.5 204.995 315.825 0.66 0.65 Same
Vanilloid-1 receptor (VR1) Oligo 3 NM_001001445 55.5 86.11 0.64 No Data
Vanilloid-receptor TrpV5 NM_001007572 59.75 92.19 0.65 No Data
Serotonin receptor: 5-HTr5(B) NM_010483 71.28 110.2 44.105 45.95 0.65 0.96 Different
P2X purinoceptor 7 NM_011027 39.67 62.72 126.79 166.995 0.63 0.76 Same
Neuropeptide Y receptor type 6 (Npy6r) NM_010935 48.42 75.78 17.315 14.335 0.64 1.21 Different
Randomly generated negative control 4 12.44 21.04 0.59 False Positive
Brain derived neurotrophic factor (BDNF) NM_007540 71.44 125.6 650.43 397.625 0.57 1.64 Different
Neurotrophin-3 (NT-3) NM_008742 50.03 94.14 15.13 31.755 0.53 0.48 Same
AMPA2  (alpha2)  Glutamate Receptor, ionotropic NM_013540 521.9 1'006 596.32 730.55 0.52 0.82 Same
Protein kinase C, gamma (Prkcc) NM_011102 150.4 304.1 125.78 1683.14 0.49 0.07 Same
Mus musculus tubulin, alpha 6 (Tuba6), mRNA, Oligo 2 NM_009448 47.11 95.81 2696.43 5372.495 0.49 0.50 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 302.6 765.6 948.37 2104.34 0.40 0.45 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 181.5 666.9 94.715 381.44 0.27 0.25 Same
Microarray GDS1406
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In all 6 inbred strains of the GDS1406 GEO dataset, the expression profile 
observed for the AMPA1 Glutamate Ionotropic Receptor, and the 
Neuropeptide Y Receptor Type 2 were similar to what was observed in the 
microarray measurements for these genes. Both genes appeared to be more 
expressed in the hippocampus on both platforms and in all strains. This means 
the expression profiles of 3 regulated genes, showed a 100% similarity in the 
microarray results and in the GDS1406 dataset for the C3H/HeJ strain and 
66.7% similarity with the GDS1406 of the 5 other strains. The list of genes, as well 
as the signal comparisons with between the microarray measurements and 
the GDS1406 data can be seen in Table 10. 
 
Table 10: Differentially expressed genes between the hippocampus and the cortex obtained in the 10 
data microarray analysis. Comparison of the signals and the fold changes of these genes, with their 
expression profiles published on the GDS1406 GEO data sets for 6 inbred mice strains. 
 
a. Comparison with the GDS1406 GEO data set for the 129S6/SvEvTac strain: 66.7% similarity 
 
 
b. Comparison with the GDS1406 GEO data set for the A/J strain: 66.7% similarity 
 
 
 
c. Comparison with the GDS1406 GEO data set for the C3H/HeJ strain: 100% similarity 
 
 
 
d. Comparison with the GDS1406 GEO data set for the C57BL/6J strain: 66.7% similarity  
 
 
 
e. Comparison with the GDS1406 GEO data set for the DBA/2J strain: 66.7% similarity 
 
 
 
 
f. Comparison with the GDS1406 GEO data set for the FVB/NJ strain: 66.7% similarity 
 
 
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Neuropeptide Y, Preproneuropeptide Y NM_023456 1.996 1.044 394.595 476.415 1.91 0.83 Different
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.429 1.007 1001.865 1734.975 0.43 0.58 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.249 0.901 81.19 278.865 0.28 0.29 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Neuropeptide Y, Preproneuropeptide Y NM_023456 1.996 1.044 442.62 376.765 1.91 1.17 Different
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.429 1.007 951.44 1887.585 0.43 0.50 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.249 0.901 84.82 400.38 0.28 0.21 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Neuropeptide Y, Preproneuropeptide Y NM_023456 1.996 1.044 497.315 377.62 1.91 1.32 Same
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.429 1.007 1083.025 1728.635 0.43 0.63 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.249 0.901 79.77 331.22 0.28 0.24 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Neuropeptide Y, Preproneuropeptide Y NM_023456 1.996 1.044 471.685 619.8 1.91 0.76 Different
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.429 1.007 926.875 1258.195 0.43 0.74 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.249 0.901 92.75 416.41 0.28 0.22 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Neuropeptide Y, Preproneuropeptide Y NM_023456 1.996 1.044 411.495 454.915 1.91 0.90 Different
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.429 1.007 895.95 1953.865 0.43 0.46 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.249 0.901 120.95 304.84 0.28 0.40 Same
Microarray GDS1406
Microarray GDS 1406 Comparison
Gene Name ID, NCBI Cortex Hippocampus Cortex Hippocampus FC in Cortex FC in Cortex of results
Neuropeptide Y, Preproneuropeptide Y NM_023456 1.996 1.044 368.86 414.075 1.91 0.89 Different
AMPA1  (alpha1)  Glutamate Receptor, ionotropic NM_008165 0.429 1.007 948.37 2104.34 0.43 0.45 Same
Neuropeptide Y receptor type 2 (Npy2r) NM_008731 0.249 0.901 94.715 381.44 0.28 0.25 Same
Microarray GDS1406
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2.5 Real-Time PCR Measurements, Telemetric Apparatus Pain 
model  
 
The low-density microarray experiments did not reveal any significant gene 
regulation linked to pain in the analyzed parts of the brain, which could be 
confirmed by Real-Time PCR. In order to see whether our microarray protocol 
was not sensitive enough to detect subtle gene expression changes linked to 
nociception, we selected 27 genes from our database based on their 
relevancy in pain research, and assessed their expression profile in the 
surgical pain model by Real-Time PCR. These genes are listed in Table 11. 
 
The amount of animals tested was increased to 6 operated animals and 6 
controls for statistical robustness. The surgical pain model was the same as 
previously described. The operated animals were anesthetized with 
Sevofluorane, subjected to a telemetric apparatus implantation, and treated 
twice daily a subcutaneous injection of Flunixin. The control animals, on the 
other hand, did not undergo surgery. They were only anesthetized, and 
treated twice daily with analgesics. After a careful observation of the mice 
behaviors, aspect and nest’s state, the decision was taken to sacrifice the 
animals one day post surgery, to be able to analyze their gene expression in a 
post recovery timepoint, at which this behavioral analysis indicated that the 
animals were still in an acute phase of recovery. 
 
The CNS of each animal was dissected, and the total RNA from brainstem, the 
hippocampus and the cortex as well as from 6 lumbar dorsal root ganglias 
was extracted. The mRNA of each of these parts was reversed in cDNA, which 
was used for the Real-Time PCR analysis. Given that Real-Time PCR is a more 
sensitive method to analyze gene expression changes than microarray, the 
fold changes were considered as significant when they were higher than 2. In 
each part of the CNS, the IL-6 Real-Time PCR reactions did not run optimally. 
The signals for the samples were inconsistent and appeared in the last cycles 
of the reaction with the signals of the negative controls. This tends to signal a 
problem in the PCR reaction of that gene. The fold changes observed for this 
gene were therefore not taken in consideration.  
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Table 11A: Statistics of the ΔCt values obtained in the bainstems of the operated and the control mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group N Mean SD SEM FC IN THE OPERATED ANIMALS
Control 6 8,69 ,636 ,260 Variances equal ,226
Operated 6 9,08 ,379 ,155 Variances different ,232
Control 6 ,64 ,273 ,111 Variances equal ,473
Operated 6 ,51 ,310 ,127 Variances different ,473
Control 6 5,51 ,353 ,144 Variances equal ,394
Operated 6 4,77 1,996 ,815 Variances different ,412
Control 6 2,72 ,581 ,237 Variances equal ,773
Operated 6 2,83 ,671 ,274 Variances different ,773
Control 6 7,76 ,365 ,149 Variances equal ,766
Operated 6 7,49 2,103 ,858 Variances different ,771
Control 6 10,93 ,441 ,180 Variances equal ,418
Operated 6 10,29 1,824 ,745 Variances different ,433
Control 6 1,02 ,084 ,034 Variances equal ,982
Operated 6 1,02 ,171 ,070 Variances different ,982
Control 6 4,79 ,617 ,252 Variances equal ,484
Operated 6 4,58 ,406 ,166 Variances different ,487
Control 6 -1,30 ,275 ,112 Variances equal ,478
Operated 6 -1,12 ,503 ,205 Variances different ,483
Control 6 3,21 ,335 ,137 Variances equal ,137
Operated 6 3,65 ,574 ,234 Variances different ,144
Control 6 5,06 15,967 6,518 Variances equal ,250
Operated 6 13,15 2,809 1,147 Variances different ,273
Control 6 5,84 ,856 ,349 Variances equal ,230
Operated 6 4,86 1,682 ,687 Variances different ,239
Control 6 -,19 ,319 ,130 Variances equal ,684
Operated 6 -,13 ,123 ,050 Variances different ,689
Control 6 10,25 ,855 ,349 Variances equal ,927
Operated 6 10,29 ,455 ,186 Variances different ,927
Control 6 -1,77 ,403 ,165 Variances equal ,822
Operated 6 -1,71 ,461 ,188 Variances different ,822
Control 6 11,34 1,286 ,525 Variances equal ,677
Operated 6 11,11 ,441 ,180 Variances different ,682
Control 6 -2,04 ,184 ,075 Variances equal ,717
Operated 6 -2,09 ,278 ,113 Variances different ,718
Control 6 4,87 ,493 ,201 Variances equal ,793
Operated 6 4,96 ,581 ,237 Variances different ,793
Control 6 6,95 1,477 ,603 Variances equal ,754
Operated 6 7,19 1,025 ,418 Variances different ,754
Control 6 -,51 ,233 ,095 Variances equal ,842
Operated 6 -,48 ,253 ,103 Variances different ,842
Control 6 ,65 3,214 1,312 Variances equal ,355
Operated 6 2,51 3,440 1,404 Variances different ,355
Control 6 -2,69 1,159 ,473 Variances equal ,780
Operated 6 -2,51 1,041 ,425 Variances different ,780
Control 6 9,20 ,863 ,352 Variances equal ,985
Operated 6 9,19 ,631 ,257 Variances different ,985
Control 6 1,89 ,175 ,071 Variances equal ,202
Operated 6 1,77 ,121 ,050 Variances different ,206
Control 6 -1,48 ,447 ,183 Variances equal ,783
Operated 6 -1,41 ,427 ,174 Variances different ,783
Control 6 6,79 ,362 ,148 Variances equal ,812
Operated 6 6,84 ,389 ,159 Variances different ,812
Control 6 ,88 ,204 ,083 Variances equal ,555
Operated 6 ,82 ,137 ,056 Variances different ,557
-1.04
1.04
-1.31
-1.08
1.20
-1.13
1.01
1.09
-1.05
-1.06
-3.64
-1.03
-1.04
1.18
1.04
1.24
-1.04
-1.18
-1.02
1.16
-1.13
-1.36
      -
1.09
-1.05
-1.06
1.00
Average Delta 
Ct
Slc6a1 Average Delta 
Ct
Tac1 Average Delta 
Ct
TacR1 Average Delta 
Ct
TrpV2
Prkcc Average Delta 
Ct
Runx1 Average Delta 
Ct
Oprs1 Average Delta 
Ct
Pomc Average Delta 
Ct
Oprd1 Average Delta 
Ct
Oprm1 Average Delta 
Ct
Npy6r Average Delta 
Ct
NTRK3 Average Delta 
Ct
NPY Average Delta 
Ct
Npy5r Average Delta 
Ct
Average Delta 
Ct
LIF Average Delta 
Ct
MapK1 Average Delta 
Ct
Gene P Value obtained on T-test
BDNF
5HTr3A Average Delta 
Ct
5HTr4 Average Delta 
Ct
Average Delta 
Ct
Creb3 Average Delta 
Ct
Dream Average Delta 
Ct
5HTr1A Average Delta 
Ct
5HTr2C Average Delta 
Ct
5HTr1D Average Delta 
Ct
Gabrg2 Average Delta 
Ct
HSP70 Average Delta 
Ct
IL6
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Table 11B: Statistics of the ΔCt values obtained in the cortices of the operated and the control mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group N Mean SD SEM FC IN THE OPERATED ANIMALS
Control 0 . . . Variances equal -
Operated 0 . . . Variances different -
Control 6 4,50 ,324 ,132 Variances equal ,012
Operated 6 3,35 ,854 ,349 Variances different ,020
Control 6 -2,16 ,529 ,216 Variances equal ,645
Operated 5 -2,36 ,855 ,382 Variances different ,663
Control 6 -,12 ,493 ,201 Variances equal ,473
Operated 5 -,30 ,236 ,105 Variances different ,450
Control 6 8,31 ,928 ,379 Variances equal ,389
Operated 6 7,24 2,774 1,133 Variances different ,402
Control 6 6,83 ,454 ,185 Variances equal ,096
Operated 5 8,03 1,521 ,680 Variances different ,154
Control 6 -1,02 ,253 ,103 Variances equal ,563
Operated 4 -1,22 ,808 ,404 Variances different ,648
Control 0 . . . Variances equal -
Operated 0 . . . Variances different -
Control 6 2,17 ,248 ,101 Variances equal ,276
Operated 5 1,90 ,512 ,229 Variances different ,321
Control 6 -2,54 ,519 ,212 Variances equal ,707
Operated 5 -2,66 ,513 ,230 Variances different ,707
Control 0 . . . Variances equal -
Operated 0 . . . Variances different -
Control 6 9,80 ,779 ,318 Variances equal ,339
Operated 6 9,26 1,075 ,439 Variances different ,342
Control 5 3,05 ,333 ,149 Variances equal ,188
Operated 3 2,66 ,412 ,238 Variances different ,242
Control 6 2,37 ,215 ,088 Variances equal ,035
Operated 5 1,88 ,425 ,190 Variances different ,060
Control 6 5,03 ,261 ,106 Variances equal ,076
Operated 6 3,94 1,312 ,536 Variances different ,100
Control 0 . . . Variances equal -
Operated 0 . . . Variances different -
Control 6 -4,82 ,403 ,165 Variances equal ,065
Operated 5 -5,46 ,619 ,277 Variances different ,086
Control 6 2,06 ,342 ,139 Variances equal ,889
Operated 5 2,02 ,558 ,250 Variances different ,895
Control 0 . . . Variances equal -
Operated 0 . . . Variances different -
Control 6 2,87 ,495 ,202 Variances equal ,184
Operated 5 2,45 ,477 ,213 Variances different ,184
Control 5 5,10 2,426 1,085 Variances equal ,884
Operated 4 5,35 2,433 1,217 Variances different ,884
Control 4 -2,19 ,431 ,216 Variances equal ,159
Operated 5 -2,74 ,568 ,254 Variances different ,147
Control 6 8,72 1,103 ,450 Variances equal ,708
Operated 5 8,49 ,779 ,348 Variances different ,699
Control 5 -,98 ,272 ,121 Variances equal ,134
Operated 4 -1,45 ,551 ,275 Variances different ,189
Control 6 -2,65 1,270 ,518 Variances equal ,269
Operated 5 -3,62 1,483 ,663 Variances different ,280
Control 6 5,79 1,111 ,453 Variances equal ,565
Operated 5 5,28 1,685 ,753 Variances different ,585
Control 6 ,89 ,420 ,171 Variances equal ,195
Operated 4 1,21 ,146 ,073 Variances different ,138
5-HTr1D Average Delta 
Ct
5HTr1A Average Delta 
Ct
5HTr2C Average Delta 
Ct
5HTr3A Average Delta 
Ct
5HTr4 Average Delta 
Ct
BDNF Average Delta 
Ct
Creb3 Average Delta 
Ct
Dream Average Delta 
Ct
Gabrg2 Average Delta 
Ct
HSP70 Average Delta 
Ct
IL6 Average Delta 
Ct
LIF Average Delta 
Ct
MapK1 Average Delta 
Ct
NPY Average Delta 
Ct
Npy5r Average Delta 
Ct
Npy6r Average Delta 
Ct
NTRK3 Average Delta 
Ct
Oprd1 Average Delta 
Ct
Oprm1 Average Delta 
Ct
Oprs1 Average Delta 
Ct
Pomc Average Delta 
Ct
Prkcc Average Delta 
Ct
Runx1 Average Delta 
Ct
Slc6a1 Average Delta 
Ct
Tac1 Average Delta 
Ct
TacR1 Average Delta 
Ct
TrpV2 Average Delta 
Ct
Gene P Value obtained on T-test
2.19
1.15
2.30
1.16
-
1.20
1.09
      -
1.46
1.31
-
1.34
-1.19
1.40
1.20
-
1.57
1.42
-1.24
-
1.13
1.51
1.46
1.17
1.39
1.97
1.03
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Table 11C: Statistics of the ΔCt values obtained in the hippocampi of the operated and the control 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group N Mean SD SEM FC IN THE OPERATED ANIMALS
Control 6 7,65 3,469 1,416 Variances equal ,417
Operated 6 9,63 4,591 1,874 Variances different ,419
Control 5 -,63 1,086 ,486 Variances equal ,403
Operated 6 -,12 ,837 ,342 Variances different ,419
Control 6 2,86 ,705 ,288 Variances equal ,413
Operated 6 3,48 1,642 ,670 Variances different ,422
Control 6 -1,05 ,666 ,272 Variances equal ,540
Operated 6 -1,33 ,813 ,332 Variances different ,541
Control 6 8,65 ,293 ,120 Variances equal ,393
Operated 6 9,22 1,538 ,628 Variances different ,410
Control 6 7,25 ,621 ,253 Variances equal ,502
Operated 6 7,83 1,946 ,795 Variances different ,512
Control 6 2,57 1,145 ,467 Variances equal ,594
Operated 6 2,87 ,743 ,303 Variances different ,596
Control 6 ,54 1,157 ,472 Variances equal ,496
Operated 6 ,90 ,443 ,181 Variances different ,505
Control 6 -,96 ,418 ,171 Variances equal ,396
Operated 6 -1,20 ,524 ,214 Variances different ,397
Control 6 -2,22 ,486 ,198 Variances equal ,902
Operated 6 -2,17 ,651 ,266 Variances different ,902
Control 6 10,37 2,216 ,905 Variances equal ,670
Operated 6 9,83 2,019 ,824 Variances different ,670
Control 6 7,27 1,252 ,511 Variances equal ,569
Operated 6 6,79 1,567 ,640 Variances different ,569
Control 6 -5,77 1,063 ,434 Variances equal ,394
Operated 6 -5,27 ,872 ,356 Variances different ,395
Control 6 -3,11 ,957 ,391 Variances equal ,847
Operated 6 -3,21 ,777 ,317 Variances different ,847
Control 6 ,58 1,249 ,510 Variances equal ,383
Operated 6 1,11 ,629 ,257 Variances different ,390
Control 6 8,98 1,283 ,524 Variances equal ,317
Operated 6 10,10 2,267 ,926 Variances different ,324
Control 6 -6,12 1,224 ,500 Variances equal ,431
Operated 6 -5,63 ,801 ,327 Variances different ,434
Control 6 3,69 1,122 ,458 Variances equal ,957
Operated 6 3,74 1,913 ,781 Variances different ,957
Control 6 6,54 ,433 ,177 Variances equal ,390
Operated 6 6,88 ,813 ,332 Variances different ,396
Control 6 2,65 ,526 ,215 Variances equal ,926
Operated 6 2,62 ,583 ,238 Variances different ,926
Control 6 2,26 3,399 1,388 Variances equal ,563
Operated 6 3,23 2,088 ,853 Variances different ,566
Control 6 -10,64 ,916 ,374 Variances equal ,789
Operated 6 -10,51 ,700 ,286 Variances different ,790
Control 6 8,51 ,884 ,361 Variances equal ,361
Operated 6 8,04 ,823 ,336 Variances different ,361
Control 6 -2,53 1,077 ,440 Variances equal ,394
Operated 6 -2,10 ,514 ,210 Variances different ,402
Control 6 -,51 1,746 ,713 Variances equal ,563
Operated 6 ,02 1,327 ,542 Variances different ,564
Control 6 7,31 ,916 ,374 Variances equal ,792
Operated 6 7,43 ,663 ,271 Variances different ,792
Control 6 -,14 ,542 ,221 Variances equal ,521
Operated 6 -,37 ,633 ,258 Variances different ,521
5-HTr1D Average Delta 
Ct
5HTr1A Average Delta 
Ct
5HTr2C Average Delta 
Ct
5HTr3A Average Delta 
Ct
5HTr4 Average Delta 
Ct
BDNF Average Delta 
Ct
Creb3 Average Delta 
Ct
Dream Average Delta 
Ct
Gabrg2 Average Delta 
Ct
HSP70 Average Delta 
Ct
IL6 Average Delta 
Ct
LIF Average Delta 
Ct
MapK1 Average Delta 
Ct
NPY Average Delta 
Ct
Npy5r Average Delta 
Ct
Npy6r Average Delta 
Ct
NTRK3 Average Delta 
Ct
Oprd1 Average Delta 
Ct
Oprm1 Average Delta 
Ct
Oprs1 Average Delta 
Ct
Pomc Average Delta 
Ct
Prkcc Average Delta 
Ct
Runx1 Average Delta 
Ct
Slc6a1 Average Delta 
Ct
Tac1 Average Delta 
Ct
TacR1 Average Delta 
Ct
TrpV2 Average Delta 
Ct
Gene P Value obtained on T-test
-1.32
-1.54
-1.50
1.09
-1.28
1.18
-1.03
1.45
1.40
-1.41
-1.26
1.02
-1.49
1.07
-1.03
-2.17
-1.40
-1.09
1.17
-3.97
1.21
-1.48
-1.09
1.39
-1.35
-1.45
-1.04
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Table 11D: Statistics of the ΔCt values obtained in the dorsal root ganglia of the operated and the 
control mice. 
 
 
 
 
In the brainstem, only one gene was downregulated in operated animals: the 
Pro-opiomelanocortine (Pomc). This gene was 3.7 times more expressed in the 
control animals. The rest of the genes showed no regulation linked to 
nociception in this part of the brain. In the cortex, 3 genes were more 
expressed in the operated animals than in the control ones: Tachikinin 1, the 
serotonin receptor 5-HTr1A and BDNF. All these genes had a 2 times higher 
expression in the operated animals. In the hippocampus, 2 genes were 
regulated: the Neuropeptide receptor Npy6r, and the 5-HTr1D, which were 
respectively 1.2 and 4 times more expressed in the control animals. The results 
obtained in the dorsal root ganglia indicated that the 5-Htr1D, 5-HTr4, 5HTr2C 
serotonin receptors, DREAM, LIF and BDNF were all 2.3 to 4.6 times more 
expressed expressed in the operated animals. On the other hand, the 
Group N Mean SD SEM FC IN THE OPERATED ANIMALS
Control 5 6,77 1,341 ,600 Variances equal ,142
Operated 4 5,58 ,497 ,249 Variances different ,125
Control 5 3,49 ,535 ,239 Variances equal ,680
Operated 4 3,36 ,311 ,156 Variances different ,662
Control 2 6,86 2,258 1,596 Variances equal ,346
Operated 3 5,40 ,724 ,418 Variances different ,524
Control 5 -4,66 1,474 ,659 Variances equal ,938
Operated 5 -4,72 ,546 ,244 Variances different ,940
Control 2 7,96 1,603 1,133 Variances equal ,258
Operated 3 6,14 1,337 ,772 Variances different ,319
Control 2 10,03 2,122 1,500 Variances equal ,259
Operated 3 8,34 ,659 ,381 Variances different ,454
Control 5 -1,39 ,954 ,426 Variances equal ,367
Operated 4 -1,86 ,142 ,071 Variances different ,335
Control 5 3,26 ,925 ,413 Variances equal ,545
Operated 4 2,90 ,690 ,345 Variances different ,531
Control 6 3,16 ,486 ,198 Variances equal ,180
Operated 6 2,57 ,883 ,360 Variances different ,188
Control 5 ,20 ,315 ,141 Variances equal ,099
Operated 5 -,17 ,317 ,142 Variances different ,099
Control 5 6,89 5,315 2,377 Variances equal ,436
Operated 5 8,94 1,733 ,775 Variances different ,451
Control 2 6,23 3,286 2,324 Variances equal ,299
Operated 3 4,03 ,406 ,235 Variances different ,516
Control 5 1,73 ,779 ,348 Variances equal ,793
Operated 4 1,86 ,581 ,291 Variances different ,785
Control 6 4,59 1,747 ,713 Variances equal ,261
Operated 6 5,79 1,741 ,711 Variances different ,261
Control 5 2,08 4,621 2,066 Variances equal ,380
Operated 4 4,34 1,389 ,695 Variances different ,347
Control 2 9,66 1,645 1,163 Variances equal ,987
Operated 2 9,60 4,395 3,108 Variances different ,988
Control 5 -3,85 1,248 ,558 Variances equal ,661
Operated 4 -4,19 ,917 ,458 Variances different ,649
Control 5 4,89 ,514 ,230 Variances equal ,939
Operated 5 4,84 1,078 ,482 Variances different ,939
Control 5 5,33 1,676 ,749 Variances equal ,999
Operated 4 5,32 3,722 1,861 Variances different ,999
Control 5 -2,19 ,795 ,355 Variances equal ,622
Operated 5 -2,38 ,314 ,141 Variances different ,629
Control 5 6,96 ,967 ,432 Variances equal ,213
Operated 4 5,53 2,099 1,049 Variances different ,276
Control 5 2,46 1,768 ,791 Variances equal ,847
Operated 4 2,70 1,650 ,825 Variances different ,846
Control 5 3,95 ,664 ,297 Variances equal ,230
Operated 5 3,47 ,506 ,226 Variances different ,232
Control 5 3,43 ,944 ,422 Variances equal ,729
Operated 4 3,69 1,279 ,640 Variances different ,741
Control 5 -5,06 ,914 ,409 Variances equal ,687
Operated 5 -5,26 ,529 ,236 Variances different ,689
Control 5 6,60 1,635 ,731 Variances equal ,801
Operated 5 6,36 1,293 ,578 Variances different ,801
Control 5 -1,43 ,554 ,248 Variances equal ,297
Operated 5 -2,21 1,446 ,647 Variances different ,314
5HTr1A Average Delta 
Ct
Average Delta 
Ct
5-HTr1D
2.75
1.04
1.30
1.15
1.18
1.28
4.60
3.24
3.53
1.09
-1.17
-1.09
1.31
2.27
1.39
-1.19
-1.20
1.00
1.27
1.03
1.51
-2.30
1.11
1.19
1.04
1.40
1.15
Average Delta 
Ct
Slc6a1 Average Delta 
Ct
Tac1 Average Delta 
Ct
TacR1 Average Delta 
Ct
TrpV2
Prkcc Average Delta 
Ct
Runx1 Average Delta 
Ct
Oprs1 Average Delta 
Ct
Pomc Average Delta 
Ct
Oprd1 Average Delta 
Ct
Oprm1 Average Delta 
Ct
Npy6r Average Delta 
Ct
NTRK3 Average Delta 
Ct
NPY Average Delta 
Ct
Npy5r Average Delta 
Ct
Average Delta 
Ct
LIF Average Delta 
Ct
MapK1 Average Delta 
Ct
IL6
Gene P Value obtained on T-test
BDNF
5HTr3A Average Delta 
Ct
5HTr4 Average Delta 
Ct
Average Delta 
Ct
Creb3 Average Delta 
Ct
Dream Average Delta 
Ct
5HTr2C Average Delta 
Ct
Gabrg2 Average Delta 
Ct
HSP70 Average Delta 
Ct
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Neuropeptide Y gene was 2.3 times more expressed in the dorsal root ganglia 
of the control animals. 
 
A t-test with a confidence interval of 95% was applied to the ΔCt values 
measured in the operated and the control animals values for each gene. In 
the brainstem, no genes showed a significant difference, as illustrated by the 
boxplots of Figure 12A. The difference 3.7 times upregulation we observed in 
the control animals could not be confirmed by the t-test of the ΔCt values. 
Indeed, the P value of that gene was 0.355. In the cortex, only the 5HTr1A 
serotonin receptor showed a significant difference (P value = 0.012). BDNF 
was 2.3 times more expressed in the brainstem of the operated animals 
according to our Real-Time PCR data, but the differences between the ΔCt 
values of that gene in the operated animals and the control ones were not 
significant according to the t-test (P value = 0.096). The boxplots on Figure 12B 
graphically illustrate the ΔCt values in the cortex. In the hippocampus, no 
significant differences could be observed. The P Values for the 5HTr1D 
serotonin receptor and the Npy6r genes had a respective value of 0.42, and 
0.32, which shows that the different observed was not significant. (Figure 12C). 
The differences observed in the dorsal root ganglia were also not significant, 
as the P Values obtained for the 5-Htr1D, 5-HTr4, 5HTr2C serotonin receptors, 
DREAM, LIF, BDNF and NPY genes are all higher than 0.05. The boxplots from 
Figure 12D illustrate the ΔCt values measured in the dorsal root ganglia. Table 
11 A, B, C and D sum up the genes analyzed, their fold change in the 
operated animals vs. the control ones measured by Real-Time PCR in the 
brainstems, cortices, hippocampi and the dorsal root ganglias respectively 
and give all the descriptive and group statistics of the Ct values. 
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Figure 12A: Boxplots of the ΔCt values obtained in the brainstems of 6 operated mice (Pain =1 on the 
figure), and 6 Control mice (Pain = 0 on the figure). No significant difference could be observed. 
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Figure 12B: Boxplots of the ΔCt values obtained in the cortices of 6 operated mice (Pain =1 on the 
figure), and 6 Control mice (Pain = 0 on the figure). The only significant difference can be observed for 
5HTr1A (P Value=0.012) 
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Figure 12C: Boxplots of the ΔCt values obtained in the hippocampi of 6 operated mice (Pain =1 on the 
figure), and 6 Control mice (Pain = 0 on the figure). No significant difference could be observed. 
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Figure 12D: Boxplots of the ΔCt values obtained in the dorsal root ganglia of 6 operated mice (Pain =1 
on the figure), and 6 Control mice (Pain = 0 on the figure). No significant difference could be observed. 
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2.6 Real-Time PCR Measurements, inflammatory pain model  
 
In order to test whether the lack of differences observed in gene expression 
was due to the pain model, the expression profiles of the 27 genes were 
tested in an inflammatory pain model. In this experiment, 6 mice received an 
intraperitoneal injection of BHV-1 immunization solution in Complete Feund’s 
Adjuvent, and 6 control animals received an intraperitoneal injection of 
vehicle solution, which does not cause inflammation. All animals were 
sacrificed 3 days after the injection. For each animal, the cortex and spinal 
cord were dissected and analyzed by Real-Time PCR. 
 
In the cortex, the PCRs for Interleukin 6, the 5-HTr1D serotonin receptor, the 
opioid receptor µ 1 and the Neuropeptide Y receptor type 6 did not run 
optimally, and their results for these genes could not be considered in the 
analysis. Similarily, the reactions for LIF, BDNF, the serotonin receptors 5-HTr4 
and 5-HTr2C and the neuropeptide Y receptor type 6 in the spinal cord 
samples did not run properly and were excluded from the study. 
 
Out of the 27 genes tested, Proopiomelanocortin (Pomc) is the only gene, 
which shows a regulation linked to the inflammatory pain. It appears to be 2.5 
times upregulated in the cortices of the animals, who were subjected to the 
CFA injection. Interestingly, this gene behaves in the opposite way in the 
spinal cords of these animals, in which it appears to be 1.8 times 
downregulated after the CFA treatment. This downregulation could be 
caused by a difference in Pomc-expressing cell numbers between the 
treated and the control spinal cords. Indeed, the CFA injection might have 
triggered the migration of dendritic cells in the spinal cords. This process 
would have decreased the proportion of cells expressing Pomc in the spinal 
cords of treated animals, and would appear as a downregulation of the 
gene, when compared with controls in which no migration of dendritic cells 
would have happened. 
 
The ΔCt values measured in the treated and the control animals were 
subjected to a T-test with a confidence interval of 95% to test the significance 
of the fold changes observed. The 2.5 times upregulation and the 1.8 
downregulation of the Pomc gene observed in the cortices and the spinal 
cords of the immunized animals were not significant according to the T-Test (P 
Value = 0.26 and 0.072, respectively). Interestingly, the T-test showed that a 
significant difference could be seen between the ΔCt values of the Slc6a1 
gene measured in the spinal cords of the immunized and the control animals 
(P Value = 0.02). However, the Real-Time PCR analysis indicated a fold 
change of 1.2 for Pomc, which means that the result of the T-test was a false 
positive. The boxplots of the ΔCt values in the cortices and the spinal cords of 
the treated and the control animals can be seen on Figure 13A and 13B. 
Table 12A and 12 B sum up the genes analyzed, their fold change in the 
treated animals vs. the control ones measured by Real-Time PCR in the cortex 
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and the spinal cord respectively and give all the descriptive and group 
statistics of the Ct values. 
 
 
 
Table 12 A Statistics of the ΔCt values obtained in the cortices of the immunized (treated) and the 
control mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group N Mean SD SEM FC IN THE TREATED ANIMALS
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 4,07800 ,476757 ,194635 Variances equal ,782
Treated 6 4,16400 ,566826 ,231406 Variances different ,782
Control 6 2,90033 ,576472 ,235344 Variances equal ,116
Treated 6 3,50300 ,633747 ,258726 Variances different ,116
Control 6 1,74983 1,233703 ,503657 Variances equal ,534
Treated 6 2,10250 ,521991 ,213102 Variances different ,540
Control 6 6,84033 ,680712 ,277899 Variances equal ,197
Treated 6 7,34033 ,566970 ,231464 Variances different ,198
Control 6 3,62450 ,434160 ,177245 Variances equal ,623
Treated 6 3,46300 ,649021 ,264962 Variances different ,625
Control 6 2,92667 ,219670 ,089680 Variances equal ,781
Treated 6 3,00967 ,678190 ,276870 Variances different ,785
Control 6 -,86383 ,219768 ,089720 Variances equal ,479
Treated 6 -,11883 2,468994 1,007962 Variances different ,494
Control 6 4,54533 ,486546 ,198631 Variances equal ,443
Treated 6 4,76850 ,482179 ,196849 Variances different ,443
Control 6 -2,20350 1,285059 ,524623 Variances equal ,198
Treated 6 -1,46750 ,243896 ,099570 Variances different ,223
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 6,49550 ,820426 ,334938 Variances equal ,341
Treated 6 6,91317 ,611124 ,249490 Variances different ,343
Control 6 2,00533 ,316134 ,129061 Variances equal ,407
Treated 5 2,26720 ,656281 ,293498 Variances different ,448
Control 6 4,97033 ,549733 ,224428 Variances equal ,577
Treated 6 5,15633 ,568757 ,232194 Variances different ,577
Control 6 4,04500 ,235980 ,096338 Variances equal ,996
Treated 6 4,04300 ,826955 ,337603 Variances different ,996
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 ,69083 ,145432 ,059373 Variances equal ,148
Treated 5 ,82460 ,131747 ,058919 Variances different ,145
Control 6 6,22750 ,599907 ,244911 Variances equal ,971
Treated 6 6,23883 ,437504 ,178610 Variances different ,971
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 -,67300 ,805235 ,328736 Variances equal ,378
Treated 6 -,27633 ,677347 ,276526 Variances different ,378
Control 6 6,05067 2,859423 1,167355 Variances equal ,258
Treated 6 3,81317 3,565783 1,455725 Variances different ,259
Control 6 -2,11133 ,190549 ,077791 Variances equal ,686
Treated 6 -1,99700 ,645800 ,263647 Variances different ,692
Control 6 9,12950 ,640605 ,261526 Variances equal ,897
Treated 6 9,20517 1,239485 ,506018 Variances different ,898
Control 6 3,44333 ,262467 ,107152 Variances equal ,954
Treated 6 3,42867 ,541737 ,221163 Variances different ,954
Control 6 -,45867 ,576235 ,235247 Variances equal ,678
Treated 6 -,28950 ,780758 ,318743 Variances different ,679
Control 6 5,05783 ,760495 ,310471 Variances equal ,496
Treated 6 5,35383 ,689788 ,281605 Variances different ,496
Control 6 4,50517 ,459103 ,187428 Variances equal ,313
Treated 5 4,84480 ,597511 ,267215 Variances different ,331
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Table 12 B: Statistics of the ΔCt values obtained in the spinal cords of the immunized (treated) and the 
control mice. 
 
 
 
 
 
Group N Mean SD SEM FC IN THE TREATED ANIMALS
Control 6 10,34 ,661 ,270 Variances equal ,596
Treated 6 10,12 ,744 ,304 Variances different ,596
Control 6 5,49 ,186 ,076 Variances equal ,135
Treated 6 5,30 ,221 ,090 Variances different ,136
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 ,23 ,212 ,086 Variances equal ,597
Treated 6 ,16 ,208 ,085 Variances different ,597
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 ,53 ,308 ,126 Variances equal ,425
Treated 6 ,67 ,299 ,122 Variances different ,425
Control 6 6,26 ,174 ,071 Variances equal ,046
Treated 6 5,97 ,265 ,108 Variances different ,050
Control 6 1,04 ,296 ,121 Variances equal ,454
Treated 6 1,14 ,162 ,066 Variances different ,459
Control 6 -4,19 ,200 ,082 Variances equal ,096
Treated 6 -4,36 ,116 ,047 Variances different ,104
Control 6 7,83 ,980 ,400 Variances equal ,756
Treated 6 7,63 1,148 ,469 Variances different ,756
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 ,78 ,169 ,069 Variances equal ,343
Treated 6 ,64 ,302 ,123 Variances different ,349
Control 6 -1,37 ,167 ,068 Variances equal ,875
Treated 6 -1,35 ,306 ,125 Variances different ,876
Control 6 2,82 ,511 ,209 Variances equal ,926
Treated 6 2,85 ,363 ,148 Variances different ,926
Control 0 . . . Variances equal -
Treated 0 . . . Variances different -
Control 6 -1,72 ,507 ,207 Variances equal ,466
Treated 6 -1,53 ,339 ,139 Variances different ,468
Control 6 3,85 ,620 ,253 Variances equal ,677
Treated 6 3,73 ,310 ,126 Variances different ,680
Control 6 8,93 ,818 ,334 Variances equal ,140
Treated 6 8,21 ,714 ,292 Variances different ,140
Control 6 -,76 ,168 ,068 Variances equal ,780
Treated 6 -,78 ,141 ,058 Variances different ,780
Control 6 8,25 ,535 ,218 Variances equal ,072
Treated 6 9,11 ,905 ,370 Variances different ,079
Control 6 1,43 ,188 ,077 Variances equal ,336
Treated 6 1,57 ,293 ,119 Variances different ,340
Control 6 6,94 ,394 ,161 Variances equal ,864
Treated 6 6,99 ,495 ,202 Variances different ,864
Control 6 1,50 ,177 ,072 Variances equal ,020
Treated 6 1,22 ,173 ,070 Variances different ,020
Control 6 -2,41 ,212 ,086 Variances equal ,405
Treated 6 -3,83 3,994 1,631 Variances different ,424
Control 6 ,34 ,280 ,114 Variances equal ,606
Treated 6 ,52 ,800 ,326 Variances different ,613
Control 6 -1,89 ,176 ,072 Variances equal ,465
Treated 6 -1,76 ,375 ,153 Variances different ,472
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Figure 13A: Boxplots of the ΔCt values obtained in the cortices of 6 immunized mice (Pain =1) on the 
figure), and 6 Control mice (Pain = 0 on the figure). No significant difference could be observed. 
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Figure 13B: Boxplots of the ΔCt values obtained in the Spinal cords of 6 immunized mice (Pain =1) on the 
figure), and 6 Control mice (Pain = 0 on the figure). No significant difference could be observed. Slc6a1 
was a false positive with a FC = 1.2 and a P value = 0.02. No other significant difference could be 
observed. 
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2.7 Whole genome experiment in the spinal cord, Telemetric 
Apparatus  
 
In order to have a further understanding of the gene expression changes 
linked to nociception, which occur in the post-operative recuperation phase 
in NMRI mice, we carried a whole genome microarray analysis. In this 
experiment, we worked with GeneChip® Mouse Exon 1.0 ST Arrays, which 
allow to study the behavior of all the exons of each gene of the murine 
organism. The surgical protocol was the same as previously described: 6 NMRI 
mice were anesthetized with Sevofluorane, subjected to a Telemetric 
Apparatus Implantation, and treated twice daily with 80 µl Flunixin (Conc.) 
injected intra-peritonealy during the recovery phase. The 6 control animals 
were subjected to the same anesthesia and analgesia, but did not undergo 
surgery. After a careful observation of each animal’s behavior, aspect, coat, 
posture, cage and nest, the decision to sacrifice them 24 hours post surgery 
was taken. At the time of sacrifice, the operated animals showed clear 
differences in their behavior when compared to the control ones. They did 
not groom, adopted an arched back position, and their nests were poorly 
elaborated, when compared to the control animals. These observations led 
to the assumption that the operated animals were indeed experiencing pain 
at this time. After sacrifice, the spinal cords were dissected, and the total RNA 
was extracted, reverse transcribed, amplified and labeled for hybridization on 
the GeneChip® Mouse Exon 1.0 ST Arrays.  
 
On the GeneChip® Mouse Exon 1.0 ST Arrays, 4 probes for the same exon are 
included in one probeset. In most cases, one probeset covers one exon, 
however more probesets cover long exons. In our experiments, 4.5 x 106 
probesets were differentially expressed between the operated animals and 
the control ones. A general asymmetry of the regulations was observed, with 
about 37% of the exon expression level changes being upregulations, and 
63% of them being downregulations. For our analyses, we worked with the 
37000 probesets, which showed the most significant fold changes.  Two types 
of analysis were carried out. The first one consisted in understanding, which 
genes tend to show a complete differential expression, and to cluster them to 
understand their function. The second analysis consisted in identifying genes, 
which were most likely to have splice variants between the two conditions. 
 
2.7.1 Whole gene regulations 
 
The goal of this analysis, was to understand, which genes have 3 or more 
probesets, which were either upregulated or downregulated in the operated 
animals and to define, which processes they might be linked to. For study of 
the downregulations, we analyzed the 4000 most significantly differentially 
expressed probesets. Out of these 4000 exons, 2823 were known and defined, 
and 1177 were not annotated sequences. We excluded genes, which had 
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two or less downregulated probesets, as well as probesets recognizing single 
intronic sequences and intergenic sequences. This filtering showed that 166 
genes had 3 or more exons, which were downregulated in the spinal cords of 
the operated animals. After a literature search, and a search on Entrez 
(NCBI), the genes were then classified according to their function. The results 
can be seen in table 13. 
 
Interestingly, 68 genes were linked to cell motility. These genes are typical 
cytoskeleton components, often implicated in skeletal muscle cell function: 
such as Actin alpha 1, or Myosin, heavy polypeptide 2. Out of this category, 
the gene, which had the most downregulated exons was the Titin gene. This 
gene had 301 probesets, which showed a 2 to 4 times downregulation. 
According to Ensembl, this gene is 278567 bp long, and has 363 exons, which 
explains the high number of probesets present. Another noticeable feature is 
that 7 genes, which had many downregulated exons in the spinal cords of 
the operated animals, are involved in neurogenesis. Taken together, this data 
could lead to the supposition that synaptic plasticity processes are 
happening in the spinal cord of the operated animals. It could also reflect 
microglia activation in the spinal cord. The activation of the immune system in 
the central nervous system also requires cellular motility, and could be explain 
the downregulations described above.  
 
Our analysis showed that 30 genes involved in inflammation, such as 
Interleukin receptor 8 beta or Annexin A1 are downregulated in the spinal 
cords of the operated mice. The other main represented categories are 
genes involved in the cell cycle (21 genes), and genes encoding channels or 
recepors (12 genes). The complete list of genes, which have at least 3 
downregulated exons in the spinal cords of the operated animals, can be 
seen in Appendix 6. 
 
 
 
Table 13: Classification of the 166 genes, which had 3 or more downregulated exons in the lumbar 
spinal cords of the operated animals. 
 
 
 
Not Annotated 1177
Gene with minimum of 3 downregulated exons 166
Examples
Cell Motility 68 Acta1, Actn2, Diap3, Myh2, Trpm2, Ttn
Inflammation 30 Il8rb, Anxa1, Fcrla, Lirb4
Cell Cycle 21 Ccna2, Bub1
Neurogenesis 7 Aspm, Comp
Channels and receptors 12 Scn10a, Scn11a
Cell differenciation 6 Mcm4, S100a4, s100a8
ATPase 5 Atp2a1, Atp6v0d2
Protein degradation 6 Bckdhb
GPI coupled receptors or related 6 Gpr128, Gpr141
Apoptosis 1 Birc5
Heterochromatin formation 1 Baz1a
Cancer 3 Cox8b, Hmmr, Fap
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For the study of the upregulated genes, we increased the number of 
screened genes, because of the asymmetry between the upregulated and 
downregulated genes. We therefore considered the 18000 most significantly 
upregulated probesets. Out of this list, 8932 were located in not annotated 
sequences, and 9068 were in exons of known genes. After excluding the 
genes, which had two or less upregulated probeset, and the probesets 
recognizing single intronic sequences or intergenic sequences, we obtained a 
list of 96 genes, which had 3 or more upregulated probesets.  After a literature 
search and a screening on Entrez, we classified the 96 genes according to 
their function.  
 
In the list of genes, which had at least 3 upregulated exons in the spinal cords 
of the operated animals, 22 genes were directly involved in axonal guidance 
and synaptic plasticity. Interestingly, 4 members of the EphA receptors family 
(Epha3, Epha4, Epha5 and Epha6), and 6 members of the Semaphorin family 
(Sema3F, Sema4A, Sema5A, Sema6A, Sema6C and Sema6D) were 
upregulated. EphA receptors are involved in the growth cone guidance of 
spinal motor neurons, and Semaphorins are one of the most important families 
of genes involved in the maintenance of neuronal networks and in axonal 
guidance. 
 
Two other noticeable functions among the 96 genes, which have 3 or more 
upregulated exons are the neuronal development (13 genes), and cell 
interaction and adhesion (8 genes).  In our experiment, one of the most 
important upregulated genes in the category of neuronal development is 
Dab1. This gene is an important element of the Reelin Dab1 pathway, which 
regulates neuronal positioning during the development. This pathway is also 
involved in Pain perception. In our microarray analysis, Reelin was 
downregulated in the operated animals. This tends to show, that the Reelin-
Dab1 pathway is active in our surgical pain model. In the cell interaction and 
adhesion category, Neural Cell Adhesion Molecule 1 and 2 are two important 
elements, as these molecules are involved the establishment of synapses 
 
Two genes directly linked to nociceptive processes had at least 3 
upregulated exons in the spinal cords of the operated mice: Gabrb2 and 
Oprm1. Interestingly, Oprm1 was present on the low-density microarray, but 
did not show any regulation in any other experiments, even in the Spinal cord. 
The other 2 key categories, which were present, were Glycosylation and 
Inflammation. These are both known to be influencing synaptic generation. 
All the classifications of the genes, which have at least 3 upregulated exons in 
the post operative phase are described in Table 14, and Appendix 7 is the 
complete list of the 96 with more than 2 upregulated exons. 
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Table 14: Classification of the 96 genes, which had 3 or more upregulated exons in the spinal cords of 
the operated animals. 
 
 
2.7.2 Clustering analysis 
 
We performed a bi-clustering meta-analysis using Genevestigator, in order to 
better understand the mechanisms in which the regulated genes from our 
study might be involved in. The lists of up- and downregulated genes, were 
clustered in Genevestigator, according to the “Stimulus” criterion. In this 
procedure, the software searches how the genes of the proposed list reacted 
to a specific stimulus in published microarrays, and performs a bi-clustering 
analysis to group genes, which showed similar regulation after specific 
stimulations. Specific cellular effects are caused by each stimulus listed in 
Genevestigator. By understanding which cellular process is triggered by the 
stimulation, one can gain information about the subset of genes, which is 
clustered according to this stimulus. 
 
2.7.2.1 Bi-clustering analysis of the downregulated genes 
 
The first clustering was performed on the 166 genes, which had 3 or more 
downregulated exons in the spinal cords of the operated animals. The goal 
was to find subsets from this gene list, which were also downregulated after 
specific stimuli. This analysis revealed that a cluster of 21 genes from our list, 
represented by 29 probesets, was also downregulated in 4 different types of 
experimental stimulations: two different experiments involving 
lipopolysaccharides, an experiment with Trichostatin A3, and a myoblast to 
myotubule in-vitro differentiation. The list of the clustered probesets and their 
corresponding genes can be seen in Table 15. The clusters can be seen in 
Figure 12 A. 
 
 
Non Attributed 8932
Gene with a minimum of 2 upregulated probesets 96
Examples
Axonal guidance and Synaptic formation 22 Epha3, Epha4, Erc5, Pcdha6, Sema5a
Neuronal Development 13 Plxdc2, Med12l, Pax6, Immp21, Dach1
Cell cell interaction and adhesion 8 Ctnna1, Ncam1, Ncam2
Glycosylation 3 Ext1, Gtdc1, Alg13
Solute carrier 8 Slc25a37, Slc25a40, Slc26a3, Slc27a2
G Protein coupled receptor 2 Lphn2, Lphn3
Inflammation 3 Pibf1, Ilf3, Pros1
Signal Transmission 6 Map4k5, Odz4, Plcl1
CNS disorders 4 Auts2, Brunol14, Hnt
Potassium channel 2 Kcnab1, Kcnc2
Exocytosis Endocytosis 2 Exoc6b, Sgip1
Nociception 2 Gabrb2, Oprm1
Cancer 4 Ptprz1, Gtf2h1, Gtf2h2, Gtf2i
Others (chaperone, mitochondrial protein…) 17 Lace1, Fads1, Dnajc2, Bai1
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Table15: Bi-clustering analysis of the 166 downregulated genes. 29 clustered probesests, which are all 
downregulated after Lipopolysaccharide 4, Lipopolysaccharide 5, Trichostatin A3, myoblast to 
myotubule differentiation stimuli. 
 
 
 
Lipopolysaccharide injections are known to stimulate the immune system, and 
have been shown to enhance axonal sprouting in injured spinal cords of rats 
(CITE Chen Q, Exp Neurol 2008). Trichostatin A3 is known to inhibit class I and II 
histone deacetylases and has been shown to differentiate neuro2a cells into 
neurons, which can form neural networks (Inokoshi et al., 1999) (cite Biochem 
Biophys Res Commun., Inokoshi J 1999).  
 
The second clustering was performed in order to find subsets of the 166 
downregulated genes, which were upregulated after specific stimuli in other 
experiments. This analysis showed that a cluster of 21 genes from our list, 
represented by 31 probesets, was upregulated after 4 different types of 
stimulations: 2 experiments involving 1-fluoro-2,4 dinitrobenzene, one involving 
ovalbumin, and  one, in which a combination of ovalbumin and particulate 
matter was used. These 21 genes are therefore downregulated in our 
experiment, but upregulated after the 4 stimuli mentioned above. The list of 
the clustered probesets and their corresponding genes can be seen in Table 
16, and the clusters can be seen in Figure 12 B. 
 
 
 
 
 
 
Probe Set ID Gene Symbol Gene Title Entrez Gene ID
1415945_at Mcm5 minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 17218 Entrez gene
1416961_at Bub1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) 12236 Entrez gene
1417910_at Ccna2 cyclin A2 12428 Entrez gene
1417911_at Ccna2 cyclin A2 12428 Entrez gene
1418264_at Cenpk centromere protein K 60411 Entrez gene
1422814_at Aspm asp (abnormal spindle)-like, microcephaly associated (Drosophila) 12316 Entrez gene
1424046_at Bub1 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) 12235 Entrez gene
1424060_at Neil3 nei like 3 (E. coli) 234258 Entrez gene
1424118_a_at Spc25 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) 66442 Entrez gene
1424278_a_at Birc5 baculoviral IAP repeat-containing 5 11799 Entrez gene
1427161_at Cenpf centromere protein F 108000 Entrez gene
1427276_at Smc4 structural maintenance of chromosomes 4 70099 Entrez gene
1429172_a_at Ncapg on-SMC condensin I complex, subunit G 54392 Entrez gene
1434767_at C79407 expressed sequence C79407 217653 Entrez gene
1435306_a_at Kif11 kinesin family member 11 16551 Entrez gene
1436186_at E2f8 E2F transcription factor 8 108961 Entrez gene
1439695_a_at Kif20b kinesin family member 20B 240641 Entrez gene
1440924_at Kif20b kinesin family member 20B 240641 Entrez gene
1444319_at E2f8 E2F transcription factor 8 108961 Entrez gene
1447363_s_at Bub1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) 12236 Entrez gene
1449171_at Ttk Ttk protein kinase 22137 Entrez gene
1450157_a_at Hmmr hyaluronan mediated motility receptor (RHAMM) 15366 Entrez gene
1450692_at Kif4 kinesin family member 4 16571 Entrez gene
1452314_at Kif11 kinesin family member 11 16551 Entrez gene
1452315_at Kif11 kinesin family member 11 16551 Entrez gene
1452459_at Aspm asp (abnormal spindle)-like, microcephaly associated (Drosophila) 12316 Entrez gene
1453748_a_at Kif23 kinesin family member 23 71819 Entrez gene
1455990_at Kif23 kinesin family member 23 71819 Entrez gene
1456280_at Clspn claspin homolog (Xenopus laevis) 269582 Entrez gene
1458447_at Cenpf centromere protein F 108000 Entrez gene
Results 
 104 
 
 
Table 16: Bi-clustering analysis of the 166 downregulated genes. 31 clustered probesests, which are all 
upegulated after the 1-fluoro-2,4 dinitrobenzene, 1-fluoro-2,4 dinitrobenzene 2, ovalbumin, and  
ovalbumin / particulate matter stimuli. 
 
 
 
 
 
 
Probe Set ID Gene Symbol Gene Title Entrez Gene ID
1415945_at Mcm5 minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 17218 Entrez gene
1416961_at Bub1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) 12236 Entrez gene
1417256_at Mmp13 matrix metallopeptidase 13 17386 Entrez gene
1417910_at Ccna2 cyclin A2 12428 Entrez gene
1417911_at Ccna2 cyclin A2 12428 Entrez gene
1420394_s_at Gp49a glycoprotein 49 A 14727 Entrez gene 
Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 14728 Entrez gene
1422016_a_at Cenph centromere protein H 26886 Entrez gene
1422814_at Aspm asp (abnormal spindle)-like, microcephaly associated (Drosophila) 12316 Entrez gene
1422944_a_at Diap3 diaphanous homolog 3 (Drosophila) 56419 Entrez gene
1422978_at Cybb cytochrome b-245, beta polypeptide 13058 Entrez gene
1424046_at Bub1 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) 12235 Entrez gene
1424118_a_at Spc25 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) 66442 Entrez gene
1424278_a_at Birc5 baculoviral IAP repeat-containing 5 11799 Entrez gene
1427161_at Cenpf centromere protein F 108000 Entrez gene
1429172_a_at Ncapg on-SMC condensin I complex, subunit G 54392 Entrez gene
1434767_at C79407 expressed sequence C79407 217653 Entrez gene
1435306_a_at Kif11 kinesin family member 11 16551 Entrez gene
1436186_at E2f8 E2F transcription factor 8 108961 Entrez gene
1436778_at Cybb cytochrome b-245, beta polypeptide 13058 Entrez gene
1436779_at Cybb cytochrome b-245, beta polypeptide 13058 Entrez gene
1436808_x_at Mcm5 minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 17218 Entrez gene
1439695_a_at Kif20b kinesin family member 20B 240641 Entrez gene
1440924_at Kif20b kinesin family member 20B 240641 Entrez gene
1447363_s_at Bub1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) 12236 Entrez gene
1449366_at Mmp8 matrix metallopeptidase 8 17394 Entrez gene
1452314_at Kif11 kinesin family member 11 16551 Entrez gene
1453748_a_at Kif23 kinesin family member 23 71819 Entrez gene
1455990_at Kif23 kinesin family member 23 71819 Entrez gene
1456280_at Clspn claspin homolog (Xenopus laevis) 269582 Entrez gene
1458374_at C79407 expressed sequence C79407 217653 Entrez gene
1460218_at Cd52 CD52 antigen 23833 Entrez gene
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Figure 12: Bi-clustering meta-analysis of the 166 genes with more than 3 downregulated exons in the 
spinal cords of the operated animals. The list of genes was clustered according to the “stimulus” criteria 
in Genevestigator, and two searches were perormed. A. Clustering in order to find subsets of the 166 
genes list, which are downregulated after specific stimuli. 29 probesets, corresponding to 21 genes are 
similarily downregulated in after Lipopolysaccharide 4, Lipopolysaccharide 5, Trichostatin A3, myoblast 
to myotubule differentiation. B. Clustering in order to find subsets of the 166 genes list, which are 
upregulated after specific stimuli. 31 probesets, corresponding to 21 genes are similarily upregulated in 
after 1-fluoro-2,4 dinitrobenzene, 1-fluoro-2,4 dinitrobenzene 2, ovalbumin, and  ovalbumin / particulate 
matter stimuli. 
 
 
2.7.2.2 Bi-clustering analysis of the upregulated genes 
 
The 96 genes, which had at least 3 upregulated exons in our microarray 
analysis, were clustered according to the criteria “Stimulus”. The first clustering 
consisted in finding subsets from this gene list, which were downregulated 
after specific stimuli in other experiments. The analysis revealed that a cluster 
of 19 probesets representing 17 genes, which were upregulated in our 
experiment, was downregulated after a chemical stimulation with 1.5-
naphtalenediamine 2 and with N-(1-naphthyl)ethylenediamine 
dihydrochloride 2. The list of the clustered probesets and their corresponding 
genes can be seen in Table 17. The clusters can be seen in Figure 13 A.  
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Table 17: Bi-clustering analysis of the 96 upregulated genes. 19 clustered probesests, which are all 
downregulated after the Chemical 1.5-naphtalenediamine 2 and N-(1-naphthyl)ethylenediamine 
dihydrochloride 2 stimuli. 
 
 
 
N-(1-naphthyl)ethylenediamine dihydrochloride 2 is used in research to 
measure Nitric Oxide concentrations (Ignarro et al., 1987). Nitric oxide has 
been shown to be a vasodilatator, but recent studies have also shown, that it 
has a role in cell proliferation, neuronal motility and synaptic maturation 
(Tegenge and Bicker, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Probe Set ID Gene Symbol Gene Title Entrez Gene ID
1418912_at Plxdc2 plexin domain containing 2 67448 Entrez gene
1419271_at Pax6 paired box gene 6 18508 Entrez gene
1420557_at Epha5 Eph receptor A5 13839 Entrez gene
1421929_at Epha4 Eph receptor A4 13838 Entrez gene
1422162_at Dcc deleted in colorectal carcinoma 13176 Entrez gene
1425840_a_at Sema3f sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F 20350 Entrez gene
1425960_s_at Pax6 paired box gene 6 18508 Entrez gene
1427307_a_at Dab1 disabled homolog 1 (Drosophila) 13131 Entrez gene
1430698_a_at Pibf1 progesterone immunomodulatory binding factor 1 52023 Entrez gene
1431675_a_at Gtf2i general transcription factor II I 100044121 Entrez gene 
LOC100044121 similar to transcription factor TFII-I-gamma 14886 Entrez gene
1431680_a_at Ptprk protein tyrosine phosphatase, receptor type, K 19272 Entrez gene
1436904_at Med13 mediator complex subunit 13 327987 Entrez gene
1439757_s_at Epha4 Eph receptor A4 13838 Entrez gene
1448955_s_at Cadps Ca2+-dependent secretion activator 27062 Entrez gene
1449958_a_at Fgf14 fibroblast growth factor 14 14169 Entrez gene
1451898_a_at Sema6c sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C 20360 Entrez gene
1455258_at Kcnc2 potassium voltage gated channel, Shaw-related subfamily, member 2 268345 Entrez gene
1455266_at Kif5c kinesin family member 5C 16574 Entrez gene
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Figure 13: Bi-clustering meta-analysis of the 96 genes with more than 3 upegulated exons in the spinal 
cords of the operated animals. The list of genes was clustered according to the “stimulus” criteria in 
Genevestigator, and two searches were perormed. A. Clustering in order to find subsets of the 96 genes 
list, which are downregulated after specific stimuli. 19 probesets, corresponding to 17 genes are similarily 
downregulated in after 1.5-naphtalenediamine 2 and N-(1-naphthyl)ethylenediamine dihydrochloride 2 
stimulations. B. Clustering in order to find subsets of the 96 genes list, which are upregulated after 
specific stimuli. 17 probesets, corresponding to 15 genes are similarily upregulated after 
lipopolysaccharide 5 and lipopolysaccharide 6 stimulations. 
 
 
Another clustering was performed in order to find, which subset of the 96 
upregulated genes was also upregulated after specific stimuli in other 
experiments. This analysis showed, that 17 probesets, corresponding to 15 
genes were upregulated in our experiment, but also after stimulations with 
Lipopolysaccharide 5 and 6. Lipopolysaccharides are known to trigger 
inflammation, and have been shown to allow axonal sprouting in injured rat 
spinal chords (Chen et al., 2008). The list of the clustered probesets and their 
corresponding genes can be seen in Table 18. The clusters can be seen in 
Figure 13 B. 
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Table 18: Bi-clustering analysis of the 96 upregulated genes. 17 clustered probesests, which are all 
upregulated after Lipopolysaccharide 5 and Lipoplysaccharide 6 stimuli. 
 
 
 
 
2.7.3 Splice variant analysis 
 
The GeneChip® Mouse Exon 1.0 ST Arrays show expression level changes  of 
each exon of the murine genome. It is therefore possible to monitor which 
genes show alternative splicing events. The genes, for which the fold changes 
of all the exons have a high standard deviation, are likely to be subjected to 
splicing events.  
 
To monitor which genes are differentially spliced between the operated mice 
and the control mice among the 37000 most significantly regulated 
probesets, the standard deviation of the various signals obtained for each 
gene was calculated, after exclusion of unspecific intronic or intergenic 
probesets, which add artefactual variability. This procedure led to a list of 
1310 genes, which can be seen in Appendix 7, along with their Ensembl Gene 
identifier and their standard deviation. Among these genes, 389 were known 
registered in Ensemble as sequences encoding unknown proteins, and 59 
were only defined with their Riken gene identifiers. The threshold, at which the 
standard deviation of the signals was considered as a significant indicator of 
alternative splicing events, was set at 0.4. The genes, which had a higher 
standard deviation than the threshold, were selected, and a list of 410 genes 
was established. This list corresponds the first 410 genes of Appendix 7. 
 
An analysis on the g:Profiler software was carried in order to gain more 
information about the 410 genes, which showed alternative splicing events. 
This software allows to group subsets from a gene list, according to their 
described biological functions. Table 19 lists the functions in which the genes, 
which have spice variants in our microarray experiment, are involved in. 
 
Most of the differentially spliced genes between the spinal cords of the 
operated mice and the ones of the controls are involved in catalytic activity 
(152 genes), are proteins from the plasma membrane (85 genes) or have a 
Probe Set ID Gene Symbol Gene Title Entrez Gene ID
1416316_at Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 26458 Entrez gene
1417730_at Ext1 exostoses (multiple) 1 14042 Entrez gene
1420694_a_at Dach1 dachshund 1 (Drosophila) 13134 Entrez gene
1422473_at Pde4b phosphodiesterase 4B, cAMP specific 18578 Entrez gene
1425841_at Slc26a7 solute carrier family 26, member 7 208890 Entrez gene
1427783_at Erbb4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 13869 Entrez gene
1434582_at Erc2 ELKS/RAB6-interacting/CAST family member 2 238988 Entrez gene
1435577_at Dab1 disabled homolog 1 (Drosophila) 13131 Entrez gene
1435578_s_at Dab1 disabled homolog 1 (Drosophila) 13131 Entrez gene
1438934_x_at Sema4a sema domain, immunoglobulin domain, transmembrane domain and short cytoplasmic domain, Semaphorin 4A20351 Entrez gene
1439717_at Gabrg3 gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 3 14407 Entrez gene
1439757_s_at Epha4 Eph receptor A4 13838 Entrez gene
1441277_s_at Ptprk protein tyrosine phosphatase, receptor type, K 19272 Entrez gene
1444906_at LOC100048050 similar to calcium-independent alpha-latrotoxin receptor homolog 2 100048050 Entrez gene 
Lphn2 latrophilin 2 99633 Entrez gene
1448110_at Sema4a sema domain, immunoglobulin domain, transmembrane domain and short cytoplasmic domain, Semaphorin 4A20351 Entrez gene
1454043_a_at Kcnab1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 16497 Entrez gene
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hydroxylase activity (85 genes). Another high proportion of genes are 
involved in nucleotide binding or ATP binding.  
 
In accordance with what was observed for the genes, which have more than 
3 up or down regulated exons, many functional categories, which regroup up 
to 39 genes, are linked to cell adhesion, extracellular matrix, cytoskeleton, 
and actin or myosin contraction. This tends to show, that cellular motility, 
which might be either linked to inflammation, or to synaptic rearrangements 
takes place, and involves various splice variants of specific genes. For 
instance, the microarray experiment reported signals with a standard 
deviation of 1.25 for Semaphorin 3F. This gene is involved in axonal guidance, 
and has splice variants, which are involved in a temporal and regional 
regulation during the maturation of the murine CNS (Kusy et al., 2003). 
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Table 18: Functional grouping of the genes, which have different alternative splicing events in the spinal 
cords of the operated and the control animals. 
 
Functional Total number of genes Category Number of analyzed genes P Value
Category in the specific  category Domain which belong to this category
catalytic activity 5817 Molecular Function 152 2.66E-05
plasma membrane 2761 Cell Component 85 1.45E-05
hydrolase activity 2568 Molecular Function 85 8.08E-07
non-membrane-bounded organelle 2245 Cell Component 75 3.06E-06
intracellular non-membrane-bounded organelle 2245 Cell Component 75 3.06E-06
nucleotide binding 2257 Molecular Function 73 1.33E-05
purine nucleotide binding 1967 Molecular Function 68 3.09E-06
ribonucleotide binding 1882 Molecular Function 66 2.74E-06
purine ribonucleotide binding 1882 Molecular Function 66 2.74E-06
adenyl nucleotide binding 1638 Molecular Function 65 4.12E-08
adenyl ribonucleotide binding 1553 Molecular Function 63 3.09E-08
ATP binding 1529 Molecular Function 62 4.12E-08
protein complex 1817 Cell Component 61 2.64E-05
cytoskeleton 1231 Cell Component 58 5.54E-10
organ development 1555 Biological Process 56 8.20E-06
plasma membrane part 1375 Cell Component 55 4.17E-07
calcium ion binding 959 Molecular Function 53 1.08E-11
transmembrane transporter activity 1052 Molecular Function 41 2.60E-05
biological adhesion 674 Biological Process 39 2.03E-09
cell adhesion 674 Biological Process 39 2.03E-09
cytoskeletal part 786 Cell Component 37 9.89E-07
MI:mmu-miR-466b-5p 1059 miRBase 37 7.57E-05
MI:mmu-miR-466e-5p 1054 miRBase 37 6.87E-05
system process 821 Biological Process 36 6.93E-06
MI:mmu-miR-324-3p 922 miRBase 33 1.20E-04
cytoskeletal protein binding 441 Molecular Function 32 2.59E-10
MI:hsa-miR-648 831 miRBase 31 9.21E-05
MI:mmu-miR-742 769 miRBase 31 2.18E-05
actin binding 306 Molecular Function 29 3.10E-12
actin cytoskeleton 278 Cell Component 23 8.05E-09
contractile fiber 90 Cell Component 23 1.51E-19
myofibril 85 Cell Component 23 3.63E-20
contractile fiber part 82 Cell Component 21 5.61E-18
sarcomere 77 Cell Component 21 1.34E-18
cell surface 305 Cell Component 20 3.07E-06
extracellular matrix 331 Cell Component 20 1.04E-05
proteinaceous extracellular matrix 317 Cell Component 20 5.48E-06
Muscle contraction 51 REACTOME 18 5.48E-16
Striated Muscle Contraction 51 REACTOME 18 5.48E-16
Release Of ADP From Myosin 51 REACTOME 18 5.48E-16
Calcium Binds Troponin-C 51 REACTOME 18 5.48E-16
Myosin Binds ATP 51 REACTOME 18 5.48E-16
ATP Hydrolysis By Myosin 51 REACTOME 18 5.48E-16
Focal adhesion 193 KEGG 17 3.23E-07
actin filament-based process 193 Biological Process 15 7.11E-06
actin cytoskeleton organization 181 Biological Process 14 1.51E-05
muscle system process 78 Biological Process 14 3.50E-10
muscle contraction 75 Biological Process 14 2.02E-10
I band 46 Cell Component 11 1.10E-09
myosin complex 62 Cell Component 11 3.17E-08
ECM-receptor interaction 80 KEGG 11 5.70E-07
striated muscle contraction 37 Biological Process 9 3.16E-08
Z disc 39 Cell Component 8 7.72E-07
actomyosin structure organization 31 Biological Process 7 1.93E-06
myosin II complex 18 Cell Component 7 2.92E-08
muscle myosin complex 16 Cell Component 7 1.08E-08
A band 10 Cell Component 6 1.12E-08
myosin filament 15 Cell Component 6 2.45E-07
striated muscle thick filament 15 Cell Component 6 2.45E-07
striated muscle cell development 20 Biological Process 5 3.54E-05
myofibril assembly 20 Biological Process 5 3.54E-05
Response to activity 7 Biological Process 4 4.99E-06
cardiac myofibril assembly 6 Biological Process 4 2.17E-06
striated muscle thin filament 10 Cell Component 4 2.86E-05
myosin light chain kinase activity 3 Molecular Function 3 7.63E-06
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3. Discussion 
 
3.1. Low-density microarray 
 
3.1.1 Whole brain microarray experiments 
 
The first protocol we established consisted in competitive hybridizations of a 
sample labeled with Alexa-555 (green) and a sample labeled with Alexa-647 
(red). These experiments were performed to analyze whether it was possible 
to detect expression level changes between whole brains of operated and 
control mice (see chapter 5.2 for the protocol). To do so, we labeled all our 
experimental samples – whether from operated animals or controls – with 
Alexa-555 and a reference mouse brain aRNA with Alexa-647.  
 
The data revealed a general bias towards the Alexa-555 signal, which 
particularly affected the genes with signals lower than 1000. This effect was 
observed regardless of whether the sample labeled in green was from an 
operated animal or from a control one (Figure 2). The quality of the 
hybridization was however very good, with mean background values below 
50 as well as a good intraslide and interslides reproducibility between the 
replicates and the samples. To assess whether this bias came from a 
biological regulation, which could enhance the gene expression levels in the 
brain of handled animals compared to the reference naïve animals, we 
performed a dye swap experiment. On one slide, the hybridized sample 
contained equal amounts of brain19 aRNA, which was derived from an 
operated animal, and labeled with Alexa-555 and of reference mouse brain 
aRNA labeled with Alexa-647. On the other slide, the sample mixture had 
equal amounts of brain 16 aRNA labeled with Alexa-647, and of reference 
mouse brain aRNA labeled with Alexa-555. On both slides, the sample labeled 
with Alexa-555 had higher signals, which meant that this effect was due to a 
dye imbalance (Figure 4). Had the effect been caused by a generally higher 
genetic expression in the brain 19 sample, the second slide would have had 
higher Alexa-647 signals. 
 
Such dye effects have been reported in previous studies (Dombkowski et al., 
2004; Tseng et al., 2001; Yang and Speed, 2002). Dombkowski et al. have 
shown by performing dye swap experiments on comparisons of gene 
expression changes between cells from breast cancer tumors at various 
stages, that dye effects influence the results obtained on 2 color arrays. 
According to their results, the comparison of ratios of the Cy3/Cy5 signals, 
with the reference samples labeled with the same dye on all slides is not 
robust enough to bypass dye artifacts. They postulate that all genes do not 
incorporate dyes with the same efficiency, and that a same gene can 
incorporate dyes differently from one labeling reaction to another. This could 
explain the general dye biases, and the need for appropriate normalization 
protocols. (Dombkowski et al., 2004). Similar observations have been made in 
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studies using a custom-made microarrays to measure gene expression 
changes in bacteria. The authors attributed the dye discrepancies to different 
chemical stability, incorporation rates, and scanning efficiency for the two 
dyes (Tseng et al., 2001). 
 
Our analysis of the raw data showed no significant gene expression 
differences between the expression levels in the brains of the operated and 
the control animals. To see whether this was due to the dye imbalance, we 
normalized our values using the locally weighed scatter plot smoothing 
(Loess) normalization, which is commonly used in the analysis of two color 
microarray data (Colantuoni et al., 2002; Workman et al., 2002; Yang et al., 
2002). This method gives robust results in the normalization of gene datasets 
with more than 1000 genes (Chiogna et al., 2009). In order to be able to use 
this normalization, only a relatively small proportion of the genes has to show 
significant expression level differences between the two co-hybridized aRNA 
samples or there has to be symmetry in the expression levels of the up/down-
regulated genes (Yang et al., 2002). This assumption cannot be true when less 
than 1000 genes are analyzed, and one has to be aware that the Loess 
normalization might give unreliable results in such a case. Given that our 
microarray had less than 1000 genes, this normalization was not optimal. On 
the scatter plots, it did seem to correct the dye imbalance, however no 
significant gene expression differences could be observed between the 
operated and the control animals. This experiment showed that this 
hybridization and normalization model was not suitable to detect relevant 
gene expression changes.  
 
Another possible explanation for the lack of relevant differences is the fact 
that the analyses were carried out with RNA extracted from the whole brain. 
Gene expression profiles are not constant between the various parts of the 
brain (Hovatta et al., 2005; Nelson et al., 2006). This means that if a gene 
expression change occurs in one part of the brain, it might not be detected in 
a whole brain analysis, as normal expression levels in the rest of the brain 
could compensate the difference. Moreover, the integration of the noxious 
signal in the brain involves specific areas of the “pain matrix” as well as the 
regions, which activate the descending pathways such as the PAG-RVM in 
the brainstem (Albe-Fessard et al., 1985; Apkarian et al., 2005; Fields, 1985, 
2000). We therefore decided to optimize the hybridization protocol to bypass 
all possible dye imbalances and to carry a more precise analysis of smaller 
parts of the central nervous system. 
 
 
3.1.2 One-color model hybridization protocol validation 
 
To bypass any dye imbalance, we developed a one-color microarray 
protocol in which all the samples were labeled with Cy5, and single 
hybridizations were performed separately. Although two color hybridization 
models are widely used for custom-made microarrays, hybridization with a 
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single color protocols with Cy5 have also been developed and used for other 
arrays such as the CodeLink Bioarrays (GE Healthcare) (Severgnini et al., 
2006). The Affymetrix microarrays are all also based on a single-channel 
model. In order to test the relevancy of a single color hybridization protocol, a 
validation experiment was carried out.  
 
The brain of 3 naïve NMRI was dissected, and hybridizations were performed 
to compare the expression levels differences between the hippocampus, the 
brainstem and the cortex. After the data acquisition, two analyses were 
performed: one on the raw data, and one on the data normalized according 
to a set of ubiquitously expressed positive control genes. The results obtained 
were compared with the ones obtained by Hovatta et al. in their microarray 
study on anxiety (Hovatta et al., 2005).  In their study, they assessed the gene 
expression level differences between various parts of the brain in 6 inbred 
mice strains: A/J, 129S6/SvEvTac, C3H/HeJ, C57BL/6J, DBA/2J, and FVB/NJ, 
and made their data publically available in the GEO dataset n°: GDS1406. 
We compared the results we obtained before and after normalization with 
the results they obtained. We primarily focused on their measurements for the 
A/J strain, because our observations were highly similar to what they 
measured in this strain. We nevertheless also compared our data with what 
they had observed for the other strains they analyzed (see chapter 3.4). 
 
When assessing whether the differentially expressed genes in our microarray 
experiments were also showing such expression level differences in the GDS 
1406 GEO datasets for the A/J mouse strain, we obtained high levels of 
similarities. We first considered the raw data, and observed that 73% of the 
genes, which were differentially expressed between the cortex and the 
brainstem according to our results, had similar expression level differences on 
the GDS1406 data. In this experiment only two genes showed different 
regulations across the two platforms: Pomc and the serotonin receptor 5HTr5B, 
which were both more expressed in the brainstem according to our data 
(Figure 9 and Table 5). In the comparisons between the brainstem and the 
hippocampus, 90% of the genes, which were regulated on the microarray 
showed similar regulations on the GEO datasets, with only one gene 
behaving differently on the two platforms: Par1, the proteinase-activated 
receptor 1 (Figure 10 and Table 7).  When considering the comparisons 
between the hippocampus and the cortex, on both platforms the similarity 
was somewhat lower. Indeed, 57% of the regulated genes on the one-color 
microarray model showed a similar behavior. In fact, out of the 14 
differentially expressed genes on the microarray, only 3 had different 
regulations on both platforms, but two other genes were not analyzed on the 
GDS1406 dataset, and one gene was a control gene (Figure 11 and Table 9). 
 
The analysis of the regulations observed on the GDS1406 A/J strain dataset for 
the differentially expressed genes on our microarray after normalization 
revealed even higher similarities. In the brainstem against cortex 
hybridizations, 100% of the differentially expressed genes in our experiment 
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behaved the same way on the GEO set (Table 6). For the brainstem against 
hippocampus analysis, 88.9% of the differentiated genes behaved the same 
way on both platforms. Only two genes had a different expression profile: 
Par1 and the heat shock 70kD protein 5, which were more expressed in the 
brainstem according to our data, but were not differentially expressed in 
these two parts of the brain on the GDS1406 dataset (Table 8). For the 
hippocampus vs. cortex hybridizations, 3 genes were differentially expressed 
in our experiment, and one of these genes, behaved differently on the GEO 
dataset: Neuropeptide Y. This brought the similarity between the two 
platforms for this experiment to 66.7% (Table 10). 
 
We performed the same comparisons, with the data for the 5 other inbred 
strains analyzed in the GDS1406 dataset. The detailed comparison tables are 
listed in chapter 3.4 (Tables 5 to 10).  
 
Overall, most of the gene expression level differences we observed between 
the cortex, brainstem and hippocampus could get confirmed in the analysis 
of the GDS1406 GEO dataset.  The lowest similarity rates were observed mostly 
in the raw data of the hippocampus vs. cortex hybridization. This is due to the 
fact that two genes, which appeared to be differentially expressed in our 
microarray had not been analyzed in the GEO dataset, and that one gene of 
our microarray was a false positive.  
 
The differences obtained with the normalized values had high similarity rates 
(between 66.7 and 100%) with the differences observed in the GDS1406 
values. For the raw data, the similarity rates were ranged between 43 and 
100%. The differences observed between our microarray data, and the 
GDS1406 data can partly be explained by the fact that different strains were 
analyzed on both platforms. NMRI mice are an outbred mice strain, whereas 
the A/J, 129S6/SvEvTac, C3H/HeJ, C57BL/6J, DBA/2J, and FVB/NJ are all 
inbred strains. The genetic background of these strains presents fundamental 
differences, which can influence gene expression profiles in the brain. This 
sometimes underlies strain specific behavioral phenotypes (Holmes, 2008). It 
has for instance been shown that BALB/cJ and DBA/2J inbred mouse strains 
that carry a specific mutation of the tryptophan hydroxylase type 2 (1473G 
allele of the Tph2 gene) exhibit significantly less serotonin expression in the 
frontal cortex and striatum compared to the C57BL/6J and 129X1/SvJ mice, 
which carry the 1473C allele of that gene (Hackler et al., 2006; Zhang et al., 
2004). Such inter-strain differences could explain the variations we observe 
between the results obtained on our microarrays performed with material 
from outbred NMRI mice, and the results available on the GDS1406 dataset, 
which are derived from 6 different inbred strains.  
 
Another explanation for the variation observed can be the fact that 2 
different platforms were used to measure the gene expression differences. 
Our experiments were carried out on a custom made microarray, and the 
GEO set experiments from Hovatta et al, were performed on Affymetrix 
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Murine Genome U74 Version 2 arrays (Affymetrix, Inc.) A study performed by 
Hester et al. addressed this issue of reproducibility of microarray data across 
various platforms. They studied the detection efficiency of 3 genomic DNA 
amplifications and 5 deletions in the genome of HL-60 leukemia cells on 6 
different platforms: Agilent, Affymetrix 500K, Affymetrix U1333 Plus 2.0, Illumina 
and RPCI 19K Bac arrays. Their results showed that although all the platforms 
detected the genetic modifications, only two of the five tested platforms 
were able to detect 10 other new genetic modifications (Hester et al., 2009). 
These differences of detection could be attributed to different sensitivities of 
the probes, as well as the different normalization procedures.  
 
Considering the fact that our protocol was able to detect gene expression 
changes, which could be in majority confirmed on a different platform and in 
different mouse strains, we could conclude that our hybridization protocol 
was able to detect relevant expression level changes in the central nervous 
system. Our analysis showed that the data normalized according to the set of 
positive control genes had higher similarity rates with the GDS1406 data, but 
the raw data also mainly detected expression changes, which could be 
confirmed in the comparison. Therefore, a dual analysis of both the raw and 
normalized data obtained with our microarray leads to relevant results. 
 
3.1.3 Microarray experiments on specific regions of the central nervous 
system 
 
The one-color hybridization protocol was followed to detect gene expression 
changes in the cortices, brainstems, hippocampi, cerebelli and spinal cords 
between 3 operated mice, and 3 controls. In the cortex and in the 
hippocampus analysis, no difference could be detected with the raw or on 
the normalized values.  
 
 
3.1.3.1 Microarray experiments on the brainstem 
 
In the analysis of the raw signals in the brainstem, one gene was 1.5 times 
upregulated in the operated animals: Neuropeptide receptor type 5 (Npy5r) 
(Table 2a). However, Real-Time PCR measurements could not confirm this 
overexpression. According to published histological studies performed on rats, 
the Npy5r is widely expressed in the brain. In the brainstem, it is particularly 
present in the Edinger-Westphal nucleus, the locus coeruleus and the 
mesencephalic trigeminal nucleus (Grove et al., 2000). Further studies on 
axotomized rats have shown that the Neuropeptide Y expression increases in 
the mesencephalic trigeminal suggesting that this Neuropeptide Y and it 
receptors could have a role in pain processing by the brainstem (Arvidsson et 
al., 1994). 
 
The results obtained with the normalized signals showed that 6 genes were 
more expressed in the brainstems of the operated mice, but could not be 
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confirmed by Real-Time PCR (Table 2b). Amongst them, 2 were control genes, 
which were obviously false positives. Two genes from the vanilloid receptors 
family showed a 1.5 times higher expression in the brainstems of the control 
animals: TrpV5, and VR1, and two genes from the serotonergic system also: 
5Htr6 and 5Htr4.  
 
The transient receptor potential vanilloid channel 5 plays an important role in 
Ca2+ homeostasis, and has been shown to be implicated in many cellular 
functions such as the regulation of cytoskeleton binding proteins, 
transcriptional control, and modulation of surface receptors in the blood and 
immune system cells (Semenova et al., 2009). Real-Time PCR studies 
performed in Balb/c mice have revealed that TrpV5 is mostly expressed in the 
lung and the kidney but it is also expressed in the brain. However more studies 
would be needed to identify the role of this gene in pain processing (Kunert-
Keil et al., 2006). The VR1 receptor is commonly known as the noxious heat 
receptor at the periphery, however patch clamp recordings performed in rats 
have shown that VR1 receptors are expressed in the paraventricular nucleus, 
where they activate glutamatergic synaptic inputs (Li et al., 2004). 
 
No studies have identified a precise expression of the 5HTr4 serotonin receptor 
in the brainstem, however, it has been shown by immunocytochemistry 
combined with a yeast-2 hybrid system assay, that this receptor is expressed in 
the striatum, the cortex, the amygdala and the hippocampus, and interacts 
with P11, a protein, which has been shown to have antidepressant properties 
(Warner-Schmidt et al., 2009). Similarly, recent clinical studies on 
polymorphisms of the 5HTr6 receptors have shown its implication in major 
depressions (Illi et al., 2009). Taken together with the downregulations we 
observed on our microarray results, one could postulate that a 
downregulation of these 2 receptors in the brainstems of the operated mice 
could be indicative of a depressive state linked to the post-operative pain. 
 
3.1.3.2 Microarray experiments on the cerebellum. 
 
The raw data obtained on the microarray comparisons of the cerebelli the 3 
operated mice and the 3 control ones revealed that 17 genes were 
differentially expressed (Table 3a), among which 15 were upregulated and 2 
were downregulated in the operated animals. Among the upregulated 
genes, the neuropeptide Y receptor Npy5r is 4 times more expressed in the 
operated animals. Interestingly, in the analysis of the normalized signals in the 
cerebellum, only one gene showed a differential expression between the 
operated and the control animals: the neuropeptide receptor type 6 Npy6r, 
which appeared to be 5.5 times more expressed in the operated animals 
(Table 3b). However all these genes appeared unchanged, when a real-time 
PCR analysis was performed on the same samples. The fold changes 
observed on the microarray could therefore not be confirmed. 
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While Npy5r has been shown to play a role in appetite as well as seizures (Lin 
et al., 2004), Npy6r has been identified in mice, but no real studies have 
shown its function in the brain. In general, neuropeptide receptors, especially 
Npy1r, have been shown to have an anxiolytic effect when activated (Lin et 
al., 2004). This could be the case in our study too. Indeed, the cerebellum is 
not only involved in motor processes, but also in emotional and behavioral 
ones (Bloedel and Bracha, 1997), and behavioral studies have shown an 
increase of exploratory behavior after a low anxiolytic dose of diazepam in 
the ANT rat line that carries a natural point mutation in a cerebellum-specific 
GABAA receptor subunit making their motor behavior abnormally sensitive to 
benzodiazepine agonists (Vekovischeva et al., 1999). This tends to show that 
the cerebellum is also involved in anxiety and fear. The upregulation of Npy6r 
that is observed in the cerebelli of the operated animals could therefore be 
linked to anxiety. 
 
Interestingly, the sodium- and chloride-dependant GABA transporter 1 
(Slc6a1) showed a 2 times higher expression in the cerebelli of the operated 
animals according to the raw data (Table 3A). This could be a further 
indication of an anxiolytic effect. Indeed, Slc6a1 knockout mice have 
reduced rates of GABA clearance in the synapses of the cerebellum, which 
lead to slower decay of spontaneous inhibitory post-synaptic currents in 
cerebellar granule cells. This causes motor disorders, gait abnormality, tremor 
and anxiety, as evidenced by lower percentages of inhibition in the prepulse 
inhibtion test for the knockout animals (Chiu et al., 2005). The upregulation of 
Slc6a1 in the cerebelli of the operated animals could therefore have a 
calming effect on mice in their post-operative phase.  
 
The α2C adrenergic receptor showed a 1.8 times higher expression in the 
cerebelli of implanted mice (Table 3a). This could be due to some impaired 
locomotor activity in the recovery phase. Schambra et al. have shown by in-
situ hybridization, that adrenergic receptors are expressed in the human 
cerebellum (Schambra et al., 2005). In the rat, α2C adrenergic receptor is 
more precisely present in nuclei, which are involved in motor function 
(Scheinin et al., 1994). 
 
The serotonin recetptor 5-HTr4 was 1.7 times downregulated in the animals, 
which underwent surgery. No study has focused on the expression pattern of 
this receptor in the cerebellum. However, it has been shown 
pharmacologically and by histochemistry on primary mouse neuron cultures, 
that the activation of this receptor activates the ERK pathway by a G-
coupled protein-independent mechanism (Barthet et al., 2007). Interestingly, 
Mapk1 is 2.1 times more expressed in the operated animals according to our 
microarray data, which indicates this pathway might be also active in the 
pain processes. Moreover, CREB3 is also 1.7 times less expressed in the 
operated animals. Western blot analysis performed with protein extracts from 
mice cerebellar neurons have shown the activation of GABAB receptor leads 
to Mapk1 phosphorylation, which in turn induces the activation of CREB (Tu et 
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al., 2007). Taken together, this data shows that these genes are present in the 
cerebellum, and the regulations observed on the microarray could indicate 
that these pathways are also active in the postoperative phase in our surgical 
pain model.  
 
3 other genes were upregulated in the operated animals were the NMDA1 
receptor, the Somatostatin Receptor 1, the Cytochrome P450, and the 
guanine nucleotide binding protein α0. Electrophysiological studies on 
Guinea Pig cerebellar slices have shown that anandamid, an endogenous 
ligand of cannabinnoid receptors, can modulate the activity of NMDA1 
receptors, by eliciting a reduced cannabinoid-induced Ca2+ flux. This process 
could be involved in pain modulation (Hampson et al., 1998). Interestingly, 
NMDA glutamate receptors and Ca2+ fluctuation control granule cell 
migration during the cerebellar development, a process which is accelerated 
by endogenous somatostatin (Yacubova and Komuro, 2003). However, no 
study has ever shown the role of somatostatin and its receptor in pain 
processing. The role of Cytochrome P450 in the cerebellum has also not been 
widely studied, but gene profiling experiments have shown that it is expressed 
in the human cerebellum, where it could be linked to anandamide signaling 
and possibly to pain modulation through the cannabinoid receptors (Stark et 
al., 2008). Another player in the cannabinoid mediated pain modulation 
might be the guanine nucleotide binding protein α0. While no studies have 
shown that this protein is linked to pain in the mouse brain, in situ hybridization 
on the brain of rats, which had received an injection of a synthetic 
cannabinoid receptor ligand, have shown that this treatment led to 
decreased levels of guanine nucleotide binding protein α0 in the cortex, and 
of guanine nucleotide binding protein α1 in the cerebellum (Rubino et al., 
1997).  
 
The two last upregulated genes in the cerebellum of the mice in pain were 
the coagulation factor II receptor-like 2 (F2rl2), proopiomelanocortin and 
NGF. No data could be found on the role of F2rl2 in the cerebellum, and more 
studies could possibly be done to verify whether this gene is expressed in the 
cerebellum and whether it plays a role in nociception. While no real 
experiments have demonstrated the role of cerebellar NGF levels and pain, it 
has been demonstrated that high levels of NGF are linked to neuronal survival 
in the central nervous system and can induce hyperalgesia (Seidel et al., 
2009).  
 
The microarray analysis of the raw data showed that the 
proopiomelanocortin gene is 1-7 times more expressed in the cerebelli of 
unoperated animals. Although no articles have demonstrated a real 
involvement in cerebellar melanocortin levels and pain, it has been 
published, Crhr1 receptor to ACTH is expressed in the cerebellum and that 
ACTH knockout mice exhibit reduced anxiety behaviors (Timpl et al., 1998). 
Therefore, the lower expression observed in the cerebelli of the mice in pain 
seems somewhat surprising, given that these mice should be experiencing 
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more anxiety than the control ones. This data was not verified by real-time 
PCR, due to unsufficient extracted material. These observations therefore still 
remain to be validated.  
 
3.1.3.3 Microarray experiments on the spinal cords. 
 
The microarray analysis performed on the spinal cords of the operated and 
control animals revealed that 6 genes were downregulated in the operated 
animals according to the raw data (Table 4a), and 3 only according to the 
normalized values (Table 4b). However, the fold changes observed were very 
high. They ranged between 245.1 and 1488.1 for the raw values, and 
between 18.3 and 61.7 for the normalized ones. Such high fold changes are 
quite untypical for microarray results, and given the poor quality of the scatter 
plots, we concluded that these differences were artefactual and insignificant. 
We however decided to perform a more detailed analysis of the possible 
gene regulations in the spinal cord using GeneChip® Mouse Exon 1.0 ST Arrays 
from Affymetrix in the final part of this project. 
 
3.1.4 General conclusions, low density microarray experiments 
 
Although the microarray analyses gave the results described above, none of 
them could be validated by Real-Time PCR. This means that at least a 
proportion of these changes were artefactual. Another explanation could be 
that the regulated genes actually underwent some alternative splicing 
events, and that the exon to which the microarray probes hybridized were 
differently regulated than the ones which are amplified in the Real-Time PCR 
reaction. However, it seems quite doubtful that alternative splicing events 
would happen in all the regulated genes from our microarray experiments.  
 
Preliminary experiments had been made before starting this project (Cinelli et 
al., 2006). A first batch of low-density microarray had been produced with 130 
genes, to test hybridization conditions and detect whether signals could be 
detected. For these experiments, the slides were spotted by Operon AG, 
according to a proprietary spotting protocol, and a similar 2-color 
hybridization model had been followed, with Cy3 and Cy5 dyes instead of 
Alexa dyes. This experiment compared the brains of 3 implanted mice with 
the brains of 3 control mice. The analysis of the raw signals detected 
expression level differences, but these differences were never confirmed by 
Real-Time PCR, and had not been reproduced. Our project was started to 
study at a deeper level whether some gene regulations associated to 
nociception could be detected in the central nervous system, reproduced 
across platforms, and used to build a diagnostic tool to monitor pain. Our 
data obtained with 2 different hybridization protocols as well as on Real-Time 
PCR shows that the signal differences detected in the preliminary phase of 
this project were probably artefactual. Indeed, microarray is a sensitive 
technique, and hybridization can give artefactual results if the GC content of 
the probes varies strongly from one probe to the other. Moreover, cross 
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hybridization problems can also influence the results. Normalizing the data 
and performing Real-Time PCR for the differentially expressed genes 
according to the microarray is an essential step in the validation of an 
experiment. Our microarray data as well as the subsequent real-time PCR 
data have shown that no expression changes could be reliably used for a 
diagnostic based on the microarray we had developed and on the models 
that we had studied. 
 
 
3.2. Real-Time PCR measurements on 27 candidate genes 
 
Given that the microarray results could not be confirmed in the Real-Time PCR 
measurements, we chose to test whether our microarray was not sensitive 
enough to detect some changes, which might indeed be happening. We 
therefore selected the most promising 27 genes of our list. These genes were 
characteristic members of the various gene categories present on our slide. 
The sample sizes were increased to 6 animals per condition for statistical 
robustness. The experiments on the telemetric apparatus implantation surgical 
pain model were carried out in four parts of the central nervous system: the 
brainstem, the cortex, the hippocampus, and the dorsal root ganglia.  
 
In the surgical pain model, only one of the observed gene expression 
differences was statistically significant. The serotonin receptor 5-HTr1A was 2.2 
times more expressed in the cortices of the operated mice (P Value=0.12) 
(Table 11B and Figure 12B). It has been shown that this gene is expressed in 
axon terminals of the serotoninergic neurons, where it acts as an 
autoreceptor. Experiments on rat striatum slices have shown that serotonin 
stimulates the 5-HTr1A receptor and thereby induces an activation of the 
cholinergic system, which is responsible for antinociception (Galeotti et al., 
1997; Gillet et al., 1985). 5HT1A receptors have been identified in the 
superficial laminae of the spinal dorsal horn, the dorsal and medial raphe 
nuclei, limbic areas of the hippocampus and lateral septum, and in the 
cortex as well (Barnes and Sharp, 1999). Our data therefore suggests that the 
significant increase observed in the operated animals is caused by central 
analgesic mechanism activation to mediate the postoperative pain. 
 
To see if the genes showed more expression level differences in another pain 
model, we performed similar Real-Time PCR measurements on central nervous 
system RNA from the mice subjected to the BHV-1 inflammatory pain model. 
In this round of experiments, we compared the expression levels in cortices 
and spinal cords of 6 immunized and 6 control animals. None of the genes 
tested showed a significant expression level difference in these parts of the 
central nervous system in this pain model. 
 
Taken together, the microarray and Real-Time PCR data showed that the vast 
majority of the commonly defined pain and anxiety genes do not show any 
expression level changes in the central nervous system and can therefore not 
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be used to monitor nociception for an objective diagnosis of pain. Most of the 
data on these genes comes from studies on transgenic animals (Lacroix-
Fralish et al., 2007), but the fact that a pain-related phenotype is observed in 
a knockout animal for a specific gene does not necessarily mean that this 
gene will exhibit expression level changes in wt animals. The research on the 
transient receptor potential melastin 8 channel (TRPM8) is a good example of 
this problematic paradox in pain research. Although behavioral tests and 
electrophysiological measurements have demonstrated that this receptor is 
involved in the transmission of noxious cold, and that its activation disminishes 
the pain sensation linked to heat (Bautista et al., 2007; Colburn et al., 2007), 
no regulation in the expression levels of this gene after a noxious cold 
stimulation could be demonstrated in wt animals.  However, it has been 
shown that knockout TRPM8-/- mice do not benefit from the analgesic effect 
associated with this receptor’s activation after a formalin injection in the 
hindpaw (Dhaka et al., 2007), and based on these results this gene is 
considered as a “pain gene”. 
 
Our data has shown that the genes, which are commonly associated to pain 
processes based on the results of transgenic studies are not regulated in the 
central nervous system of wt mice subjected to a surgical or inflammatory 
pain models.  This observation raises the question of the suitability of 
monitoring nociception by measuring gene expression changes. Indeed, the 
activation of a protein involved in the transmission of a nociceptive signal is 
not necessarily linked to a differential expression of the gene encoding it. On 
the other hand, it is possible that the common “pain genes” are not the ones 
which are regulated during the transmission of a nociceptive signal. To verify 
this hypothesis, further experiments have therefore to be performed to identify 
the genes, which are really regulated by nociception in the central nervous 
system and which could be good candidates for the monitoring of 
nociception in laboratory animals. 
 
 
3.3 Whole Genome experiment on the spinal cord 
 
No differential expression could be observed in the genes we selected for our 
study. Even if these genes had been established as being linked to a pain 
phenotype in transgenic animal models, our microarray and real-time PCR 
results have shown that they cannot be used to monitor nociception in the 
central nervous system of wt mice because their expression remains unaltered 
in the pain models we have studied. In order to observe which genes show a 
differential expression due to nociceptive processes and to find potential new 
genes, which would show a regulation linked the transmission of the 
nociceptive signal we performed a whole genome analysis. 
 
Our experiment compared the spinal cords of 6 mice, which underwent the 
telemetric apparatus implantation with those of 6 control mice. We used 
GeneChip® Mouse Exon 1.0 ST Arrays for this analysis, to be able to detect not 
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only whole gene regulations, but also possible alternative splicing events. 63% 
of the regulations observed in the operated animals were downregulations, 
therefore, in the analysis of the whole gene regulations, the most significant 
4000 downregulated probesets, and the 18000 most significant upregulated 
probesets were considered. We excluded the probesets, which had intronic 
or intergenic regulated sequences because they consist in undefined regions, 
which are located near an exon and could probably be regulated like this 
exon. However, they have not yet been defined as exons. We also excluded 
non-annotated sequences, which correspond to unknown putative probesets 
found bioinformatically. Among the first 4000 downregulated genes, 166 had 
a minimum of 3 downregulated exons. Among the first 18000 upregulated 
genes, only 96 had at least 3 upregulated exons. A search for the signals of 
the 230 genes, which we studied on the low-density microarray, confirmed 
that these genes do not show any expression level difference between the 
operated and the control mice. These genes are therefore not good 
candidates for the establishment of a microarray diagnostic tool for the 
monitoring of nociception in laboratory animals. 
 
In order to identify which of these genes show similar regulations in other 
experimental conditions, we performed a bi-clustering meta-analysis using 
Genevestigator (Nebion AG) on the 166 downregulated genes. The goal was 
to find which stimuli had induced either a downregulation or an upregulation 
of these genes in other experiments.  The analysis of the downregulated 
genes revealed that 29 probesets corresponding to 21 genes were also 
downregulated in 4 different stimuli experiments: 2 experiments involving 
lipopolysaccharide stimulations, one with trichostatin A3 stimulation, and one 
consisting in myoblast to myotubule differentiation (Table 15 and Figure 12a). 
Lipopolysaccharide has been shown to enhance axonal sprouting in spinal 
cords of rats, after a lesion. This effect can even be seen in a 
lipopolysaccharide injection performed 4 months after the lesion (Chen et al., 
2008). Trichostatine A3 is a cell cycle inhibitor, which deactivates class I and II 
histone deacetylases, and can be used with butyrolactone I to differentiate 
neuro2a cells into neurons capable of forming functional neural networks 
(Inokoshi et al., 1999). The fact, that the 21 of the genes, which had more than 
3 downregulated exons in our microarray study were also downregulated 
following these stimulations, tends to show that processes linked to neuronal 
rearrangements were also happening in the spinal cords, during the post 
operative phase of our surgical pain model. 
 
The clustering of the 166 downregulated genes, to find which stimulus had 
induced an upregulation of these genes, revealed that a cluster from 21 
genes had been upregulated after 4 other experimental stimulations:  two 
different experiments in which stimulations with 1-fluoro-2,4 dinitrobenzene 
(DNFB) were applied, one where ovalbumin was used, and one where a 
combination of ovalbumin and particulate matter was applied (Table 16 and 
Figure 12b). Both ovalbumin and 1-fluoro-2,4 dinitrobenzene are causing 
inflammation. ovalbumin i
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DNFB is known to induce inflammation and enhance contact hypersensitivity, 
and it has been postulated, that a key element in this process is the migration 
of dendritic cells to lymph nodes. This migration involves called plexins, which 
have a high similarity to semaphorins (Walzer et al., 2005). Interestingly, 
sproteins are essential keyplayers in axonal guidance. 
 
The most interesting feature of this bi-clustering analysis is that the 21 genes 
are identical in both lists. This means that these 21 genes, which are amongst 
the 166 genes with more than 3 downregulated exons in the operated 
animals, are downregulated after the Lipopolysaccharide 4, 
Lipopolysaccharide 5, Trichostatin A3, myoblast to myotubule differentiation 
stimuli, and upregulated after the 1-fluoro-2,4 dinitrobenzene, 1-fluoro-2,4 
dinitrobenzene 2, ovalbumin, and  ovalbumin / particulate matter. All these 
stimuli involve cell migration, either in neurons, dendritic cells, or muscle cells. 
This tends to show, that these 21 genes are also involved in cell migration or 
cellular movements in the spinal cord of the mice used in our experiments, 
during the post-operative phase.  
 
Two other clusterings were performed on 96 genes, which showed a 
complete upregulation in the spinal cords of the operated mice, to see which 
genes among these had been down- or up- regulated in previous stimulation 
experiments. The first clustering showed that a cluster of 17 genes represented 
by 19 probesets had been downregulated after a chemical stimulation with 
1.5-naphtalenediamine and with N-(1-naphthyl)ethylenediamine 
dihydrochloride, which is usually used to measure nitric oxide concentration 
(Table 17 and Figure 13a). In the central nervous system, nitric oxide is 
involved in neuronal motility and synaptic formation. Indeed, in the human 
neuronal precursor cell line NT2, the use of a nitric oxide synthase inhibitor 
blocks migration, and on the contrary, the application of a nitric oxide donor 
or a cGMP analog, the migration is enhanced. This tends to show that the 
NO-cGMP-PKG signaling cascade is essential for the appropriate cell 
migration in the developing human brain (Ignarro et al., 1987; Tegenge and 
Bicker, 2009). 
 
The clustering of the 96 upregulated genes to find subsets of genes, which 
were also upregulated in other experiments showed that 15 genes 
represented by 17 probesets were upregulated in 2 experiments using 
lipopolysaccharide as a stimulus (Table 18 and Figure 13b). As previously 
mentioned, lipopolysaccharide can induce axonal sprouting after an injury 
(Chen et al., 2008).  
 
The comparison of the two lists obtained after the clustering revealed that 3 
genes, which are upregulated in our experiment, are present in both clusters: 
the EPH receptor A 4 (Epha4), Disabled Homolog 1 (Dab1), and Protein 
Tyrosine Phosphatase Receptor type K (Ptprk).  Epha4 has been shown to be 
involved in adult neurogenesis, and soluble versions of Ptprk are known 
stimulate neurite outgrowth (Drosopoulos et al., 1999).  Dab1 is a key member 
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of the Reelin-Dab1 pathway. This pathway regulates neuronal positioning 
during development, and has recently been shown to differentially contribute 
to acute and persistant pain (Akopians et al., 2008). Interestingly, our 
microarray also revealed that Reelin was downregulated in the spinal cords of 
the operated mice. Taken together, these results tend to show that the Dab1-
Reelin pathway is also activated in the spinal cord of these animals. 
 
The final part of the analysis consisted in finding which categories of genes 
were exhibiting alternative splicing events in the spinal cords of the operated 
animals. To do so, we calculated the standard deviations of all the probe 
signals for each of the top 37000 probesets were calculated. After exclusion 
of the non-annotated sequences, as well as the genes, which contained 
intergenic and intronic probesets, we obtained a list of 1310 probesets. From 
this list, we selected the genes for which, the standard deviation of the signals 
was higher than 0.4, and we obtained a final list of 410 probesets, which 
showed alternative splicing events. A functional profiling analysis revealed 
that the main roles of these genes were catalytic, and hydroxylase activities.  
20,7% of these genes, were plasma membrane proteins, and interestingly, 10% 
of the alternatively spliced genes were linked to cell adhesion, cytoskeleton, 
actin, and myosin contraction. This tends to show, that cellular motility, which 
might be either linked to inflammation, or to synaptic rearrangements takes 
place, and involves various splice variants of specific genes. For instance, the 
microarray experiment reported signals with a standard deviation of 1.25 for 
Semaphorin 3F. This gene is involved in axonal guidance, and has splice 
variants, which are involved in a temporal and regional regulation during the 
maturation of the murine central nervous system (Kusy et al., 2003). 
 
Taken together, the results of the whole genome microarrays have shown that 
gene expression changes happen in the spinal cord in the surgical pain 
model. Genes linked to cell motility, cell-cell adhesions, cytoskeleton and 
extracellular matrix seem to be highly regulated, or alternatively spliced. This 
could be explained by the migration of cells fro the immune system, or by a 
neuronal rearrangements linked to synaptic plasticity. Cell motility in pain is a 
growing field of research. It has for instance recently been shown in vitro, that 
morphine increases microglial migration via an interaction between the µ-
opioid and P2X(4) receptors, a process which could be underlying the 
tolerance hyperalgesic side effect of morphine (Horvath and DeLeo, 2009). 
Synaptic plasticity also occurs in the spinal cord, and contributes to an 
enhanced responsiveness of motoneurons in the central nervous system. This 
process is called central sensitization (Ikeda et al., 2009; Woolf and Salter, 
2000). The expression level changes observed in the spinal cord during post-
operative phase could therefore be mediating central sensitization states, 
which contribute to pain maintenance.  
 
Taken together, our data shows that the gene expression changes linked to 
nociception are subtle and complicated. The altered pain related 
phenotypes observed in transgenic animals do not necessarily reflect the 
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physiological expression regulations, which occur in wild-type animals 
experiencing pain. The gene expression changes do not occur in genes, 
which are directly involved in the transmission of the nociceptive message 
such as channels or receptor. We observed them for genes, which are 
involved in other processes such as neuronal circuit rearrangements or 
inflammation. These observations could not only lead to diagonostic tools for 
the monitoring of nociception and pain, but they could also help to better 
understand the processes and the key players involved in the generation the 
pain sensation. 
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4. Conclusions and Outlook 
 
 
Longer lasting pain like the one that occurs after a surgery involves processes, 
which could modify the expression levels of genes, to maintain the 
nociceptive message transmission in the CNS. Therefore, monitoring 
expression level changes in the brain or the spinal cord of mice in a post-
operative recovery phase could possibly help to objectively detect changes 
linked to pain. If these changes were reproducible and characteristic of pain, 
microarrays could be used in every day laboratory work to detect pain. 
 
To identify potential genes involved in pain mechanisms, we screened the 
literature and established a set of 230 genes. Half of these genes were also 
defined by Lacroix-Fralish et al. as the commonly known “pain genes” 
(Lacroix-Fralish et al., 2007), the other half consisted in genes linked to stress 
and anxiety (see Appendix 1). Most of these genes induced pain-related 
behaviors in transgenic animal models, and therefore represented good 
candidates for the monitoring of nociception. In the first part of this project, 
we have established a low-density microarray hybridization and normalization 
protocol in one color, which bypassed dye imbalances that occur in two-
color models. This protocol was followed to detect gene expression changes 
between the hippocampus, the brainstem and the cortex in 3 naïve NMRI 
mice. The genes regulations obtained in this experiment were compared to 
publically available microarray data of a gene profiling study carried out in 
the brain for 6 inbred mice strains (Hovatta et al., 2005). Our results were highly 
similar to the ones obtained in this experiment, despite strains and 
experimental platforms differences. The microarray protocol was therefore 
able to detect relevant gene expression changes in the CNS, and could 
therefore be applied in future experiments. 
 
We then applied this microarray protocol to detect potential gene expression 
changes in the brainstem, cortex, hippocampus, cerebellum and spinal cords 
of mice, which were in the postoperative phase after a telemetric apparatus 
implantation. In previous experiments, these mice exhibited higher heart rates, 
which were indicative of pain (Arras, 2007; Arras et al., 2007). The microarrays 
detected some regulations in the brainstem, the cerebellum and the spinal 
cords. These regulations albeit interesting, could not be confirmed by Real-
Time PCR measurements, and were therefore probably artefactual. Further 
Real-Time PCR measurements to evaluate the genetic regulations in the 
brainstem, the hippocampus, the cortex and the DRGs on the 26 more potent 
candidate genes confirmed this tendency, as only one of them showed a 
significant upregulation in the cortices of the operated animals. This gene was 
the serotonin receptor 5HTr1A. We performed similar Real-Time PCR 
experiments in the cortices and the spinal cords of mice, which had been 
immunized against the BHV-1 virus, and which were experiencing 
inflammatory pain. None of the 26 genes showed a significant, regulation. 
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Our data generally shows, that all the commonly known “pain genes” except 
the 5HTr1A receptor are not regulated in the surgical or the in inflammatory 
pain model, although they all induce a pain-associated phenotype in 
transgenic mice. They can therefore not be used for a diagnostic tool of pain 
based on gene expression level assessments.  
 
Further studies should however be performed on other animal models for pain 
to test whether the 5HTr1A upregulation observed in the cortices of the 
animals in pain can be reproduced in other pain models. We were able to 
observe it in our surgical pain model, but not in the inflammatory one. One 
could measure the expression levels of the 5-HTr1A receptor by Real-Time PCR 
in chronic pain models such as nerve ligations to understand better if the 
expression levels of this gene only increase in longer lasting pain. Recent 
clinical studies on elderly people who had suffered from a hip fracture have 
shown that higher 5-HTr1A are linked to a higher risk of post-traumatic 
depression characterized by a lower general activity (Lenze et al., 2008). 
Other studies have shown that certain alleles of that gene are associated with 
a higher risk of depression (Kishi et al., 2009).  Therefore, the higher expression 
we have measured in the cortices of the operated mice was maybe a sign of 
a depressive state caused by a post-operative distress. In that sense, 
measuring the expression levels of that gene after an experimental procedure 
could give some indication of the level of suffering experienced by the 
animal. 
 
In the final part of the project we performed whole genome microarray 
analyses to detect regulations that occur at the exon level. The experiments 
were performed in the spinal cords of mice, which had been subjected to our 
surgical pain model. The goal of this experiments was to identify, which genes 
have a differential expression or are subjected to alternative splicing events, 
during the transmission of a longer-lasting nociceptive signal. The results first 
confirmed that the 230 genes on which we had focused in the beginning do 
not show any regulation. However, we were able to show, that significant and 
relevant whole gene expression changes, as well as alternative splicing 
events happen in the spinal cords of the operated animals.  
 
We identified 166 genes, which were downregulated in the post-operative 
phase. Among these, 21 genes had also been down- or up-regulated in 
stimulation experiments, which induce cell motility and axonal sprouting. The 
second analysis revealed 96 upregulated genes in the operated animals.  
Among these, 19 had been downregulated in previous stimulation 
experiments, which enhance neuronal motility, and 17 had been upregulated 
in previous experiments, which induce axonal growth. Moreover, a functional 
classification revealed that the main regulated genes were linked the 
cytoskeleton, cell motility and extracellular matrix. The 5HTr1A serotonin 
receptor that was upregulated in the cortex of the operated mice during our 
low-density microarray experiment showed no expression level changes in the 
spinal cord in this experiment. The 166 downregulated genes and the 96 
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upregulated ones which were revealed in this experiment could potentially 
be good candidates for building a diagnostic tool based on pain. 
Technology advancements have allowed the establishment of high 
throughput real-time PCR measurements (Schmittgen et al., 2008). This 
method could be used to measure precisely the expression levels of these 
genes in other parts of the CNS, as well as in other pain models, to determine 
whether they can really be used as indicators for the levels of pain 
experiences by an animal. Comparative studies of the expression profiles in 
various parts of the CNS could then determine whether some signature 
patterns are characteristic of some specific pain models. 
 
Our data has shown that the most important 410 genes, which underwent 
alternative splicing were linked to cell motility, cytoskeletal processes as well 
as inflammation. The role of alternative splicing in pain is a growing field of 
research. It has been shown that various splice variants of the Prrxl1 gene 
contribute to the development of the murine nociceptive system (Rebelo et 
al., 2009). This gene also appeared in our experiments, as being subjected to 
some alternative splicing linked to pain in the spinal chords of the operated 
mice. Deep sequencing experiments of all the splice variants of the top 410 
genes, which came out of our experiments could provide us with better 
information on the exons of each genes, which are alternatively spliced 
during the transmission of the nociceptive signal. This could open the door the 
the generation of transgenic animals, which would either over express or not 
express at all certain splice variants of a gene. Studying their responses to 
common behavioral tests for pain could allow us to reach a further 
understanding of the role of splice variants in the generation and the 
transmission of a nociceptive signal. 
 
Taken together, our data shows that cell motility probably contributes to the 
nociceptive signal, and could be an interesting parameter to study, to 
possibly monitor nociception. This migration could be linked to neuronal 
rearrangements, or the movements of dendritic cells, or components of the 
immune system. Further functional experiments on cell migration, and its role 
on nociception are needed to understand in what extent synaptic plasticity, 
and neuronal rearrangements, and general cell motion contribute to the 
maintenance of pain, in surgical and inflammatory models. Prager-Khoutorsky 
et al. have recently shown on Aplysia neurons, that actin-perturbing drugs 
such as cytochalasin B, latrunculin A, or jasplakinolide inhibit axonal motility by 
blocking neurite retraction  (Prager-Khoutorsky and Spira, 2009). It could be 
interesting to submit mice to spinal injections of these drugs, and to test how 
these animals respond to common behavioral tests for pain such as the hot 
plate tests. Such experiments could give some indication on the eventual role 
of neuronal motility in the transmission of shorter lasting nociceptive signals. 
 
The initial aim of this work was to establish a low density microarray which 
could be used as a diagnostic tool to evaluate pain in the central nervous 
system of laboratory animals. Our projects has shown that the genes 
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commonly refered to as the pain-genes based on the studies of transgenic 
animals do not show any characteristic gene expression changes in our 
surgical and inflammatory pain models. They were therefore good 
candidates for such the establishment the array. In that sense, the initial goal 
of this project was not reached. However, the second part of the project has 
revealed that gene expression changes occur in the spinal cord of mice 
subjected to our surgical protocol. All the regulated or alternatively spliced 
genes identified in this experiment could be important new candidate genes 
for the monitoring of nociception, and it would be interesting to test if the 
regulations in other pain models are similar to what we have observed, and to 
test precisely by real-time PCR, which of these genes would be the most 
relevant candidates for a diagnostic tool to monitor pain in laboratory 
animals. This tool could then be routinely used in animals, which are subjected 
to experimental procedures, or to new, uncharacterized transgenic animals 
to monitor nociception, and to take the appropriate analgesic measures to 
abolish their pain. 
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5. Material and methods 
5.1 Low density microarray establishment 
 
5.1.1 Gene selection and probes design 
 
A litterature search was performed in order to screen genes, which were 
linked to nociception. The criterion of selection was their relevancy in pain 
research. The genes were related to pain induced behaviors in knockout 
animals, or in transgenic animals, which were either overexpressing the gene. 
Other genes were encoding proteins, which were expressed in nerve ligation 
models. In addition to these, signal transduction molecules were added, as 
well as genes for channels, and receptors. Table 1, in the results chapter sums 
up the various categories of genes present in the microarray design. A final 
set of 199 genes was selected for the analysis.  
 
For slide orientation as well as for data normalization purposes, 19 positive 
control genes, which are ubiquitously expressed and 8 spikes sequences were 
also included in the probes design. 11 negative controls, which were either 
derived from the E. Coli genome or randomly generated, were also 
considered, in order to monitor the hybridization quality. This brought the final 
number of probes produced to 238. 
 
The probes were designed and produced by Operon Biotechnologies GmbH 
in Germany. They were 70mer oligonucleotides, corresponding to a sequence 
located in the last 750 nucleotides at the 3’ ending of each gene. Given that 
RNA degradation starts in the 5’ ending of a gene, having probes, which 
recognize the 3’ terminal of RNA can help to bypass due to degradation. 
Moreover, this technology offers the advantage of minimizing secondary 
structures, which have high melting temperatures, and therefore allows 
hybridization reactions to run at normal temperatures. The probes were 
synthesized without being coupled to an amino-linker, as it is not required for 
the coupling to epoxy slides. Amino linkers are easily subjected to oxidation, 
which disminishes the quality of the probes. 
 
 
5.1.2 Spotting of oligos 
 
The Lyophilized 70mer oligonucleotides were diluted in RNAse free water 
(Qiagen®) to bring them to a final concentration of 100µM.  For the 2 first 
designs of the slide, the spotting was performed on a Perkin Elmer Piezzorray 
contact printer at the Functional Genomics center in Zürich. For this printing, 
the probes were diluted in 20x SSC to bring them to a final concentration of 
20µM in 3x SSC (20µl 70mers 100µM, 20µl 20x SSC, 65µl Rnase free H2O), and 
40µl of each probe was then transferred to a 384 well plate, according to a 
specific design.  
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5.2 Animal handling and treatments 
 
5.2.1 Animal housing 
 
The experiments requiring a telemetric apparatus implantation were 
performed on male HsdHan:NMRI mice, which were obtained from a 
commercial supplier (Harlan, Horst, The Netherlands). The animals were 4 
weeks old at arrival, and underwent the telemetric apparatus implantation 
after an adaptation period of 4 weeks. At the time of implantation, the 
animals had a weight ranging from 32g to 48g.  
 
The experiments on inflammatory pain were performed on 12 male A129 mice 
obtained from a commercial supplier (Harlan, Horst, The Netherlands) All 
animals were 4 months old at the time of the immunization,  
 
The housing conditions were identical for both strain used in this project. The 
mice were kept in type 3 filter-top clear-transparent plastic cages (425 mm × 
266 mm × 150 mm, floor area 820 cm2) with autoclaved dust-free sawdust 
bedding (80–90 g/cage) and autoclaved hay (18–20 g/cage) as nesting 
material. They had unrestricted access to sterilized drinking water were fed a 
pelleted and extruded mouse diet (Kliba No. 3431, Provimi Kliba, Kaiseraugst, 
Switzerland) ad libitum. The dark/light cycle consisted of 12/12h. Each male 
was housed with an ovariectomized female, but after the surgery, they were 
housed individually, to avoid companion’s actions on the readout. 
 
5.2.2 Telemetric implantation  
 
Mock TA10ETA-F20 telemetric transmitters (Data Sciences International, St. 
Paul, MN, USA), which have the same size, shape and weight as the original 
ones were implanted, when the mice were 8 weeks old.  The mice were 
anesthetized by inhalation of the volatile anesthetic sevoflurane (Sevorane™, 
Abbott, Cham, Switzerland) at a concentration of 8-4.5% in 100% oxygen at a 
flow rate of 200 ml/min. The anesthetic gas was administered with a nose 
mask. This anesthesia protocol was performed on the operated animals as 
well as on the control ones. The surgery time was approximately of 1h per 
animal, and for each operated animal, one control was always kept under 
anesthesia during he same time. 20 min prior to the end of the anesthesia, the 
operated and the control animals received an intraperitoneal injection of 
100µl Flunixin, 150µl Borgal and 1ml Ringer Lactate. After surgery, both the 
operated and the control animals were treated twice daily with a 
subcutaneous injection of 2µl/g body weight Flunixin (Biokema Flunixine™, 
Biokema SA, Crissier-Lausanne, Switzerland) until sacrifice. 
 
For each operated animals, the surgery consisted in a mid line laparotomy 
was performed to open the abdominal cavity, in which the telemetric 
transmitter’s body was implanted.  One telemetry lead was tunneled 
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subcutaneously from the thorax to the neck, and the wired electrode was 
fixed between the muscles located right of the trachea. The second wired 
loop was sutured to the xiphoid process with a silk thread. The muscles and 
skin were then closed with resorbable sutures. 
 
For the whole brain microarray experiment, and for the microarray 
experiments performed on parts of brain, 3 mice were operated, and 3 mice 
were used as control, and 2 mice were used as reserve animals. All animals 
were sacrifieced 2 days post surgery. For the Real Time PCR experiments on 
parts of the Central Nervous System, and for the GeneChip® Mouse Exon 1.0 
ST microarray on the Spinal Cords: 6 animals were operated, 6 were used as 
controls, and 2 were reserve animals. The 12 animals used for the Real-Time 
PCR measurements were sacrificed 2 days after the surgery, and those used 
for the whole genome microarray experiment were sacrificed 1 day after 
surgery.   In each case, the mice were sacrificed by cervical dislocation. 
 
 
5.2.3 Inflammation model 
 
All the 12 mice used in that experiment were implanted as previously 
described with TA10ETA-F20 telemetric transmitters (Data Sciences 
International, St. Paul, MN, USA) at 10 weeks of age. The post-implantation 
convalescence period was set at 8 weeks. The mice were then randomly 
divided into two groups: 6 mice were subjected to the BHV-1 immunization 
protocol, and 6 underwent a control injection.  
 
The BHV-1 immunization solution consisted of UV-inactivated BHV-1 
(corresponding to the antigenic mass of 107 TCID50 live BHV-1) in 50 µl cell 
culture medium (DMEM supplemented with 2% FBS, 100 units/ml Penicillin G, 
and 75 units/ml Streptomycin), which was emulsified with 50 µl CFA (Sigma-
Aldrich Corp. St. Louis, MO, USA, F-5881, Lot 014K8927). 100 µl of the freshly 
prepared solution was injected to each of the 6 immunized mice. For the  
6control animals, the vehicle solution (100 µl, DMEM supplemented with 1% 
FBS, 50 units / ml Penicillin G, and 37.5 units / ml Streptomycin), containing 
neither BHV-1 nor FA, was injected intraperitoneally. 
 
The injected and the control animals were all sacrificed 3 days after the 
injection. For each animal, the Cortex and Spinal Cord were dissected and 
analyzed by Real-Time PCR. 
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5.3 Central nervous system dissection, and tissue preservation 
 
5.3.1 Brain dissection  
 
Immediately after having been sacrificed by cervical dislocation, the heads 
of the mice were cut with scissors at the cervical level. The brain extractions 
were performed fast to avoid RNA degradation. After a complete removal of 
the skin and muscle to reveal the mouse skull, the interparietal bone was cut 
surgical scissors in the middle until the Lambda, and carefully removed, with 
forceps to reveal the cerebellum. Two cuts were performed along the jaw 
and the mandibule of the animals, and the parietal bone was then cut in half 
along the sagittal suture with surgical scissors, from the Lambda to the 
Bregma. The coronal suture was then cut transversally, and the two halves of 
the parietal bone were carefully removed with a forceps. The brain was then 
taken out with a forceps, after cutting the optical nerves. It was placed on a 
Parafilm M (American National CanTM, cut in half along the fissura 
longitudinalis cerebri, and preserved in 2ml RNAlater solution (Qiagen) at 4°C 
overnight, and were then further dissected for the experiments performed on 
parts of the central nervous system, or were then stored at -80°C. 
 
For the experiments performed on parts of the central nervous system, each 
half brain was dissected as follows. The cerebellum was first removed from 
each brain half with a forceps, and the cortex was carefully pealed off, 
revealing the hippocampus, which was then cut away. The brainstem was 
then removed, by dissecting the Pons along the Fissura Transversa Cerebri, 
and the Fissura Posterolateralis. Each of these parts immediately stored in 2ml 
RNAlater solution (Qiagen) at 4°C overnight, and then kept at -80°C. 
 
 
5.3.2 Spinal cord dissection  
 
Directly after the cut in the cervical region to remove the head, the mouse 
was fixed by pinning each paw to the surface. The skin was cut longitudinally 
from the neck to the tail of the animal, the muscles were cut and removed 
and another transversal cut was performed in the sacral region with strong 
surgical scissors, to expose the of the spinal cord. A laminectomy was 
performed by cutting each vertebra longitudinally with sharp small surgical 
scissor, on each side, and by removing the upper lamina progressively with 
forceps until the beginning of the spine curve. At this point, the dorsal lamina 
was removed, to expose the lumbar part of the spinal cord. Forceps were 
used to delicately remove the spinal cord, which was immediately placed in 
2ml RNALater solution (Qiagen). 
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5.3.3 Dorsal root ganglia dissection  
 
After the removal of the spinal cord, 6 lumbar dorsal root dorsal root ganglia 
were explanted from the vertebrae with a forceps, and their afferents were 
cut. They were then stored in 1ml RNALater solution (Qiagen). 
 
5.4 RNA extraction 
 
5.4.1 Whole brain RNA extraction 
 
For this RNA extraction, the RNeasy® Mini kit from Qiagen was used. The 
extraction was performed on the right hemisphere of the Brains. Each 
hemisphere was transferred to 8ml RLT buffer 10% β-Mercaptoethanol (Sigma-
Aldrich) and was homogenized for 30s with a Rotor-Stator. 600µl from each 
homogenate were then transferred in 1.5 microfuge tubes (Eppendorf AG) 
and centrifuged 3 minutes at maximum speed, while the rest the 
homogenate was stored at -80°C for further possible use. The centrifuged 
supernatant was then precipitated with 600µl 70% Ethanol (Sigma-Aldrich), 
and successively applied on 2 RNeasy columns, and the RNeasy® Mini kit 
protocol for animal tissues was performed to extract the total RNA. In the final 
step, the RNA was eluted in 50µl RNase-free water (Qiagen). The RNA quality 
was controled on a Bioanalyzer 2100 Nano Chip (Agilent) according to the 
manufacturer’s instructions, and the concentration was measured on a 
Nanodrop ND 1000 spectrophotometer (Thermo Scientific). Each total RNA 
sample was stored at -80°C until use. 
 
  
5.4.2 Parts of brain RNA extraction 
 
The RNA from all the analyzed parts of brain were extracted using the RNeasy® 
Mini kit (Qiagen). The cortices, cerebelli, brainstems were all homogenized in 
1.2 ml RLT buffer 10% β-Mercaptoethanol (Sigma-Aldrich). The Hippocampi 
were homogenized in 600µl of the same buffer. All the parts were 
homogenized with the Mixer Mill MM 300 after having placed a stainless steel 
bead (Qiagen) in the respective microfuge tubes (Eppendorf AG). For each 
cerebelli, brainstems, and hippocampi, 4 homogenization cycles of 2 min at 
20 Hz were performed. For the cortices, 8 homogenization cycles of 2 min at 
20 Hz were necessary. For all the homogenates, the extraction process was 
the same: 300µl homogenate were centrifuged for 3 minutes at full speed, 
while the rest of the homogenate was stored at -80°C for further use. After 
centrifugation, the supernatant was transferred to another microfuge tube, 
and were precipitated with 300µl 70% Ethanol (Sigma-Aldrich). The 600µl of 
precipitated homogenate were then successively transferred to RNeasy 
columns, and the RNeasy® Mini kit protocol for animal tissues with DNase 
digestion was followed for the total RNA purification. In the final step, the 
 Material and methods  
 138 
volume of RNas-free water used for the elution was 50µl (Qiagen). The RNA 
quality was assessed on a Bioanalyzer 2100 Nano Chip (Agilent) according to 
the manufacturer’s instructions, and the concentration was measured on a 
Nanodrop ND 1000 spectrophotometer (Thermo Scientific). All the total RNA 
samples were then kept at -80°C until use. 
 
 
5.4.3 Spinal cord RNA extraction 
 
The Spinal cord RNA was extracted with the RNeasy® Mini kit (Qiagen). They 
were transferred in 1.2ml RLT buffer 10% β-Mercaptoethanol (Sigma-Aldrich). 
A stainless steel bead (Qiagen) was added to each sample, and 6 
homogenization cycles of 2 min at 20Hz were performed on the Mixer Mill 
MM300. The homogenates were then centrifuged at maximum speed for 
3min, after which 350µl were transferred to a new microfuge tube and 
precipitated with 350µl 70% Ethanol (Sigma-Aldrich). The rest of the 
homogenate was stored at -80°C. The precipitated homogenate were then 
applied successively to their respective RNeasy column, and the RNeasy® Mini 
kit (Qiagen) for animal tissues with DNase digestion protocol was followed to 
extract the total RNA. The elution step was performed with 50µl RNase-Free 
water. The total RNA concentration of each sample was measured on a 
Nanodrop spectrophotometer (Thermo Scientific), and the RNA quality was 
checked on a Bioanalyzer 2100 Nano Chip (Agilent) following to the 
manufacturer’s instructions. The Spinal Cord total RNA samples were then 
stored at -80°C until use. 
 
 
5.4.4 Dorsal root ganglia RNA extraction 
 
This RNA extraction was performed with the RNeasy® Mini kit from Qiagen. The 
dorsal root ganglia were transferred in 350µl RLT buffer 10% β-
Mercaptoethanol (Sigma-Aldrich). A stainless bead was added to each 
microfuge tube, and 4 homogenization rounds of 2 min at 20hz were 
performed.  The samples were then centrifuged at full speed for 3 min, and 
the supernatant were transferred to new microfuge tubes (Eppendorf AG). 
The RNA precipitation was achieved by adding 350µl 70% Ethanol (Sigma-
Aldrich). After that step, the precipitated homogenates were successively 
applied to their respective RNeasy column, and the rest of the extraction was 
done according the animal tissue protocol with DNase digestion from the 
RNeasy® Mini kit (Qiagen). The RNA quality was assessed with a Bioanalyzer  
2100 Nano Chip (Agilent) following to the manufacturer’s guidelines, and the 
concentration was measured by spectrophotometry on a NanoDrop ND 1000 
(Thermo Scientific). The samples were then stored at -80°C until use. 
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5.5 aRNA amplification for low density microarray hybridization 
 
The Ambion Amino Allyl MessageAmpTM II aRNA Amplification Kit (Applied 
Biosystems®) was used to amplify every aRNA sample hybridized on the low-
density microarray. For the amplification reactions of the aRNA derived from 
whole brains, the hippocampi, cerebelli, cortices and brainstems, 1µg of total 
RNA was used at the beginning of the reaction. For the amplification 
reactions of the aRNA derived from the spinal cords and the dorsal root 
ganglia, 500ng of total RNA was used to start the reaction. 
 
All the reactions were followed according to the protocol provided by the 
manufacturer. The first step consisted in a reverse transcription of the mRNA 
into cDNA. Depending on which part of the central nervous system was 
studied, samples of 1µg or 500ng total RNA were aliquoted. 1µl of T7 Oligo(dT) 
Primers were added, and the volume of each sample was then completed to 
12µl with RNase free Water. The samples were incubated 10 min at 70°C for 
the annealing of the Oligo (dT) Primers. 8µl Reverse transcription Master Mix 
containing 2µl 10x First Strand Buffer, 4µl dNTP Mix, 1µl RNase Inhibitor and 1µl 
ArrayScript were added to each sample. The reverse transcription reaction 
was carried at 42°C during 2h, and the samples were placed on ice. 
 
For the synthesis of the second strand cDNA, 80µl Second Strand Master Mix 
containing 63µl RNase free water, 10µl 10x Second Strand Buffer, dNTP Mix, 2µl 
DNA Polymerase and 1µl RNase H, were added to each sample. The reaction 
was carried out at 16°C during 2h, and the cDNA was then purified according 
to the manual’s instructions, and each cDNA sample was eluted twice in 9 µl 
RNAse free water at 50°C, which brought the final cDNA volume to 
approximatively 14µl, as some water does not flow through the column. 
 
The in vitro transcription of the RNA was carried out directly after the cDNA 
purification. In the case of the total brain and the spinal cord samples, 26µl in 
vitro transcription Master Mix, containing 3µl amino-allyl UTP (50mM), 12µl ATP, 
CTP, GTP Mix (25mM), 3µl UTP (50mM) 4µl T7 10x Reaction Buffer, 4µl T7 Enzyme 
Mix, were added to each sample, and the reaction was carried out overnight 
at 37°C. For the invitro transcriptions of the cerebellum, brainstem, 
hippocampus and cortex aRNA, 26µl in vitro transcription Master Mix, 
containing 12µl ATP, CTP, GTP Mix (25mM), 6µl UTP (50mM) 4µl T7 10x Reaction 
Buffer, 4µl T7 Enzyme Mix, were added to and the reaction was also carried 
out overnight at 37°C.   
 
At the end of all in vitro transcription reactions 60µl RNase-free water were 
added to the samples.  The manufacturer’s protocol was followed to purify 
the aRNA. The elution was performed with 100µl Nuclease heated at 55°C. 
After purification, the aRNA quality was assessed on a Bioanalyzer Nano Chip 
(Agilent) following to the manufacturer’s instructions and the concentration 
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was measured by spectrophotometry on a NanoDrop ND 1000 (Thermo 
Scientific). 
 
5.6 aRNA labeling 
 
5.6.1 Whole brain and spinal cord aRNA labelling 
 
The aRNA amplified from the whole brains mRNA or from the spinal cord 
mRNA were labelled with Molecular ProbesTM Alexa Fluor Succinimidyl Esther 
dyes from InvitrogenTM. For each labelling reaction, 15µg of aRNA were 
vacuum dried on an EppendorfTM Concentrator 5301 at RT, and resuspended 
in 9µl Coupling Buffer. The Alexa Fluor were resuspended in 11µl DMSO and 
added to the resuspended aRNA. The mixes were incubated for 30 min at 
room temperature in the dark, after which 4.5µl 4M Hydroxylamine were 
added to quench the labeling reaction. After a 15 min long incubation at 
room temperature in the dark, 5.5µl RNase free water was added to each 
tube. The labeled aRNA solutions were then purified by according to the 
manufacturer protocol, and immediately used for hybridization. 
 
For the microarray experiments performed on whole brains, the aRNA samples 
derived from the Brains of the 3 operated and the 3 control animals were 
labeled with Alexa Fluor-555 dyes (InvitrogenTM) and the aRNA derived from 
the brains of 3 naive NMRI mice were labeled with Alexa Fluor-647 
(InvitrogenTM). For the microarray measurements done on spinal cords, all the 
samples were labeled with Alexa Fluor-555 (InvitrogenTM) solely. 
 
For the dye swap experiments, 2 aRNA samples from brain n°19, which was 
extracted from one of our operated animals were respectively labeled with 
Alexa Fluor-555 (InvitrogenTM)  and Alexa Fluor-647, and 2 reference brains  
aRNA samples, derived from naive NMRI mice were respectively labeled with 
Alexa Fluor-555 (InvitrogenTM) and Alexa Fluor-647 (InvitrogenTM). 
 
5.6.2 Parts of brain aRNA labelling 
 
The aRNA amplified from the mRNA purified extracted from the cerebelli, 
cortices, hippocampi and brainstems were labeled with Cy5-ULS dyes, using 
ULSTM aRNA Fluorescent Labelling Kit from KreatechTM Biotechnology.  The 
labeling mixes contained of 2µg Cy5, 2µl 10x Labelling solution, and were 
completed to a final volume of 20µl with RNAse free water. The samples were 
then incubated for 15 min at 85°C to allow the dye coupling reaction. At the 
end of the reaction, 80µl RNAase free water was added to each sample, and 
the labelled aRNA was purified following the RNA Cleanup protocol of the 
RNeasy® Mini kit from Qiagen. The elution step was performed with 30µl RNase 
free water.  
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5.7 aRNA Hybridization  
 
5.7.1 Whole brain aRNA hybridization 
 
Prior to the hybridization, the labeled aRNA and the Ambion SlideHyb™ Glass 
Array Hybridization Buffer #1 (Applied Biosystems®) were heated 10 min at 
70°C for linearization. The aRNA concentration and the dye incorporation 
were then measured by spectrophotometry on a Nanodrop ND 1000 (Thermo 
Scientific). The six samples to hybridize on the slides were prepared by mixing 
1.5µg brain of interest aRNA (from either an operated or a control mouse) 
labeled with Alexa Fluor-555 (InvitrogenTM), 1.5µg reference brain aRNA (from 
naïve NMRI mice) labeled with Alexa Fluor-647 and by completing the 
volume to 150µl with SlideHyb™ Glass Array Hybridization Buffer #1 (Applied 
Biosystems®) (Applied Biosystems®), which prevented the unspecific binding of 
the sample to the slide.  
 
For the dye swap experiment, 2 samples were prepared. The first one 
contained 1.5µg brain 19 aRNA (derived from an operated mouse) labeled 
with Alexa Fluor-555 (InvitrogenTM) and 1.5µg reference brain aRNA (from 
naïve NMRI mice) labeled with Alexa Fluor-647 in a final volume of 150µl 
SlideHyb™ Glass Array Hybridization Buffer #1 (Applied Biosystems®) (Applied 
Biosystems®). The second one contained 1.5µg brain 19 aRNA (derived from 
an operated mouse) labeled with Alexa Fluor-647 (InvitrogenTM) and 1.5µg 
Reference Brain aRNA (from naïve NMRI mice) labeled with Alexa Fluor-555 in 
a final volume of 150µl SlideHyb™ Glass Array Hybridization Buffer #1 (Applied 
Biosystems®) (Applied Biosystems®). 
 
All the hybridization were performed according to the following protocol 
 
The spotted sciCHIP Epoxy slides (Scienion, Art. SE-011) were placed in a 
Tecan Hybridization Station 4800 (Tecan, Männedorf, Switzerland) and 
washed as follows: 
 
• 1min 30s at 10°C in 2x SSC, 0.5% SDS 
• 30s at 23°C in 0.5x SSC, 0.5% SDS 
• 30s at 23°C in 0.1x SSC 
 
The slides were then blocked in 50 mM Ethanolamine (Sigma-Aldrich), 0.1 M 
Tris (pH 9) for 30min, and washed as follows: 
 
• 4min at 23°C in RNase Free Water 
• 30 s at 23°C in 2x SSC, 0.5% SDS 
 
After this step, the aRNA sample mixes were injected to their respective 
chambers, and the hybridization reaction was carried out at 42°C during 16h. 
The slides were then washed as follows: 
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• 30 s at 23°C in 2x SSC, 0.5% SDS, 4 times 
• 30 s at 23°C in 0.5x SSC, 0.5% SDS, 4 times 
• 30s at 23°C in 0.1x SSC, 2 times 
 
At the end of the hybridization, the slides were dried with N2 during 4min 30s 
at 30°C, and scanned immediately. 
 
 
 
Figure 1: Scheme of the hybridized samples in the 2 color hybridizations of the whole Brain aRNA 
 
 
 
 
 
 
5.7.2 Spinal cord aRNA hybridization 
 
 
The labeled spinal cord aRNA and the Ambion SlideHyb™ Glass Array 
Hybridization Buffer #1 (Applied Biosystems®) were heated 10 min at 70°C for 
linearization before the sample preparation. The dye incorporation and the 
aRNA concentration were measured on a Nanodrop ND 1000 (Thermo 
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Scientific) spectrophotometer. The six samples to hybridize on the slides were 
prepared. Each sample had a volume of 150µl and contained 1.5µg spinal 
cord aRNA (from either an operated or a control mouse) labeled with Alexa 
Fluor-647 (InvitrogenTM) in SlideHyb™ Glass Array Hybridization Buffer #1 
(Applied Biosystems®) (Applied Biosystems®), which prevented the unspecific 
binding of the sample to the slide. 
 
The spotted sciCHIP Epoxy slides (Scienion, Art. SE-011) were placed in a 
Tecan Hybridization Station 4800 (Tecan, Männedorf, Switzerland), and the 
washing, blocking and hybridization steps were identical as for the whole 
Brain aRNA hybridization. At the end of the hybridization, the slides were dried 
with N2 during 4min 30s at 30°C, and scanned immediately. 
 
 
 
Figure 2: Scheme of the hybridized samples in the 1 color hybridizations performed for the Spinal Cord 
and the parts of Brain aRNA. 
 
 
 
5.7.3 Parts of brain aRNA hybridization 
 
 
Before the beginning of the hybridization, the samples and the KreaBlock 
Buffer (KreatechTM Biotechnology) were heated 10min at 70°C. The dye 
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incorporation and the aRNA concentration were then measured on a 
Nanodrop ND 1000 (Thermo Scientific) spectrophotometer. The samples were 
then prepared by mixing 1.5µg part of brain of interest aRNA (from either an 
operated or a control mouse), ¼ of the final volume KreaBlock Buffer 
(KreatechTM Biotechnology), and by completing with RNase free water to a 
final volume of 160µl. 
 
The spotted sciCHIP Epoxy slides (Scienion, Art. SE-011) were placed in a 
Tecan Hybridization Station 4800 (Tecan, Männedorf, Switzerland). 160µl 50 
mM Ethanolamine (Sigma-Aldrich), 0.1 M Tris (pH 9) were injected in each 
chamber, and the blocking reaction was carried out for 30 min at 50°C.  The 
slides were then washed as follows: 
 
• 30s at 23°C in RNase free water, 3 times 
• 30s at 50°C in 4x SSC, 0.1% SDS, 4 times 
• 30s at 23°C in RNase free water, 3 times 
 
The slides were then boiled during 1min in MiliQ water (MiliporeTM) to denature 
any denature any secondary structure of the probes, and placed again in 
the Tecan Hybridization Station 4800 (Tecan, Männedorf, Switzerland). The 
following washing steps were performed: 
 
• 30s at 10°C in 2x SSC, 0.5% SDS 
• 30s at 23°C in 0.5x SSC, 0.5% SDS 
• 30s at 23°C in 0.1x SSC 
 
After washing, the labeled aRNA samples were injected to their respective 
chambers, and the hybridization reaction was performed at 42°C during 16h. 
The slides were then washed as follows: 
 
• 30 s at 23°C in 2x SSC, 0.5% SDS, 5 times 
• 30 s at 23°C in 0.5x SSC, 0.5% SDS, 5 times 
• 30s at 23°C in 0.1x SSC, 2 times 
 
At the end of the hybridization, the slides were dried with N2 during 4min 30s 
at 30°C, and scanned immediately. 
 
 
5.7.4 Slide scanning and data quantification 
 
The hybridized microarrays were scanned using the Agilent DNA Microarray 
Scanner and Feature Extraction Software (Agilent Technologies Inc., Santa 
Clara CA, United States). The quantification of the pixel intensity of each spot 
with local background correction the slides was done using Genespotter 
(MicroDiscovery GmbH, Berlin, Germany).  
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5.8 Low density microarray data analysis and normalization 
 
All the data interpretion and statistical analysis were performed on 
GeneSpring GX 7.3.1 (Agilent Technologies Inc., Santa Clara CA, United 
States).  
 
5.8.1 Whole brain hybridization data 
 
The Alexa Fluor-555 signal values were labeled as “Signal”, and the Alexa 
Fluor-647 values were labeled as “Control”. The normalization chosen for 
these experiments was the Loess normalization (locally weighted scatterplot 
smoothing), which combines linear least square regression with non-linear 
regression to normalize all the points of the plots independently, to align the 
curve of highest density. 
 
Two analyses were run in parallel: one on the raw values of the “Signal” and 
the “Control”, and one on their normalized values. In each case, a scatter 
plot of one “Signal” in function of its corresponding “Control” was observed, 
to assess the quality of the hybridization. 
 
One parameter was set: “Pain” and “Non Pain”. For the values from the 3 
slides on which aRNA derived from the brain of an operated mouse was 
hybridized, the “Pain” parameter was set. For the values from the 3 slides on 
which aRNA derived from the brain of a control mouse was hybridized, the 
“Non Pain” parameter was set. An analysis of variance (P value = 0.1) was 
then performed according to the “Pain”/”Non Pain” parameter to detect 
possibly differentially expressed genes. 
 
 
5.8.2 Spinal cord and parts of brain hybridization data 
 
In this case, all the samples were labeled with only one dye: Alexa Fluor-647 
for the spinal cord aRNA, and Cy5 for the parts of Brain aRNA. In each case 
the data processing was the same. The values were all labeled as “Signal”, 
and for each gene, the signals measured on the slides on which some aRNA 
derived from an operated animal was hybridized, were parametered as 
“Pain”, and the signals measured on the slides on which some aRNA derived 
from a control animal was hybridized were labeled as “Non Pain”. 
 
The normalization chosen for all these experiments was the “normalize to a set 
of positive control genes”. The identifiers of the 19 ubiquitously expressed 
positive control genes was uploaded, and the normalization consisted in 
fitting the positive controls to the curve of highest density, and to normalize all 
the other signals accordingly.  
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Two analyses were run in parallel: one for the raw values, and one for the 
normalized values. In both cases, a scatter plot of the “Pain” values in 
function of the “Non Pain” values was established to control the 
hybridization’s quality. After that, volcano plots, which plot for each gene’s -
log10(P Value) in function of the log2(Fold Change) were used to filter the 
genes which had a Fold Change>1.5 and a P Value<0.05. 
 
5.8.3 Comparison between parts of brain hybridization data 
 
In this analysis, the “Pain” parametered values were excluded. For all the 
“Non Pain” parametered signals, a new parameter was set: “Parts of CNS”, 
for which 3 different possibilities were entered: “Brainstem”, “Cortex”, 
“Hippocampus”.  
 
The normalization chosen for all these experiments was the “normalize to a set 
of positive control genes”. The identifiers of the 19 ubiquitously expressed 
positive control genes was uploaded, and the normalization consisted in 
fitting the positive controls to the curve of highest density, and to normalize all 
the other signals accordingly.  
 
For each part of central nervous system comparison, two analyses were run in 
parallel: one for the raw values, and one for the normalized values. In both 
cases, a scatter plot of the values of one of the ”Parts of central nervous 
system” in function of the values of another “Parts of central nervous system” 
was established to control the hybridization’s quality. After that, volcano plots, 
which plot for each gene’s -log10(P Value) in function of the log2(Fold 
Change) were used to filter the genes which had a Fold Change>1.5 and a P 
Value<0.05. 
 
5.9 Low-density microarray protocol validation 
 
The protocol validation was carried out on the genes, which showed different 
expression profiles between the brainstem, the hippocampus, and the cortex. 
For each comparison, the list of differentially expressed genes was established 
according for the analyses made on both the raw and the normalized values. 
The fold changes of the differentially expressed genes were calculated and 
compared with the Fold obtained by Hovatta & al in their published model for 
mouse anxiety (Hovatta et al., 2005). In their study, they have assessed the 
expression profiles of the whole genome in parts of the central nervous sytem 
of 6 inbred mice strains: 129S6/SvEvTac, A/J, C3H/HeJ, C57BL/6J, DBA/2J, and 
FVB/NJ. They have worked with Affymetrix Murine Genome U74 Version 2 
Arrays, and their results are stored in the GEO dataset, under the following ID 
number: GDS1406. 
 
The fold changes of the differentially expressed genes in the low-density 
microarray experiments on parts of the bain were then compared to the fold 
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changes published in the GDS1406 GEO data set for the same genes in the 
same parts of the Brain in 6 inbred mice strains. A gene was considered 
differentially expressed, when his fold change was higher than 1.3 on the 
dataset. The comparison results were labeled as “Same”, when the fold 
changes obtained on the low-density experiment and the GDS1406 dataset 
were both upregulated or downregulated, and as “Different” if one platform 
showed the gene to be upregulated and the other showed it to be 
downregulated or unchanged. For each comparison a percentage of 
similarity was calculated with the number of “Same” obtained. 
 
 
5.10 Quantitative Real Time PCR analysis 
 
5.10.1. Reverse transcription of total RNA 
 
Prior to every Quantitative Real-Time PCR reaction, the sample’s mRNA was 
reverse transcribed into cDNA. For all the total RNA samples extracted from 
the hippocampus, brainstem, cortex and cerebellum, the procedure was the 
same. The samples were prepared by mixing 0.5µg Total RNA, 2µl 10mM dNTP 
Mix (InvitrogenTM), 1µg Oligo (dT)12-18 Primer (InvitrogenTM), and by completing 
with RNase-free water to a final volume 26µl. All the reaction mixes were then 
heated at 65°C for 5 min 
 
A reverse transcription Master Mix was added to every sample. It contained 
8µl 5x First Strand Buffer (InvitrogenTM), 2µl 0.1M DTT (InvitrogenTM), 2µl RNAsin 
40 U/µl (PromegaTM), 2µl Superscript III Reverse Transcriptase (InvitrogenTM) 
(200U/µl) To control the efficiency of the reverse transcription, negative 
control samples (RT NEG Control cDNA) were prepared for every reaction. 
They consisted of the same samples, to which the following Master Mix was 
added: 8µl 5x First Strand Buffer (InvitrogenTM), 2µl 0.1M DTT (InvitrogenTM), 2µl 
RNAsin 40 U/µl (PromegaTM), 2µl RNase-Free water. 
 
All the samples and the negative controls were then incubated for 2h at 50°C 
and 15 min at 70°C, for the reverse transcription reaction. 
 
 
5.10.2 Quantitative Real-Time PCR analysis of the differentially 
expressed genes in the low density microarray experiment 
 
All the primers were designed using the Clone Manager 7 software (Sci-Ed 
SoftwareTM) in order to amplify a 300-400bp PCR product close to the 3’ 
terminal of the mRNA of the differentially expressed genes from the low-
density microarray data. Table 1 contains a list of the primers designed for the 
Real-Time PCR measurements. All the primers were synthesized commercially 
(Microsynth AG) 
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For each reaction, the protocol followed was the same. The primers were 
diluted to a final concentration of 10mM, And the cDNAs obtained after the 
reverse transcription were diluted 20x.  For each part of the brain, 6 samples 
were prepared (3 derived from operated mice, and 3 coming from control 
mice). Each sample contained 2µl cDNA 1/20, 10µl QuantiTectTM SYBR Green 
PCR Master Mix (Qiagen), 1µl Forward (FWD) Primer, 1µl Backwards (BKD) 
Primer and 6µl H2O.  
 
For each Real-Time PCR reaction, 3 Reverse Transcription negative control 
samples, and one Real-Time PCR Negative Control sample were pipetted. 
Each of the 3 Reverse Transcription negative control samples contained 2µl RT 
NEG Control cDNA 1/20, 10µl QuantiTectTM SYBR Green PCR Master Mix 
(Qiagen), 1µl Forward (FWD) Primer, 1µl Backwards (BKD) Primer and 6µl H2O.  
The Real-Time PCR Negative Control sample contained 10µl QuantiTectTM 
SYBR Green PCR Master Mix (Qiagen), 1µl Forward (FWD) Primer, 1µl 
Backwards (BKD) Primer and 8µl H2O. 
 
For every Real-Time PCR round, the reactions were carried on all the samples 
and negative controls for the gene of interest, and also for the β-Actin gene. 
The β-Actin Real-Time PCR signals of each sample were used for normalization 
purposes. Each sample, and negative controls were pipetted in triplicates. 
 
Table 1: Primes used in the Real-Time PCR measurements performed to verify the low-density microarray 
data. The primers are noted in the 5’- 3’ direction. 
 
 
 
All the PCR reactions were performed on a Rotor-Gene 6000 (Corbett 
ResearchTM) Real-Time PCR machine. For every reaction, the same 
program was used: 
• 15min 95°C 
Gene Name Primer Names Primer Sequence
Neuropeptide Y FWD GCTAGGTAACAAGCGAATGG
Neuropeptide Y BKD GATGAGATGAGGGTGGAAAC
Vanilloid Receptor TrpV5 FWD GACCTGCCAATTACAGAGTG
Vanilloid Receptor TrpV5 BKD GCTATTGCTGCTTAGGGATG
Vanilloid 1 Receptor VR1 FWD TCCTGTTACTGGCCTATGTG
Vanilloid 1 Receptor VR1 BKD TGCTATGCCTATCTCGAGTG
5HTr4 FWD TCCTCTGGCTTGGCTATATC
5HTr4 BKD CTTAGGACTGGCTTCGTTTC
Npy5r FWD AAGCAGAAGCGACCGCACTC
Npy5r BKD CTACGCTGCCTCTATAGTCC
NPY6r  FWD ACTCCAACTCCAGGGAATAG
NPY6r BKD TAGGTGTTGGCTGGTTTGTG
MapK1 FWD CTGCATACTGGTGTCATTGG
MapK1 BKD CTATGTGGCATGCAGTGTAG
Sodium and Chloride dependent GABA Transporter 1 FWD CTCGTGCCGTAGCTTCTTAG
Sodium and Chloride dependent GABA Transporter 1 BKD GGGAAGAGCTGGTAGATTGC
Guanine nucleotide binding protein alpha 1 FWD CCGACTACGATGGACCTAAC
Guanine nucleotide binding protein alpha 1 BKD TGCAAGCCTCATGCCTTTGG
Nerve Growth Factor alpha (NGF)  FWD TGCTGTGCCTCAAGCCAGTG
Nerve Growth Factor alpha (NGF)  BKD CAGTGATGTTGCGGGTCTGC
Alpha 2C Adrenergic Receptor  FWD CCAGCCAGCTCTTCAACTTC
Alpha 2C Adrenergic Receptor  BKD GGCTCATGTGTCCCTCTCAG
NMDA Receptor 1 FWD AGCAACGCAAGCCCTGTGAC
NMDA Receptor 1 BKD ATCCGCTTCGACTCGCTACG
Creb3 FWD GTGTTCTGGTCCTCGTGTTC
Creb3 BKD GAAGGGCTGTGGTTAGGTTG
Pomc FWD GGCCTGACACGTGGAAGATG
Pomc BKD CAGCACTGCTGCTGTTCCTG
Actin FWD CAGCCAGGCTGTGCTGTCCCTGTATGC
Actin BKD GATCTTCATGGTGCTAGGAGCCAGAGC
Creb3 
Pomc
Guanine nucleotide binding protein alpha 1
Nerve Growth Factor alpha (NGF)
Alpha 2C Adrenergic Receptor  
NMDA Receptor 1 
Neuropeptide Y Receptor 5
Neuropeptide Y Receptor 6
MAP Kinase 1 (Erk 2)
Sodium and Chloride dependent GABA Transporter 1
Neuropeptide Y
Vanilloid Receptor TrpV5
Vanilloid Receptor VR1
Serotonin Receptor 5HTr4
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• 45 repeats cycles: 
o 15s denaturation at 94°C 
o 30s annealing at 60°C 
o 30s elongation at 72°C 
 
• melt from 72°C to 95°C, with 5s hold at each step 
 
 
5.10.3 Quantitative Real-Time PCR analysis of 27 selected genes 
 
These Real-Time PCR measurements were performed on the brainstems, 
cortices, hippocampi, cerebelli and dorsal root ganglia of 6 operated and 6 
control mice for the surgical pain model, as well as on the cortices and the 
spinal cords of 6 mice, which underwent an intraperitoneal injection of CFA, 
ans 6 control mice, which received an intraperitoneal injection with medium, 
for the inflammatory pain model. All the mRNA samples were reverse 
transcribed into cDNA as previously described. 
 
The primers of the 27 genes analyzed in these Real-Time PCR measurements 
are listed in Table 2. Each primer was diluted to a final concentration of 
10mM. 
 
In a 96 well plate (BRAND), the cDNAs were diluted 20 times. All the wells from 
the column contained 20µl 1/20 cDNA of one specific sample. For each 
sample, the PCR master mixes were prepared as follows: 500µl QuantiTectTM 
SYBR Green PCR Master Mix (Qiagen), 50µl Forward (FWD) Primer, 50µl 
Backwards (BKD) Primer. Each Master Mix was specific for a gene and was 
then distributed in the 8 wells of a 96 well plate column (BRAND), at a volume 
of 65µl Master Mix / well.  
 
The content of the cDNA 96-well plates and the Master Mixes 96-well plates 
were then mixed in a 384-well plate (Genetix®) by a Beckman FX plate 
pipetting robot according to a specific design. Basically, each well contained 
8µl cDNA 1/20 and 12 µl Real-Time PCR MasterMix. Every well across the same 
row of the plate contained the same cDNA. And every well across a same 
column contained a Master Mix specific for one gene. Every column was 
pipetted in duplicates. With this design, every sample and negative controls 
were pipetted in duplicates, to bettor monitor eventual artifacts in the 
reaction. 
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Table 1: Primers used for the Real-Time PCR of 27 selected genes. The primers are noted in the 5’- 3’ 
direction.  
 
 
5.10.4 Data interpretation 
 
In all the Real-Time PCR reactions, the Ct value of each sample was 
normalized to the Ct value of the β-Actin gene for the same sample, to 
obtain the sample’s ΔCt value. The mean of the normalized Ct values of the 6 
operated animals, as well as the one of the 6 control animals were then 
calculated. The ΔΔCt was then calculated as follows: 
 
Gene Name Primer Names Primer Sequence
IL6_FWD CCAACAGACCTGTCTATACC
IL6_BKD GGACTCTGGCTTTGTCTTTC
HSP70_FWD GTGACAGCTGAAGACAAAGG
HSP70_BKD GGCTTTCCAGCCATTCAATC
5HTr3A_FWD TACAGCGGCCAGTACCTGAC
5HTr3A_BKD AGTGGCGGATGGAGGATAGC
Tac1_FWD ACCAGATCAAGGAGGCAATG
Tac1_BKD ACTGCTCACTGACACAGATG
TacR1_FWD GCCCTGGGAACCTATAACTG
TacR1_BKD CAACAAGAGCGATGGCACTG
Runx1_FWD CCAGGGACATTCGGTCTTAG
Runx1_BKD TACCGACCTGGCTGAAAGAG
Oprs1_FWD AGCTGCAGTGGGTATTTGTG
Oprs1_BKD AAGTGTCGGCTAGTGCAAAG
OprD1_FWD CAAGGCTGTGCTCTCCATTG
OprD1_BKD GCAGTAGCATGAGGCCATAG
Gabrg2_FWD CCTGACATCGGAGTGAAACC
Gabrg2_BKD GCAGGAGTGTTCATCCATTG
Npy_FWD GCTAGGTAACAAGCGAATGG
Npy_BKD GATGAGATGAGGGTGGAAAC
TprV2_FWD TCCTCACCTACGTCCTACTG
TprV2_BKD CCTCTGAGGCACTGTTCTTC
Npy5r_FWD AAGCAGAAGCGACCGCACTC
Npy5r_BKD CTACGCTGCCTCTATAGTCC
Slc6a1_GABAtr1_FWD CTCGTGCCGTAGCTTCTTAG
Slc6a1_GABAtr1_BKD GGGAAGAGCTGGTAGATTGC
MapK1_FWD CTGCATACTGGTGTCATTGG
MapK1_BKD CTATGTGGCATGCAGTGTAG
Pomc_FWD GGCCTGACACGTGGAAGATG
Pomc_BKD CAGCACTGCTGCTGTTCCTG
5HTr1d_FWD TGGGTGCTGGTGGGTGTTTC
5HTr1d_BKD TGTCCTGCTGACGGCTTTGC
Creb3_FWD GTGTTCTGGTCCTCGTGTTC
Creb3_BKD GAAGGGCTGTGGTTAGGTTG
5HTr1A_FWD CCCTTCAGCTGTATCTTTCC
5HTr1A_BKD GTGCGTCTTCTCCACAGAAC
Oprm1_FWD ACGGCTAATACAGTGGATCG
Oprm1_BKD AACACGCAATACGGCAAACC
NTRK3_FWD GCATGTCCAGGGACGTCTAC
NTRK3_BKD TAGGGCAGACTCTGGGTCTC
Prkcc_FWD AGCTGTGGCCATCTGCAAAG
Prkcc_BKD GCATCTGGGTGCACGAAGTC
DREAM_FWD GATAAGGGAGGTCCTTAGAG
DREAM_BKD TAAGGGATGCAGCAGGTTAG
LIF_FWD CCACGGCAACCTCATGAACC
LIF_BKD TTGCACAGACGGCAAAGCAC
BDNF_FWD CAGGCAGAATGAGCAATGTC
BDNF_BKD CCATAGAAGTGAGGGACTCA
5HTr4_FWD TCCTCTGGCTTGGCTATATC
5HTr4_BKD CTTAGGACTGGCTTCGTTTC
5HTr2C_FWD CCTGTCTCTGCTTGCAATTC
5HTr2C_BKD GTCATTGAGCACGCAGGTAG
NPY6r_FWD ACTCCAACTCCAGGGAATAG
NPY6r_BKD TAGGTGTTGGCTGGTTTGTG
Brain Derived Neurotrophic Factor BDNF
Serotonin Receptor 5-HTr4
Serotonin Receptor 5-Htr2C
Neuropeptide Y Receptor Type 6 NPY6r
neurotrophic tyrosine kinase, receptor, type 3 NTRK3
Protein Kinase C Gamma Prkcc
Kv channel interacting protein 3, calsenilin Dream
Leukemia Inhibiting Factor LIF
Serotonin Receptor 5HTr1d
cAMP responsive element binding protein 3 Creb3
Serotonin Receptor 5-HTr1A
Opioid Receptor mu 1 Oprm1
Neuropeptide Y Receptor Type 5 NPY5R
Solute carrier family 6 (neurotransmitter transporter, GABA), member 1
Map Kinase 1 (Erk2)
Proopiomelanocortin
Opioid receptor delta 1Oprd1
GABA A receptor, subunit gamma 2 Gabrg2
Neuropeptide Y
Transient receptor potential cation channel, subfamily V, member 2  TrpV2
Tachykinin Receptor 1 TacR1
Runt related transcription factor 1Runx1
Opioid receptor sigma 1 Oprs1
Interleukin 6 IL6
Heat Shock Protein HSP70
Serotonin Receptor 5-HTr3A
Tachykinin 1 Tac1
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ΔΔCt = Mean(ΔCtOPERATED ANIMALS) - Mean(ΔCtCONTROL ANIMALS) 
 
The fold change (FC) of each gene’s expression level in the operated animals 
was calculated as follows:  
 
FC = 2-(ΔΔCt) 
 
5.11 GeneChip® Mouse Exon 1.0 ST Arrays 
 
5.11.1 cRNA preparation 
 
The quality of the isolated RNA was determined with a NanoDrop ND 1000 
(NanoDrop Technologies, Delaware, USA) and a Bioanalyzer 2100 (Agilent, 
Waldbronn, Germany). The cDNA was prepared from total RNA using a 
primer mix and reverse transcriptase (RT) (WTOvation Pico System, NuGEN, 
3300-12). The primers have a DNA portion that hybridizes either to the 5’ 
portion of the poly (A) sequence or randomly across the transcript. SPIA 
amplification, a linear isothermal DNA amplification process, was used to 
prepare single-stranded cDNA in the antisense direction of the mRNA starting 
material. Single-stranded cDNA quality and  
quantity was determined using NanoDrop ND 1000 and Bioanalyzer 2100. 
Single-stranded cDNA (3ug) was converted into sense target cDNA (ST-cDNA) 
using WT-Ovation™ Exon  (Cat # 2000-12). Fragmented and biotin-labeled ST-
cDNA targets were generated with the FL- Ovation cDNA Biotin Module V2 
(NuGEN, 4200-12).  
 
 
5.11.2 Hybridization and data processing 
 
Biotin-labeled single-stranded cDNA targets (5ug) were mixed in 220 µl of 
Hybridization Mix (Affymetrix Inc., P/N 900720) containing a Hybridization 
Controls and Control Oligonucleotide B2 (Affymetrix Inc., P/N 900454). 
Samples were hybridized to Affymetrix Mouse Exon 1.0 ST Arrays for 18h at 
45°C. Arrays were then washed using an Affymetrix Fluidics Station 450 FS450 
0001 protocol. An Affymetrix GeneChip Scanner 3000 (Affymetrix Inc.) was 
used to measure the fluorescent intensity emitted by the labeled target.  
 
Raw data processing was performed using the Affymetrix AGCC software. 
After hybridization and scanning, probe cell intensities were calculated and 
summarized for the respective probe sets using Exon Level:  All: RMA Sketch.  
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5.11.3 Data analysis and Normalization 
 
The raw data from the microarrays have been summarized using RNA 
algorithm as implemented in “affy” package of BioConductor (Gentleman et 
al., 2004) and then analyzed using the “exonmap” package (Okoniewski and 
Miller, 2008; Okoniewski et al., 2007) connected to the X:MAP database (Yates 
et al., 2008)  
 
The report including all 1.2M probesets with the genes to which they are 
assigned was created. Each probeset was identified according to genome 
and Ensembl genes matching as: 
 
• Exonic: matching a known exon in a unique way 
• Intronic: matching a known gene in a unique way, but not matching 
any of known exons 
• Intergenic: not matching any of known genes 
• Multitarget: matching the genome in more than one place at least with 
a part of probes belonging to the probeset. Multitarget probesets with 
several matches to the genome are most likely matching a protein 
domain, those with many (ca >5) are considered repetitive matches 
and their expression measurements are usualy close to the saturation 
level. 
 
For each probeset, the fold change (log2 ratio) and p-value of the t-test have 
been calculated to filter out the most up and -downregulated probesets.  
Multi-exonic genes with several probesets showing consistently significant fold 
change (eg FC(log2) >1) have been selected as a potential targets for furter 
investigation. For genes with small number of exons, just one probesets is 
Enough to consider regard the gene as significantly expressed. 
 
 
5.11.4 Clustering analysis 
 
A bi-clustering using Genevestigator® (NebionTM) (Hruz, 2008) was performed. 
The lists of up- and downregulated genes were uploaded in the Clustering 
toolset, and clustered according to the “Stimulus” criterion. The meta analysis 
was carried out on the data obtained with Affymetrix Mouse 430_2: 40k 
Arrays. A total of 2974 datasets were included in the study among which 2591 
were GEO datasets, 157 came from the ArrayExpress database, 208 from the 
Neuroscience Microarray Consortium, and 18 from other sources. All the data 
were normalized according to the GCOS algorithm (GeneChip® Operating 
Software, AffymetrixTM). In the clusterings, the BiMax algorithm grouped genes, 
which showed similar regulation profiles after specific stimuli listed in 
Genevestigator.  
 
Two clusterings were performed for the genes, which had 3 or more 
downregulated exons on the microarray analysis: one to group the genes, 
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which were similarly upregulated after specific stimuli, and one to group the 
genes, which were similarly upregulated after specific stimuli. Similar 
clusterings were performed for the genes, which had 3 or more 
downregulated exons on the microarray analysis. A literature search was then 
performed to understand which cellular process was triggered by the stimuli, 
to which the clustered genes reacted. 
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